DDrare: Database of Drug Development for Rare Diseases

46. 悪性関節リウマチ　［臨床試験数：1,999，薬物数：1,752（DrugBank：321），標的遺伝子数：172，標的パスウェイ数：213］

Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Drug = (+) erythromefloquine; (+)erythromefloquine; (3r,4r)-4-methyl-3-(methyl-1h-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-; (3r,4r)-4-methyl-3-(methyl-1h-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile,; (3r,4r)-4-methyl-3-(methyl-1h-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-; (3r,4r)-4-methyl-3-(methyl-1h-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-piperidinepropanenitrile,; (cdp6038; 0109-0012a 100 mg/ml; 0109-0012a 25 mg/ml; 0109-0012a 50 mg/ml; 0114-0006b; 0881; 1 ml 0.9 % nacl; 1,5-anhydro-2,3-dideoxy-3-[[(1r,3s)-3-[[7,8-dihydro-3- (trifluoromethyl)-1,6-naphthyridin-6(5h)-yl]c; 100 mg lx3305 qd; 13-valent pneumococcal conjugate vaccine; 15-o labeled water; 150 mg lx3305 qd; 18f-fdg; 18f-ge-180; 1h-pyrazol; 2 million hmsc/kg; 2-{7-[1,1-dimethyl-3-(4-sulfobutyl)-benz[e]indolin-2-ylidene]-1,3,5-heptatrienyl}-1,1-dimethyl-3-(sulfobutyl)-1h-benz[e]-indolium hydroxide,inner salt; 200 mg lx3305 qd; 23-valent pneumococcal polysaccharide vaccine; 250 mg lx3305 bid; 250 mg lx3305 qd; 2593; 300 mg lx3305 qd; 331731-18-1; 4 million hmsc/kg; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl] benzenesulfonamide; 40 mg msb11022; 400 mg lx3305 qd; 42942019; 5-chlor-6'-methyl- 3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridin; 50 mg ap1189; 50 mg etanercept; 50 mg lx3305 qd; 500 mg lx3305 qd; 6 million hmsc/kg; 6-(nitrooxy)hexyl(2z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate; 68ga-bnota-prgd2; 7-valent pneumococcal conjugate vaccine; 70930.00.00; 89zr-dfo-czp; 9512; 99mtc-3prgd2; 99mtc-rhannexin v-128; 99mtc-s-hynic certolizumab pegol; A natural remedy for rheumatoid arthritis vs. common drugs; Ab1010; Aba, open-label (ol); Abatacept; Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept (bms-188667); Abatacept (iv); Abatacept + csdmard; Abatacept + methotrexate; Abatacept + vaccines; Abatacept injection; Abatacept placebo; Abatacept prefilled syringe; Abatacept, rituximab or tocilizumab; Abbv-105; Abbv-105, a-1519938.0; Abbv-257; Abbv-3373; Abp 501; Abp 710; Abp 710 - biosimilar to infliximab; Abp 798; Abp 798 - biosimilar to rituximab; Abt 494; Abt 494 12mg; Abt 494 3mg; Abt-122; Abt-494; Abt-humira; Abx464; Abx464 100mg; Abx464 50mg; Ac430; Acalabrutinib; Aceclofenac; Acellbia; Acetaminophen; Acetaminophen tablets; Acetate; Acetylsalicylic acid; Acetylsalicylzuur cardio pch disp tablet 80mg; Actemra; Actemra(eu-licensed); Acthar; Acthar gel; Acthar injectable product; Active comparator; Acycloguanosine; Acz885; Acz885 (investigational); Acz885 drug substance; Ad 452; Ad 452 18 mg tablet; Ad 452 4.5 mg tablet; Ad 452 9 mg tablet; Adalimumab; Adalimumab (ada); Adalimumab (humira); Adalimumab (humira®); Adalimumab (up to 9 months exposure); Adalimumab 40 mg; Adalimumab 40 mg subcutaneous (sc) every other week (eow); Adalimumab 40mg q2w; Adalimumab 80 mg; Adalimumab pfs and pen; Adalimumab with methotrexate; Adalimumab-eu; Adalimumab-pfizer; Adalimummab; Adefovir; Adenin; Adl5859; Administration of cimzia®; Agm 719; Agrippal s1 (influenza vaccination); Ain457; Ak106-001616; Ald518; Ald518 monoclonal antibody (anti il-6 mab); Alemtuzumab; Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994; Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994); Alendronat teva; Alendronate; Alendronate versus alfacalcidol (1-alpha oh vitamin d); Alendronic acid; Alfacalcidol; Alkaline phosphatase; Allogeneic mesenchymal precursor cells; Allopurinol; Aluminium; Aluminium phosphate; Alx-0061; Alx-0061 nanobody; Amg 108; Amg 162; Amg 357; Amg 570; Amg 592; Amg 714; Amg 719; Amg 827; Amg 827 140 mg; Amg 827 210 mg; Amg 827 70 mg; Amg592; Aminopterin; Amoxapine; Amoxapine & dipyridamole; Amoxicilina; Amoxicillin; Amp-110; Anakinra; Anakinra (kineret®); Anakinra (r-methuil-1ra); Anakinra and peg stnf-r1; Andecaliximab; Angiotensin; Angiotensin receptor blockers; Anifrolumab; Anifrolumab (medi-546); Anti human granulocyte-macrophage colony-stimulating factor (gm-csf) monoclonal antibody; Anti il-1beta antibody; Anti il-1beta antibody, subclass igg4; Anti il-1ß antibody; Anti il-1ß antibody, subclass igg4; Anti lp40 antibody, subclass igg4 la294; Anti tnf + meth; Anti-c5ar; Anti-cd20 small modular immunopharmaceutical, wye-400087; Anti-gm-csf receptor alpha; Anti-il-20; Anti-il-20 (109-0012); Anti-il-6 mab; Anti-inflammatory drugs; Anti-pandemic h1n1 influenza vaccine; Anti-thymocyte globulin; Anti-tnf; Anti-tnf biologics; Anti-tnf biologics therapy; Anti-tnf humanized antibody fab fragment - peg conjugate; Anti-tnf suspended perioperatively; Anti-tnf therapy; Anti-tnf therapy (etanercept or adalimumab); Anti-tnfa continued perioperatively; Anti-tumor necrosing factor (tnf) therapy; Antihistamine; Ap1189; Apl a12; Apremilast; Apremilast 20 mg; Apremilast 30 mg; Ara290; Arava; Arava 20 mg filmdrasjerte tabletter; Arava 20 mg tablets (aventis pharmaceutical, inc.); Arava®; Arcoxia; Arry-371797, p38 inhibitor; Arry-438162; Arry-438162, mek inhibitor; Art621; Arthroscopy & saline irrigation alone; Ascal(r) / carbasalate calcium; Asendis 50 mg; Ask8007; Asp1707; Asp2408; Asp2409; Asp5094; Aspirin; Aspirin 81mg tablet; Aspirin tablets; Atacicept; Atn-103; Atn-103 10 mg q4wks; Atn-103 10 mg q8wks; Atn-103 30 mg q4wks; Atn-103 80 mg q4wks; Atn-103 80 mg q8wks; Atorvastatin; Atorvastatin tablet 20 mg; Auto injector; Autologous apoptotic cells injection; Autologous mesenchymal stem cells; Autologous stromal vascular fraction cells; Ave9897; Avelox- moxifloxacin; Avelox®; Azathioprin; Azathioprine; Azd5672; Azd9056; Azd9056 hydrochloride; Azd9567; Azd9567 10 mg; Azd9567 125 mg; Azd9567 155 mg; Azd9567 20 mg; Azd9567 40 mg; Azd9567 80 mg; Azd9567 monohydrat; Azd9567 monohydrate; Baminercept; Baminercept alfa; Baminercept alfa (bg9924); Baricitinib; Baricitinib, olumiant®; Bat1806; Bat1806 injection; Bay1834845; Bcd-055; Bcd-089, 162 mg, s/c, q2w; Bcd-089, 162 mg, s/c, qw; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Belatacept; Belimumab; Belimumab 1 mg/kg; Belimumab 10 mg/kg; Belimumab 4 mg/kg; Benepali; Benzimidazole; Benzimidazole,5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 h-benzimidazole; Betamethasone; Betamethasone acibutate; Bg00012; Bg9924; Bgx-0214; Bi 655064; Bi 695500; Bi 695501; Bi 695501 autoinjector; Bi 695501 prefilled syringe; Biap; Bibr 796 bs; Bicain spinal; Biib023; Biib057; Biil 284 bs high dose; Biil 284 bs low dose; Biil 284 bs medium dose; Bimekizumab; Binyrebarkhormon; Binyrebsrkhormon; Biodmards; Biologic agents; Biologic dmard; Biologic tnfi; Biological agents; Biologics; Biosimilar; Biosimilar infliximab; Biosimilar product to adalimumab; Birb 796 bs, high dose; Birb 796 bs, low dose; Blood; Blood sample; Blood samples; Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Bms-188667; Bms-582949; Bms-582949 and methotrexate; Bms-817399; Bms-945429; Bms-986104; Bms-986142; Bms-986142 200mg; Bms-986142 350mg; Bms-986195; Bms-986251; Borage seed oil; Bortezomib; Bovine intesastinal alkaline phosphatase (biap); Bow015; Br9001; Br900a; Bredinin; Bredinin tablet 150mg; Bredinin tablet 50mg; Brl-049653; Bt061; Bt061 (cd4 monoclonal antibody); Bt971; Btt-1023; Bucillamine; Bupivacaine; Bupivacaine hydrochloride; Buprenorphine; Buprenorphine transdermal patch; C. albicans; C10aa05; Caffeine; Calcitriol; Calcium; Calcium and cholecalciferol; Calcium carbonate; Calcium citrate; Cam-3001; Canakinumab; Canakinumab (investigational); Canakinumab (proposed); Cannabidiol; Cannabidiol tablet 10 mg; Capture; Carbasalate calcium; Carbon; Carbonate; Cc-292; Cci-779; Ccx 354; Ccx 354-c; Ccx354; Ccx354-c; Cdmard; Cdp6038; Cdp870; Cdp870 100mg; Cdp870 200mg; Cdp870 400mg; Cdp870 fab'-peg; Ce 224,535; Ce-224,535; Celbesta®; Celebrex; Celebrex 200 mg; Celebrex 200 mg capsule, hard; Celebrex®; Celecoxib; Celecoxib 200mg capsule; Ceramic on polyethylene articulation; Certolizumab; Certolizumab pegol; Certolizumab pegol (cdp870, tradename cimzia); Certolizumab pegol (cdp870, tradename cimzia)(prefilled syringes at the dose of 200mg); Certolizumab pegol (czp); Certolizumab pegol + methotrexate (mtx); Cetrorelix; Cf101; Cf101 1 mg; Cf101 2 mg; Cfz533; Ch-1504; Ch-4051; Chicken; Chicken type ii collagen; Chimeric human-murine igg1 <monocolonal antibody; Chimeric human/mouse anti-cd-20 monoclonal antibody; Chlor; Chloride; Chloroquine; Cholecalciferol; Chong kun dang tofacitinib tablet; Chromium; Chs-0214; Ciclosporin; Cimzia; Cimzia 200 mg injeksjonsvæske, oppløsning; Cimzia 200 mg solution for injection; Cimzia®; Citalopram; Citrate; Ckd-374 5mg tab.; Classic dmards treatment group; Clazakizumab; Clindamycin; Clofarabine; Cmab008; Cnto 136 100 mg; Cnto 136 25 mg; Cnto 136 50 mg; Cnto 148; Cnto 1959; Cnto 1959 igg; Cnto1275; Cnto148; Cnto6785; Co-medication: synthetic dmards; Cobalt; Cobiprostone; Cod liver oil; Coenzyme q10; Colecalciferol; Collect of 10 ml of peripheric blood for dna extraction; Combination; Combination fish oil and borage seed oil; Combination of minocycline and mtx or mtx alone; Combination steroid; Commercial formulation etanercept; Comparator: diclofenac; Comparator: diclofenac sodium; Comparator: naproxen tablet 500 mg; Control; Control group; Control intervention (no dexamethasone); Conventional dmard combination; Conventional dmards; Corn; Corn oil capsules; Corticosteroid and non-biological agents.; Corticosteroid or nsaid; Corticosteroids; Corticotrophin; Corticotrophin 80 units; Corticotropin; Cp 690,550; Cp-195,543; Cp-690,55-10; Cp-690,550; Cp-690,550 (tasocitinib); Cp-690,550 (tofacitinib); Cp-690,550 + methotrexate; Cp-690,550-10; Cp-690-550; Cp690,550; Cr 1; Cr 2; Cr 3; Cr6086; Cr6086z; Creatine; Creatinine; Crx-102; Crx-102 (2.7/180); Crx-102 (2.7/360); Crx-139; Crx-150; Csdmards; Ct- p10; Ct-p13; Ct-p17; Ct-p17 sc; Ctla4ig; Cura-100; Curcumin; Curcumin (longvida™); Cyclophosphamide; Cyclosporine; Cyklokapron®; D569 tab.; Dacortin; Dacortin ®; Dalacin c phosphate; Decortin; Decortin 5mg tablets; Decortin®; Decrease tocilizumab, abatacept; Dekavil; Deltacortene forte*10cpr 25mg; Deltacortril enteric; Denosumab; Depalgos*20+325mg 28cpr rp; Depo medrol; Depo-medrone; Dexamethason; Dexamethasone; Dextromethorphan; Dextromethorphan hydrobromide; Diacerein; Diazepam; Diazepam, melatonin; Dibase*im os 2f 1ml 300000ui/m; Diclofenac; Diclofenac + omeprazole; Diclofenac natrium pch retard tablet mga 75mg; Diclofenac sodium; Dietary supplement omega3 fatty acids aand vitamins; Digoxin; Dimeythl fumarate; Dipotassium salt; Diprofos depot; Dipyridamole; Disease modified antirheumatic drugs or biological agents; Disease-modifying antirheumatic drug; Disease-modifying antirheumatic drugs (dmards); Dmard; Dmard cessation; Dmard maintenance; Dmard therapy; Dmards; Dmards (disease-modifying antirheumatic drugs); Dmards or biologics; Dnaj peptide; Donepezil; Dose level 1; Dose level 2; Dose level 3; Dose level 4; Double-blind abatacept; Double-blind adalimumab; Doxycycline; Drl_ri; Dronabinol; Dronabinol capsule 2.5. mg; Drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom; Dwp422 25mg; E-device; E6011; Ebetrexat; Ec 3.1.3.1; Edoxaban; Efalizumab; Efexor; Efexor xl 75 mg; Efexor xl 75 mg (venlafaxine); Eldecalcitol; Emea/h/c000262; Enalapril; Enalapril maleate; Enbrel; Enbrel (etanercept); Enbrel 25 mg injeksjonsvæske, oppløsning i ferdigfylt sprøyte.; Enbrel 25 mg powder and solvent for solution for injection; Enbrel 25mg pfs; Enbrel 25mg pfs inj.; Enbrel 50 mg powder and solvent for solution for injection; Enbrel 50 mg solution for injection in pre-filled syringe; Enbrel 50mg pfs; Enbrel 50mg pre-filled pen; Enbrel 50mg pre-filled syringe; Enbrel auto injector; Enbrel liquid; Enbrel pre-filled pen; Enbrel pre-filled syringe; Enbrel®; Enbrel® 50 mg solution for injection in pre-filled syringe; Engineered humanized monoclonal anti-human cd19 antibody. lot numbers: 1-fin-1588 (9.6mg/ml); Enia11; Enoxaparin; Entecavir; Epax 6000 ee 1000mg (0.6 gr dha+epa); Epaxal; Epinephrine; Epoetin alfa; Erb-041; Erbium citrate; Ergocalciferol; Ermm-1; Esomeprazole; Esomeprazole 20 mg; Estradiol; Eszopiclone; Etanercept; Etanercept (enbrel); Etanercept (enbreltm); Etanercept + methotrexate; Etanercept , methotrexate; Etanercept / autoinjector a; Etanercept 50mg; Etanercept biosimilar; Etanercept liquid; Etanercept or adalimumab; Etanercept pre-filled syringe sq injection; Etanercept treatment; Etanercept via autoinjector a; Etanercept via autoinjector b; Etanercept, other biologics, disease-modifying antirheumatic drugs (dmards), etc; Ethinyl estradiol; Etn alone; Etn+mtx; Etodolac; Etoricoxib; Eu-humira; Eu/1/99/126/017; Eu/1/99/126/020; Evobrutinib; F8il10; Famotidine; Fang yi qing feng shi granule; Fang(30); Fb704a; Fendrix; Fendrix suspension for injection; Fendrix suspension for injection hepatitis b (rdna) vaccine (adjuvanted, adsorbed).; Fentanyl; Fentanyl transdermal patch; Ferrograd; Ferrograd folic tablets; Filgotinib; Filgrastim; Fish oil; Fish oil supplement; Fish oil, gamma-linolenic acid; Fkb327; Fkb327 ai; Fkb327 pfs; Fludarabine; Fluorine f 18; Flurbiprofen; Focetria; Focetria (monovalent mf59-adjuvanted vaccine); Folate; Folatescan (technetium tc 99mec20); Folic (or folinic) acid; Folic acid; Folic acid or folate; Folinic acid; Fontolizumab; Fosd; Fostamatinib; Fostamatinib 50 mg blue film-coated tablet; Fostamatinib disodium; Fostamatinib disodium (r935788); Fpa008; Fr104; Fsme-immun; Furestem-ra inj; Furestem-ra inj.; Fx125l; Gadobutrol; Gadolinium; Gamma-linolenic acid; Gck 100 mg; Gck 200 mg; Gck 300 mg; Gdc 0853; Gdc-0853; Gdc-0853 ro7010939; Gerilimzumab; Gfi 38518168-aek-b-007; Ginger; Ginseng; Ginsenoside; Glpg0259; Glpg0634; Glucocorticoid; Glucocorticoid agent; Glucocorticoids (permitted,not necessary); Glucophage (metformin); Glucosamine; Gm-csf; Gold; Golimumab; Golimumab 100 mg; Golimumab 100 mg injections; Golimumab 2 mg/kg iv; Golimumab 50 mg; Golimumab 50 mg injections; Golimumab final vialed product (fvp); Golimumab intravenous; Golimumab intravenous (iv); Golimumab liquid in prefilled pen; Golimumab liquid in prefilled syringe; Golimumab liquid in vial; Golimumab pre-filled syringe; Gp2013; Gp2013 - a proposed biosimilar rituximab; Gp2015; Gp2017; Grapefruit; Grc 4039; Green tea; Green tea group; Group 1 or orencia treated group; Growth hormone; Gs-4059; Gs-5745; Gs-6034; Gs-9876; Gsk1827771; Gsk1841157; Gsk2982772; Gsk2982772 60 mg; Gsk2982772a, where a denotes the free base; Gsk3117391; Gsk3152314a; Gsk315234; Gsk315234 injection 100mg/ml; Gsk3196165; Gsk3196165 dose 1; Gsk3196165 dose 2; Gsk3196165 dose 3; Gsk706769; Gum arabic; Guna-anti interleukin 1; Guna-antiinterleukin 1 alfa; Guna-antiinterleukin 1 beta; Guna-interleukin 10; Guna-interleukin 4; Gw274150; Gw274150 tablets; Gw406381; Gw406381x; Gw856553; H.p. acthar gel; Ha20 (immu-106); Hb-admsc; Hbvaxpro; Hbvaxpro 5 micrograms/0.5 ml; Hbvaxpro 5 micrograms/0.5 ml suspension for injection hepatitis b vaccine (rdna); Hbvaxpro® 40 micrograms; Hd-tiv; He3286; Hematopoietic stem cell transplantation; Hepatitis a vaccine; Hepatitis a vaccine and tetanus vaccine; Hepatitis b vaccine (rdna); Hepatitis b virus surface antigen recombinant (s protein); Herpes zoster vaccine; High dose of biil 284 bs tablets; Hl237; Hlx01; Hm71224 food effect; Hm71224 multiple ascending dose; Hm71224 single ascending dose; Hmpl-523; Hril-2 active; Huang qi gui zhi wu wu granule; Huc-msc + dmards; Huc-msc suspension; Human anti tnf-alpha monoclonal antibody; Human anti-tnf igg1 monoclonal antibody; Human anti-tnf-alpha monoclonal antibody; Human anti-tnfalfa; Human monoclonal antibody directed against cd20 on b-cells; Human recombinant igg1, lambda; Humanised anti-cd 20 antibody; Humanised anti-cd4 igg1 monoclonal; Humanized immunoglobulin gamma 1 (igg1) kappa monoclonal antibody; Humanized tnfa monoclonal antibody; Humax-cd20; Humax-cd4; Humira; Humira (adalimumab); Humira 40 mg injeksjonsvæske, oppløsning, i ferdigfylt sprøyte; Humira 40 mg solution for injection in pre-filled syringe; Humira 40 mg/0.8 ml solution for injection; Humira 40mg solution for injection in pre-filled syringe (adalimumab); Humira 40mg/0.8ml solution for injection in pre-filled syringe; Humira sc; Humira*sc 2sir+f 40mg 0,8ml+2t; Humira, 40 mg solution for injection in pre-filled syringe; Humira®; Humira® (adalimumab); Humira® 40 mg solution for injection in pre-filled syringe; Hyaluronic acid; Hydroxide; Hydroxychloroquine; Hydroxychloroquine sulfate; Hydroxycholoquine; Hydroxycloroquina; Hylase; Hzt-501; Ib-meca; Ibandronate; Ibuprofen; Ibuprofen pch tablet 600mg; Icg-pulsion; Icp-022; Idec-c2b8 (rituximab); Iguratimod; Iguratimod (careram); Il-2; Il-6 receptor inhibitor, recombinant humanized monoclonal antibody; Ilv-094; Imatinib; Immune ablation and hematopoietic stem cell transplant; Immunoscintigraphy with radiolabeled cimzia®.; Immunosporin; Impact; Incb018424; Incb028050; Incb028050 phosphate; Incb028050 phosphate salt; Incb047986; Indocyanine green; Indocyanine green(icg); Infliximab; Infliximab (inf) + mtx, db; Infliximab (remicade); Infliximab + methotrexate (mtx); Infliximab 10 mg/kg; Infliximab 3 mg/kg; Infliximab [infliximab biosimilar 3]; Infliximab biosimilar; Infliximab control; Infliximab group; Infliximab increased dose; Infliximab increased frequency; Infliximab, etanercept; Infliximab, etanercept, adalimumab; Infliximab, methylprednisolone, methotrexate; Infliximab-eu; Infliximab-pfizer; Influenza vaccine; Influvac; Infusion without ald518`; Inn - filgotinib; Inn not available; Innovator infliximab; Insulin; Integrative medicine; Interleukin 10; Interleukin 2; Interleukin 4; Intra-articular compound betamethasone; Intra-articular tocilizumab; Intraarticular betamethasone; Intraarticular dexamethasone; Intraarticular injection; Intraarticular morphine; Intravenous (iv) abatacept; Intravenous dexamethasone 1 mg; Iodine; Ipi 145; Ipi-145; Isis 104838; Isis crp rx; Itacitinib; Iv abatacept; Iv golimumab; Jak1 / jak2 inhibtor; Jhl1101; Jnj-16240159-aac; Jnj-38518168; Jnj-38518168 (10 mg); Jnj-38518168 (3 mg); Jnj-38518168 (30 mg); Jnj-38518168 / mtx; Jnj-38518168 50-mg over encapsulated tablet; Jnj-39758979; Jnj-39758979 / mtx; Jnj-39758979-aac - enteric coated tablet - 10 mg; Jnj-39758979-aac - enteric coated tablet - 100 mg; Jnj-39758979-aac - enteric coated tablet - 30 mg; Jnj-40346527; Jnj-40346527-aac - capsule - 50 mg; Jte-051; Juanbi pill; K-832; Kb003; Kc706; Kenalog; Ketoprofen; Keyhole limpet hemocyanin; Kineret*sc 7sir 100mg 0,67ml; Kineret®; Kineret® (anakinra); Kolbet; Kr002524; Kunxian capsule; L-000124467; L-000124467 (freebase); L-000124467-009j (succinat; L-000883191; L-001069957; L01xc02; L04041); L04aa24; L04ab01; L04ab04; L04ab05; L04ab06; L04ac07; Lacosamide; Lamivudine; Lantarel; Large protein molecule; Lbal; Lbec0101; Ld-aminopterin; Ledertrexate; Leflunomide; Leflunomide (permitted, not necessary); Leflunomide 20 mg tablets (geneva pharmaceutical); Leflunomide 20mg tab; Leflunomide-sulfasalazine-hydroxychloroquine; Leucovorin; Levobupivacaine; Lidocaine; Lingzhi and sen miao san; Linolenic acid; Lipitor®; Lisinopril; Lnp1955; Lodotra®; Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol); Long-chain n-3 pufa; Long-circulating liposomal prednisolone; Loratadine; Losartan; Losec; Lovastatin; Low dose of biil 284 bs tablets; Loxoprofen; Lts 0.25mg; Lts 0.5mg; Lts 1.0mg; Lumiracoxib; Lx3305; Lx3305 dihydrate; Lx3305 high dose; Lx3305 low dose; Lx3305 mid dose; Ly2127399; Ly2127399 (tabalumab); Ly2189102; Ly2439821; Ly3009104; Ly3090106 - iv; Ly3090106 - sq; Ly3337641; M2951; M923; Mabioncd20; Mabthera; Mabthera (rituximab); Mabthera 500 mg; Mabthera 500 mg (10mg/ml); Mabthera 500 mg concentrado para solución para perfusión; Mabthera 500 mg concentrate for solution for infusion; Mabthera 500 mg konzentrat zur herstellung einer infusionslösung; Mabthera 500mg; Mabthera infusions; Mabthera*ev 1fl 50ml 500mg; Mabthera/rituxan; Mabthera®; Mabthera® (rituximab); Mabthera®, 100 mg concentrate for solution for infusion; Magnesium; Manufacturerd by cambridge therapeutic antibody centre, burroughs wellcome, glaxo wellcome); Maraviroc; Masitinib; Masitinib (ab1010); Masitinib 3 mg; Masitinib 6.0 mg; Masitinib mesylate; Mavrilimumab; Mavrilimumab 100 mg; Mavrilimumab 150 mg; Mavrilimumab 30 mg; Mbs2320; Mdx-1100; Mdx-1342; Medi-522; Medi4920; Medi5117; Medrol 4 mg tablets; Medrol a 16 mg tablets; Melatonin; Meloxicam; Meloxicam 0.125 mg/kg; Meloxicam 0.25 mg/kg; Meloxicam ampoule; Meloxicam cf tablet 7,5mg; Meloxicam oral suspension; Meloxicam tablet; Meriva; Mesalazine; Mesenchymal cell transplantation; Metex 10 mg/ml injektionslösung, fertigspritze; Metex 10mg tabletten; Metex 2,5mg; Metex 2,5mg tabletten; Metex 50 mg/ml injeksjonsvæske, oppløsning i ferdigfylt sprøyte; Metex 7,5mg tabletten; Metex®; Metex® 50 mg/ml injektionslösung, fertigspritze; Metformin; Metformin/cp-690,550; Methorexate; Methotrexat; Methotrexat hexal® 2,5 mg tabletten; Methotrexat lederle 2.5mg tablets; Methotrexate; Methotrexate 'lederle' 2,5mg tablets; Methotrexate 'lederle' 2.5mg tablets; Methotrexate (metoject® prefilled pen); Methotrexate (mtx); Methotrexate + biologic administration; Methotrexate + infliximab; Methotrexate + methylprednisolone; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate - amneal; Methotrexate - dava; Methotrexate - delay; Methotrexate - etanercept - prednisolone arm; Methotrexate - immediate; Methotrexate 2.5 mg tablets; Methotrexate 2.5mg tablets; Methotrexate 2.5mg tablets bp; Methotrexate 50mg/ml solution for injection, pre-filled syringe; Methotrexate as methotrexate disodium; Methotrexate capsules; Methotrexate disodium; Methotrexate pfizer 2,5 mg tabletter; Methotrexate placebo; Methotrexate plus enbrel or enbrel alone; Methotrexate plus erb-041 for 12 weeks; Methotrexate plus sulfasalazine; Methotrexate pre-filled pen; Methotrexate prefilled pen; Methotrexate prefilled syringe; Methotrexate sodium; Methotrexate sodium 2.5mg tablets; Methotrexate sodium tablets 2.5 mg; Methotrexate(mtx); Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol.; Methotrexate(necessary); Methotrexate*100cpr 2,5mg; Methotrexate, leucovorin and bms-986142; Methotrexate,adalimumab; Methotrexate-lachema; Methotrexate-sulfasalazine-hydroxychloroquine; Methotrexate® 2.5 mg tablets; Methotrextate; Methoxsalen; Methyl 1-[n6-(3-iodobenzyl)-adenin-9-yl]-beta-dribofuronamide; Methyl 1-[n6-(3-iodobenzyl)-adenin-9-yl]-ß-dribofuronamide; Methylaminopterin; Methylprednisolone; Methylprednisolone sodium succinate; Methylprednisone; Metoject; Metotrexato; Metotrexato sodio; Metronidazol; Metronidazole; Mextrex; Micellar paclitaxel for injection; Microgynon® 30 (oral contraceptive); Midazolam; Milnacipran; Minocycline; Minodronate; Minodronic acid; Misoprostol; Mizoribin; Mk-0663; Mk-0873; Mk-8457; Mk-8457 100 mg; Mk-8808; Mk0359; Mk0663, etoricoxib; Mk0812; Mk0812 / duration of treatment: 12 weeks; Mk0966; Mln3897; Mlta3698a; Mm-093; Monitor; Montelukast; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142; Mor103; Morab-022; Morphine; Morphine hexal; Morphine sulfate; Morphinsulfat; Moxifloxacin; Mp-435(dose1) + methotrexate; Mra (tocilizumab); Mra(tocilizumab); Mra-sc; Mrc375; Mrc375 150mg; Msb11022; Mt203; Mtrx1011a; Mtx plus anti-tnf; Mtx start; Mtx therapy; Multigrain powder (s); Mushroom extract; Mussel oil capsules; N-3 lc-pufa; N.a.; Namilumab; Namilumab (mt203); Nanocort; Naprosyn 500 mg; Naproxen; Naproxen (ec-narosyn) delayed release tables, 375 (syntex (usa), inc.); Naproxen 10 mg/kg; Naproxen 500 mg tablets (pn 200 minus omeprazole); Naproxen delayed release tables, 375 (gevena pharmaceuticals, inc.); Naproxen oral suspension; Naproxen pch tablet 500mg; Naproxen sodium 550mg tablet; Natalizumab; Natriumklorid 9mg/ml; Nc-503 (anti-amyloidotic (aa) agent); Nerve block; New formulation adalimumab; New formulation etanercept; Ni-0101; Ni-071; Niclosamide; Nimesulide; Nitric oxide; Nitroglycerine; Niubangzi pill; Nivolumab; Nnc 0109-0000-0012; Nnc 0141-0000-0100; Nnc 0142-0000-0002; Nnc 0151-0000-0000; Nnc 142-0002; Nnc0109-0012; Nnc0114-0000-0005; Nnc0114-0006; Nnc0142-0002; Nnc0151-0000-0000; Nnc0215-0384; Nnc151-0000; Non-anti-tnf biologics; Non-biologic anti-rheumatic drugs; Non-biologic disease modifying anti-rheumatic drug (dmard); Non-biological dmard's; Non-mtx dmards (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin); Non-steroidal anti-inflammatory drug (nsaid); Nonbiologic dmards of investigator's choice; None; None as of yet; Norethindrone; Normal saline; Nsaids; Nsaids (permitted,not necessary); Null; Nulojix; Ocrelizumab; Ocrelizumab / rhumab 2h7; Ocrelizumab 500mg; Ocrelizumabu 200mg; Ocrelizumabu 50mg; Ofatumumab; Olikizumab; Olokizumab; Olokizumab 120 mg; Olokizumab 240 mg; Olokizumab 60 mg; Olokizumab 64 mg sc q2w; Olokizumab 64 mg sc q4w; Olokizumab 64mg q2w; Olokizumab 64mg q4w; Olokizumab q2w; Olokizumab q4w; Olumiant; Omega-3; Omega-3 and vitamin e supplementation; Omega-3 fatty acid; Omega3; Omega3 fatty acids; Omegaven (10% fish-oil emulsion; Omeprazole; Oncoxin + viusid; Open-label abatacept; Open-label adalimumab; Open-labeladalimumabrescue; Oral bovine type ii collagen; Oral methotrexate; Oral scio-469 capsule; Orencia; Orencia (abatacept); Orencia 125 mg; Orencia 125 mg solution for injection; Orencia 125 mg, solution injectable en seringue préremplie; Orencia 250mg powder for concentrate for solution for infusion; Orencia abatacept; Orencia subcutaneous injection; Originator; Originator (legacy) drug; Originator rituximab - rituxan ® or mabthera ®; Ortho-novum® 1/35; Otelixizumab; Other biological agent; Other biologics; Other dmards; Other non steroidal anti-inflammatory drugs (nsaids) except etodolac; Otl38; Overencapsulated prednisolone tablets; Oxicodone dc.it; Oxycodone; Oxycodone by patient-controlled analgesia (pca); Oxygen; Ozoralizumab; P38 (4) map kinase inhibitor; P38 inhibitor (4); P38 inhibitor (4) 150mg; P38 inhibitor (4) 25mg; P38 inhibitor (4) 300mg; P38 inhibitor (4) 50mg; P38 inhibitor (4) 75mg; P38(4) map kinase inhibitor; Paclitaxel; Panax quinquefolius; Pandemrix,; Paracetamol; Paracetamol (acetaminophen); Paracetamolo dc.it fu; Parecoxib; Paroxetine; Paroxetine & prednisolone; Paroxetine hydrochloride 10 & 20 mg and prednisolone 1 mg bp; Part a; Part b; Patient current care; Patient treated with dmard; Patients' existing non-steroidal anti-inflammatory drug (nsaid) at approved doses; Pd 0360324; Pda001; Peficitinib; Pegsunercept; Pegsunercept (peg stnf-ri); Pelubiprofen; Pelubiprofen 30 mg; Peri-neural dexamethasone 1 mg; Permitted dmards; Persantin 100 mg and; Pertussis vaccine; Pf-04171327; Pf-04171327 10 mg; Pf-04171327 25 mg; Pf-05280586; Pf-06410293; Pf-06438179; Pf-06650833; Pf-06651600; Pf-06835375; Pg-760564; Ph-797804; Phase 1: conventiaonal dmard; Phase 1: etanercept; Phase 1: methotrexate; Phase 2: optional etn, ssz, hcq, mtx; Phosphate; Pig whipworm eggs; Pioglitazone; Pirfenidone; Pl 00095/5079r; Pla + mtx switched to aba+ mtx, db; Pla-695; Placebo; Plaebo; Plaquenil; Plaquenil 200 mg filmdrasjerte tabletter; Plasma analysis for bacterial translocation; Platelet rich plasma; Plx3397; Plx5622; Pn 200 tablets (500 mg naproxen and 20 mg omeprazole); Pneumo23 / pneumovax; Pneumococcal conjugate vaccine; Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) conjugated to crm197 carrier protein and adsorbed on aluminium phosphate; Pneumococcal polysaccharide serotype 1, 2, 3, 4, 5, 6b, 7f, 8, 9n, 9v, 10a, 11a, 12f, 14, 15b, 17f, 18c, 19a, 19f, 20, 22f, 23f and 33f; Pneumococcal polysaccharide serotype 1, 3, 4, 5, 6a, 6b, 7f, 9v, 14, 18c, 19a, 19f and 23f; Pneumococcal polysaccharide vaccine; Pneumococcal polysaccharide vaccine (23 valent); Pneumovax; Pneumovax 23; Potassium; Potassium supplement; Pr-06410293; Pralia 60 mg subcutaneous injection syringe(denosumab); Pralia 60mg subcutaneous injection syringe(denosumab); Pravastatin; Prd4862257; Pre-filled syringe; Pred; Pred + meth; Prednihexal; Prednihexal® 10mg tabletten; Prednihexal® 20mg tabletten; Prednihexal® 5mg tabletten; Prednihexal® 5mg tabletten, prednihexal® 10mg tabletten; Prednihexal® 5mg tabletten, prednihexal® 20mg tabletten; Predniso; Prednisolon; Prednisolone; Prednisolone & dipyridamole; Prednisolone 20 mg; Prednisolone 40 mg; Prednisolone 5 mg; Prednisolone tablets bp; Prednisolone tablets usp 5 mg; Prednisolone-dipyridamole; Prednison; Prednisone; Prednisone 15 mg; Prednisone 5 mg; Prednisone 7.5 mg; Prednisone tablets usp, 1 mg; Prednisone tablets usp, 5 mg; Pregabalin; Prevenar 13; Prevenar vaccination; Prevenar vaccine; Previously known as r935788; Primus; Pro283698; Probiotic capsules containing lactobacillus rhamnosus gr-1 and l. reuteri rc-14; Progressive spacing of tnf-blocker injections; Propofol; Propolipid; Proposed inn - filgotinib; Propsoed inn - filgotinib; Protein; Prtx-100 at 1.5 mcg/kg; Prtx-100 at 12.0 mcg/kg; Prtx-100 at 240 mcg; Prtx-100 at 3.0 mcg/kg; Prtx-100 at 420 mcg; Prtx-100 at 6.0 mcg/kg; Puerarin; Puerarin injection 400 mg; Puerarin tablet 50 mg; Qal964; Qingkailing injection 40 ml; Quensyl; R788; R788 sodium hexahydrate, rig2-01, rig-g; R788 sodium, r788 na, r788; R935788; Radiofrequency; Raloxifene; Raloxifene hydrochloride; Ramelteon; Ramipril; Rapamycin; Raptiva 100 mg/ml powder and solvent for solution for injection; Rayos (delayed-release prednisone); Rc18 160 mg plus mtx; Rebamipide; Recombinant factor fc fusion protein; Recombinant human anti il-22 monoclonal antibody igg1; Recombinant human mab of igg4 subtype; Recombinant human monoclonal antibody; Recombinant human monoclonal antibody to inerleukin-1beta of the igg1-k-class; Recombinant humanised anti-human monoclonal antibody directed against the il-6r; Recombinant humanized anti-human monoclonal antibody directed against the il-6r; Recombinant tnf-a receptor: igg fc fusion protein; Reference1505; Regn88; Remicade; Remicade (infliximab); Remicade 100 mg pulver til konsentrat til infusjonsvæske, oppløsning.; Remicade*ev f 100mg+f 2ml; Remicade®; Remicade® (infliximab); Remsima; Remsima (infliximab); Remsima - 100 mg polvere per concentrato per soluzione per infusione - uso endovenoso - flanconcino (vetro) - 1 flaconcino; Repository corticotropin injection; Response to anakinra associated with methotrexate; Response to infliximab associated with methotrexate; Reumatocept (etanercept); Revamilast; Rgb-03; Rheumatoid arthritis with disease-modifying drugs (dmards); Rhumab 2h7; Rhumab to il-17a (igg1-k-class); Rhustoxicodendron 30; Rhutnfr; Rhutnfr:fc; Ribazen; Riboflavin; Rifampicin; Rimacalib; Risedronate; Ritumax®; Rituxan; Rituxan (inn: rituximab), brand name in the united states; Rituxan/sait101; Rituxan®; Rituxan® (rituximab); Rituximab; Rituximab - mabthera; Rituximab [mabthera/rituxan]; Rituximab [mabthera]; Rituximab mabthera; Rituximab, mtx, folic acid; Rituximab, observational study amon patients with active ra; Rituximab-eu+ rituximab-pfizer x 2 courses; Rituximab-pfizer (pf-05280586) x 3 courses; Rituximab-us + rituximab-pfizer x 2 courses; Rivaroxaban; Ro 001-9265/f02-01; Ro 002-9893/f02; Ro 45-2294; Ro 487-7533; Ro 487-7533/f01; Ro 487-7533/f10; Ro 487-7533/f10-02; Ro 487-7533/f10-04; Ro 496-4913; Ro 496-4913/f03; Ro 551-6922; Ro actemra; Ro-actemra; Ro001-9265/f04; Ro0029893; Ro045-2294; Ro04877533; Ro0506997; Ro4402257; Ro487-7533; Ro487-7533/f01-f05; Ro487-7533/f10-04; Ro4877533; Ro4877533 (tcz); Ro7010939; Ro7123520; Ro7123520/f03-01; Roactemra; Roactemra 162 mg; Roactemra 162 mg solution injectable en seringue préremplie; Roactemra 20 mg/ml concentrado para solución para perfusión; Roactemra 20 mg/ml concentrate for solution for infusion; Roactemra 20 mg/ml concentrate for solution for infusion.; Roactemra 20 mg/ml, concentrado para solución para perfusión; Roactemra®; Roactemra®ev product code: prd82321; Roactmera; Rob 803; Rob 803 (9-chloro-2,3-dimethyl-6-(n,n-dimethylaminoethylamino-2-oxoethyl)-6h-indolo[2,3-b] quinoxali; Rob 803 12.5mg capsule; Rob 803 15mg capsule; Rob 803 25mg capsule; Rob 803 6.25mg capsule; Ropivacaine; Rosiglitazone; Rosiglitazone extended release tablets; Rosiglitazone maleate; Rosiglitazone xr; Rosuvastatin; Roxithromycin; Rtnv148b igg; Rupatadine; Rwj-445380 100 mg; Rwj-445380 200 mg; Rwj-445380 300 mg; Rwj-445380 capsule 100 mg; Rwj-445380 capsules 150 mg; Rwj-445380 capsules 50 mg; Rwj-445380-002; S(-)-3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1(2h)-yl]-n,4-dimethylbenzamide; Sait101; Sait101 (proposed rituximab biosimilar); Salazopyrin en 500 mg enterotabletter; Salazopyrin en-tabs; Salazopyrine; Salazosulfapyridine; Same; San-300; Sar153191; Sar153191 (regn88); Sarilumab; Sarilumab sar153191 (regn88); Sb-681323; Sb-681323 oral tablets; Sb-681323 tablets; Sb2 (infliximab biosimilar); Sb2 (proposed biosimilar to infliximab); Sb4 (etanercept biosimilar); Sb4 (proposed biosimilar to etanercept); Sb5 (proposed biosimilar to adalimumab); Sbi-087; Sc golimumab; Sc12267; Sc12267 (4sc-101); Sch 900259; Scio-469; Sd-qiv; Seasonal influenza vaccine; Secukinumab; Secukinumab (ain457); See d.3.9.3 'other descriptive name' below; Sham; Shingrix; Shr0302; Sildenafil; Simponi; Simponi 50 mg injeksjonsvæske, oppløsning i ferdigfylt sprøyte.; Simponi®; Simvastatin; Sirolimus; Sirukuma; Sirukumab; Sirukumab 100 mg; Sirukumab 50 mg; Ski-o-703; Ski-o-703 capsule; Smp-114; Sodium aurothiomalate; Sodium aurothiomalate (intramuscular gold); Sodium chloride; Sodium-[o-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate; Solu-medrone 125mg; Solu-medrone 2 gram; Solu-medrone 2mg; Somatropin; Somatropin [rdna origin] for injection; Ssr150106xb; Sta 5326 mesylate; Stable weekly dose of methotrexate; Statins; Stem cell transplantation; Steroids; Stnf-r1; Stool analysis; Subcutaneous (sc) abatacept; Subcutaneous abatacept; Subcutaneous tocilizumab; Subcutaneous(sc) abatacept; Subcutanious administration; Sublingual nitroglycerine; Sulfasalazine; Sulfate; Sulphasalazine; Sulphasalazine + hydroxychloroquine or prednisolone; Sunflower oil; Sunpharma1505 1; Sunpharma1505 2; Suspension ir; Synovial biopsy; Synthetic dmard(s); Systemic non-biological treatments; T-614; T0001; Ta-650 (infliximab); Ta-650 10 mg/kg; Ta-650 3 mg/kg; Ta-650 6 mg/kg; Tab08; Tabalumab; Tabalumab auto-injector; Tabalumab prefilled syringe; Taci-fc5; Tacrolimus; Tacrolimus (prograf®); Tacrolimus with methotrexate; Tak-715; Tak-783; Tas5315 high dose; Tas5315 low dose; Tasocitinib; Tasocitinib plus methotrexate; Tc 99m tilmanocept; Tc99m-tilmanocept; Tdmards; Teriparatide; Tetanus + pnemococcal vaccines alone; Tetanus toxoid adsorbed booster vaccine; Tetanus toxoid adsorbed vaccine; Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed); Tetraccycline; Tetraccycline-hydrochloride; Tetracycline; The effectiveness of xeljanz in rheumatoid arthritis patients; Therapy with disease-modifying anti rheumatic drugs (dmard); Ticagrelor; Tick-borne encephalitis virus (inactivated); Tilmanocept; Titan; Tl011; Tl011, anti cd20, for the treatment of rheumatoid arthritis; Tmi-005; Tmi-005 (way-177005); Tnf alpha blockers; Tnf alpha inhibitors; Tnf antagonist; Tnf antagonist (enbrel, humire, remicade, cimzia, symponi); Tnf blockers (infliximab, adalimumab, etanercept); Tnf blockers monotherapy; Tnf inhibitor; Tnf inhibitor/tcz; Tnf inhibitors; Tnf start; Tnf-a antagonists, non-tnfs, dmard non-biologics; Tnf-alpha antagonist and other biotherapy; Tnf-alpha antagonists; Tnf-alpha inhibitor; Tnf-blockers suspension in patients with rheumatoid arthritis; Tnf-k; Tnf-kinoid; Tnfr:fc; Tnr-001; To be confirmed; Tocilizumab; Tocilizumab (actemra®); Tocilizumab + methotrexate(mtx); Tocilizumab 162 mg; Tocilizumab 162mg/0.9ml jeringa sc; Tocilizumab [roactemra/actemra]; Tocilizumab [roactemra]; Tocilizumab prefilled syringe; Tocilizumab sc; Tocilizumab+methotrexate(mtx); Tocilizumab, abatacept; Tocilizumabum; Tofacitinib; Tofacitinib (xeljanz); Tofacitinib 5 mg; Tofacitinib 5 mg [xeljanz]; Tofacitinib 5mg po bid; Tofacitinib citrate; Tofacitinib citrate (clinical trial image); Tofacitinib citrate (commercial image); Tofacitinib citrate cp-690550; Tofacitinib with methotrexate; Tofacitinib without methotrexate; Tofacitinib/baricitinib; Toldc; Tolerogenic dendritic cells; Tolicizumab; Topical compound tripterygium; Topical tripterygium gel; Tramadol; Tramadol hydrochloride + acetaminophen; Tranexamic acid; Tranilast; Treatment a; Treatment b; Treatment c; Treatment of mtx; Treatment of mtx and hcq; Treatment of mtx and twhf; Treatment of tcm; Treatment of twhf; Tregalizumab; Trexan; Trexan+salazopyrin+oxiklorin+prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Triam 40 mg lichtenstein; Triamcinolonacetonid; Triamcinolonacetonid ep; Triamcinolone; Triamcinolone acetonide; Triamcinolone hexacetonid (lederspan); Triamcinolone hexacetonide; Triamcinolone hexacetonide (lederspan); Trichuris suis ova; Tripterygium; Tripterygium wilfordii; Tripterygium wilfordii hook f; Tripterygium wilfordii hook f (twhf); Trivalent inactivated influenza vaccine; Tru-015; Ts-152; Tuberculin ppd; Tuberculin ppd rt 23 ssi for mantoux testing; Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); Twhf; Uc-msc+dmards; Uc-mscs; Ucb4940; Uk-427,857; Umbilical cord mesenchymal stem cells; Umbilical cord-derived mesenchymal stem cells (uc-mscs); Upadacitinib; Urine samples taken to measure methotrexate and its major metabolite 7-oh-methotrexate level; Ustekinumab; Uvadex; Uvedose; Valdecoxib; Vancomycin; Varicella zoster vaccine; Vay736; Velcade®; Veltuzumab; Veltuzumab solution 75mg/ml; Venlafaxine; Venlafaxine hydrochloride; Venous blood sample; Vitamin d; Vitamin d in arm b; Vitamin d3; Vitamin e; Vitamin k; Voltrarol sr; Vx-509; Vx-702; Warfarin; Water; Way-177005; Whale blubber oil; Whey protein&prebiotic supplement; Xeljanz; Xeljanz 5mg tablet; Xenp5871; Xinfeng capsule; Xmab5871_0.3mg; Xmab5871_1.0mg; Xmab5871_10.0mg; Xmab5871_3.0mg; Xmab®5871; Xoma 052; Yellow fever vaccine; Yellow fever vaccine (17d); Yisaipu; Ylb113; Yra-1909 high dose; Yra-1909 low dose; Yra-1909 mid dose; Z102; Z102 (prednisolone and dipyridamole).; Zd 4522; Zoledronate; Zoledronic acid; Zostavax (varicella zoster virus) vaccine; Zostavax vaccine; [18f]peg-folate

No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02903212	March 2020	27 May 2019	Tolerance and Effectiveness of Cell Therapy by Autologous Apoptotic Cells in the Treatment of Rheumatoid Arthritis	Tolerance and Effectiveness of Cell Therapy by Autologous Apoptotic Cells in the Treatment of Rheumatoid Arthritis	Arthritis, Rheumatoid	Biological: Autologous apoptotic cells injection	Centre Hospitalier Universitaire de Besancon		Not recruiting	18 Years	80 Years	All	22	Phase 1/Phase 2
2	NCT04086745	January 2, 2020	11 November 2019	A Study of Baricitinib in Participants With Rheumatoid Arthritis	A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Baricitinib;Drug: TNF Inhibitor	Eli Lilly and Company	Incyte Corporation	Not recruiting	18 Years	N/A	All	1300	Phase 4
3	NCT04115423	January 1, 2020	14 October 2019	A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab	A Retrospective Cohort Study to Examine the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab Compared With Tumor Necrosis Factor Inhibitors Using the National Health Insurance Database	Infection;Rheumatoid Arthritis	Drug: Tocilizumab;Drug: Tumor Necrosis Factor Inhibitor (etanercept, infliximab, adalimumab, and golimumab)	Sungkyunkwan University	Ministry of Food and Drug Safety, Korea	Not recruiting	18 Years	N/A	All	4540	Phase 4
4	NCT04117165	January 1, 2020	14 October 2019	Assessment of the Clinical and Medico-economic Impact of SinnoTest® in Patients With Rheumatoid Arthritis	Assessment of the Clinical and Medico-economic Impact of SinnoTest®, a Software That Predicts the Effectiveness of Biotherapy Treatments, in Patients With Rheumatoid Arthritis (RA)	Arthritis, Rheumatoid;Biological Therapy	Diagnostic Test: Biotherapy Prescription with SinnoTest® software;Drug: Patient Current Care	University Hospital, Grenoble		Not recruiting	18 Years	70 Years	All	180	N/A	France
5	NCT04115397	January 2020	22 October 2019	Bisphosphonates for the Treatment of Seropositive Musculoskeletal Complaints	Towards Efficient Prediction and Prevention of Rheumatoid Arthritis	Seropositive Muskuloskeletal Complaints	Drug: Zoledronic Acid;Drug: Placebo	Karolinska Institutet		Not recruiting	18 Years	N/A	All	80	Phase 4
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	NCT04078191	December 2019	16 September 2019	Comparison of Tc 99m Tilmanocept Quantitative Imaging With Immunohistochemical (IHC) Analysis of CD206 Expression in Synovial Tissue of Subjects With Rheumatoid Arthritis (RA)	A Comparison of Tc 99m Tilmanocept Quantitative Imaging With Immunohistochemical (IHC) Analysis of CD206 Expression in Synovial Tissue From Subjects Clinically Diagnosed With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Tc 99m tilmanocept	Navidea Biopharmaceuticals		Not recruiting	18 Years	N/A	All	24	Phase 2	United Kingdom
7	JPRN-jRCTs071190030	01/11/2019	5 November 2019	Non-inferiority trial of efficacy after switching from Remicade to infliximab BS[CTH] in rheumatoid arthritis patients	Non-inferiority trial of clinical non-relapse rate after switching from Remicade to infliximab BS[CTH] in rheumatoid arthritis patients with clinical remission, a multicenter prospective trial - IFX-SIRIUS STUDY I	Rheumatoid arthritis	Rheumatoid arthritis patients who have been treated with Remicade over 24 weeks and persisted with clinical remission are switched to infliximab BS [CTH] from Remicade. The dose and infusion intervals of infliximab BS[CTH] are kept unchanged from those of Remicade.	Atsushi Kawakami		Recruiting	>= 20age old	Not applicable	Both	80	Phase 4	none
8	NCT04134728	November 1, 2019	4 November 2019	Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors	A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors	Arthritis, Rheumatoid	Biological: GSK3196165;Biological: Sarilumab;Drug: Placebo to GSK3196165/ Sarilumab;Drug: csDMARDs	GlaxoSmithKline	Iqvia Pty Ltd	Not recruiting	18 Years	N/A	All	525	Phase 3	United States
9	NCT04130178	October 25, 2019	28 October 2019	Nerve Block of the Proximal Interphalangeal Joints PIPs in Rheumatoid Arthritis (RA) Patients: a Prospective Pilot Study	Nerve Block of the Proximal Interphalyngeal Joints PIPs in Rheumatoid Arthritis (RA) Patients: a Prospective Pilot Study	Rheumatoid Arthritis	Drug: Nerve block	Sohag University		Recruiting	18 Years	N/A	All	42	N/A	Egypt
10	NCT04120831	October 7, 2019	22 October 2019	TOLERA: Tolerance Enhancement in RA	Sequential B Cell/T Cell Therapy to Re-induce Humoral Immune TOLErance in ACPA- Positive Rheumatoid Arthritis A Prospective, Randomized Controlled Open Label Single-centre Clinical Trial in Adult Subjects With Active ACPA-positive Rheumatoid Arthritis Failing Methotrexate	Rheumatoid Arthritis	Drug: Abatacept Injection	University of Erlangen-Nürnberg Medical School		Recruiting	18 Years	N/A	All	20	Phase 2	Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
11	JPRN-JapicCTI-194932	01/10/2019	5 November 2019	An Extension Study of TS-152 in Subjects with Rheumatoid Arthritis	An Extension Study of TS-152 in Subjects with Rheumatoid Arthritis	Rheumatoid Arthritis	Intervention name : ozoralizumab INN of the intervention : ozoralizumab Dosage And administration of the intervention : Subcutaneous injection of TS-152 30mg or TS-152 80mg every 4 weeks Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : -	Taisho Pharmaceutical Co.Ltd		Recruiting	20		BOTH	505	Phase 3	Japan
12	NCT04077567	October 1, 2019	22 October 2019	An Extension Study of TS-152 in Subjects With Rheumatoid Arthritis	An Extension Study of TS-152 in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: TS-152	Taisho Pharmaceutical Co., Ltd.		Recruiting	20 Years	N/A	All	505	Phase 3	Japan
13	NCT03828344	October 2019	11 February 2019	Safety and Tolerability of a Single Intravenous Infusion of BX-U001 in Refractory Rheumatoid Arthritis	A Phase 1 Randomized, Placebo-Controlled, Double-Blind Study of the Safety and Tolerability of a Single Intravenous Infusion of BX-U001, a Human Umbilical Cord Tissue Derived Mesenchymal Stem Cell Product, for Refractory Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: hUC-MSC suspension;Biological: Placebo	Baylx Inc.		Not recruiting	18 Years	70 Years	All	16	Phase 1
14	NCT04136262	October 2019	4 November 2019	Tripterygium Wilfordii Hook F and Methotrexate for Postmenopausal Women With Rheumatoid Arthritis	Tripterygium Wilfordii Hook F and Methotrexate for Postmenopausal Women With Rheumatoid Arthritis: a Randomized Controlled Trial	Rheumatoid Arthritis	Drug: Tripterygium wilfordii Hook F (TwHF);Drug: Methotrexate;Other: Dummy Tripterygium wilfordii Hook F (TwHF)	Guang'anmen Hospital of China Academy of Chinese Medical Sciences		Not recruiting	N/A	N/A	Female	300	Phase 2/Phase 3
15	ChiCTR1900026257	2019-09-28	30 September 2019	A Randomized, Double-Blind Clinical Trial for Effect of Wisconsin Ginseng (Panax quinquefolius) in Improvement of Rheumatoid Arthritis Associated Fatigue	Efficacy, dose comparison, and safety of Wisconsin Ginseng (Panax quinquefolius) in patients with rheumatoid arthritis associated fatigue: Three-arm parallel, multicenter, randomized, double-blind, placebo-controlled, phase 2 trial	Rheumatoid arthritis (RA)	High-dose experimental group :6000mg Wisconsin ginseng (Panax quinquefolius) herb intervention: 3000mg, orally, twice daily (bid) Capsule (6 capsules / 500mg) ;Low-dose experimental group:3000mg Wisconsin ginseng (Panax quinquefolius) herb intervention: 1500mg, orally, twice daily (bid) Capsule (3 capsules / 500mg); 3000mg Placebo: 1500mg, orally, twice daily (bid) Capsule (3 capsules / 500mg) ;Control group :6000mg Placebo: 3000mg, orally, twice daily (bid) Capsule (6 capsules / 500mg) ;	Zhejiang Provincal Hospital of TCM		Not Recruiting	18	70	Both	High-dose experimental group :30;Low-dose experimental group:30;Control group :30;	Phase 2	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
16	NCT03971253	September 2, 2019	28 October 2019	Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis	Japan Post-Marketing Surveillance - Specified Drug Use-results Survey for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis	Rheumatoid Arthritis (RA)	Drug: Peficitinib	Astellas Pharma Inc		Recruiting	N/A	N/A	All	3000	Phase 4	Japan
17	NCT03895879	September 2019	30 September 2019	Use of Tocilizumab Drug Levels to Optimize Treatment in RA	Concentration-guided Dose Reduction Versus Standard Dosing in Tocilizumab-treated Rheumatoid Arthritis Patients: a Randomised, Multicenter, Non-inferiority Trial (TODORA)	Rheumatoid Arthritis	Drug: Tocilizumab	Reade Rheumatology Research Institute	ZonMw: The Netherlands Organisation for Health Research and Development	Recruiting	18 Years	N/A	All	98	Phase 4	Netherlands
18	NCT03938701	September 2019	26 August 2019	Fluorescence Imaging of Disease Activity in IBD and Rheumatoid Arthritis Using OTL38	Fluorescence Imaging for the Evaluation of Disease Activity in IBD and Rheumatoid Arthritis Using the Fluorescent Tracer OTL38 Targeting the Folate ß Receptor: a Single-center Pilot Study	IBD;Rheumatoid Arthritis	Drug: OTL38;Device: Fluorescence Imaging	University Medical Center Groningen	GlaxoSmithKline;On Target Laboratories, LLC;VU University Medical Center	Not recruiting	18 Years	N/A	All	30	Phase 1	Netherlands
19	NCT03976245	September 2019	22 July 2019	Advanced Therapeutics in Rheumatoid Arthritis (RA)	Advanced Therapeutics in Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Etanercept;Drug: tofacitinib	Lawson Health Research Institute	Academic Medical Organization of Southwestern Ontario	Not recruiting	18 Years	N/A	All	144	Phase 4	Canada
20	JPRN-JapicCTI-194928	26/8/2019	10 September 2019	-An assessor-blinded, subject-blinded, double-dummy, active-controlled, randomised trial to compare the safety and efficacy of subcutaneous methotrexate (MJK101) with oral methotrexate in methotrexate-naive subjects with active rheumatoid arthritis followed by an open-label, single-arm extension to assess the long-term safety of MJK101	An assessor-blinded, subject-blinded, double-dummy, active-controlled, randomised trial to compare the safety and efficacy of subcutaneous methotrexate (MJK101) with oral methotrexate in methotrexate-naive subjects with active rheumatoid arthritis followed by an open-label, single-arm extension to assess the long-term safety of MJK101	Rheumatoid Arthritis	Intervention name : methotrexate INN of the intervention : methotrexate Dosage And administration of the intervention : Part 1: 7.5 mg MJK101 (SC) or dummy MJK101 (SC) will be administered once a week over a period of 12 weeks. Part 2: All subjects will receive once-weekly MJK101 (SC) for 12 months. At Trial Week 12, the once-weekly dose of MJK101 (SC) will be determined according to the disease activity status of the subject and an assessment of safety. If the subject has not met a low disease activity status at the visits every 4 weeks and has been well tolerated, then the once-weekly MJK101 (SC) dose will be increased by 2.5 mg to a maximum dose of 15 mg. Control intervention name : methotrexate INN of the control intervention : methotrexate Dosage And administration of the control intervention : Part 1: 8 mg MTX (oral) or placebo MTX (oral) will be administered once a week over a period of 12 weeks. The oral administration of MTX or placebo MTX will be divided into 2 doses to be administered approximately within a 12-hour interval.	medac GmbH		Recruiting	20	75	BOTH	100	Phase 3	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
21	NCT04004429	August 26, 2019	11 November 2019	A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease	A Double-blind, Multicenter, Two-part, Randomized, Placebo-controlled Study of the Safety, Tolerability, and Efficacy of 4 Weeks Treatment With AP1189 in Early Rheumatoid Arthritis (RA) Patients With Active Joint Disease	Rheumatoid Arthritis	Drug: 50 mg AP1189;Drug: AP1189;Drug: Placebo	SynAct Pharma Aps		Recruiting	18 Years	85 Years	All	90	Phase 2	Denmark
22	ChiCTR1900025013	2019-08-08	27 August 2019	Clinical observation of multiple dose use of tranexamic acid in patients with rheumatoid arthritis after total knee arthroplasty	Effects of multiple dose use of tranexamic acid on blood loss and inflammatory factors after total knee arthroplasty in patients with rheumatoid arthritis	Total knee arthroplasty	group 1:Intravenous infusion of 1g of tranexamic acid + 100 ml 3 hours after surgery, intravenous infusion of 100 ml of normal saline 6 and 12 hours after surgery.;group 2:Intravenous infusion of 1g of tranexamic acid + 100 ml of normal saline at 3, 6, and 12 hours after surgery;	Guanghua Hospital, Shanghai University of Traditional Chinese Medicine		Recruiting	50	75	Both	group 1:38;group 2:38;	Phase 4	China
23	ChiCTR1900024902	2019-08-01	27 August 2019	A randomized, double-blind, prospective, controlled trial for Yishen-Tongbi-Tang in the treatment of active rheumatoid arthritis	A randomized, double-blind, prospective, controlled trial for Yishen-Tongbi-Tang in the treatment of active rheumatoid arthritis	Rheumatoid Arthritis	Experimental group:Traditional Chinese medicine (Yi-Shen Tong-Bi Tang);Positive control group:Methotrexate;	The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine		Not Recruiting	18	65	Both	Experimental group:50;Positive control group:50;	N/A	China
24	NCT02418273	August 1, 2019	16 December 2017	Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders	Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders: a Pilot Study	Osteoporosis;Juvenile Rheumatoid Arthritis;Dermatomyositis;Polyarthritis;Systemic Lupus Erythematosis;Vasculitis;Glucocorticoid-induced Osteoporosis	Drug: denosumab	Indiana University		Not recruiting	4 Years	16 Years	All	24	Phase 1/Phase 2	United States
25	NCT04068246	August 1, 2019	2 September 2019	The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients	The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.	Rheumatoid Arthritis	Drug: Metformin	Sadat City University		Recruiting	18 Years	N/A	All	100	Early Phase 1	Egypt
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
26	ChiCTR1900025021	2019-07-25	27 August 2019	Safety, Tolerance and Pharmacokinetics of Single Administration of Meloxicam Suspension Injection in Healthy Chinese Subjects	Safety, Tolerance and Pharmacokinetics of Single Administration of Meloxicam Suspension Injection in Healthy Chinese Subjects	Osteoarthritis, rheumatoid arthritis	A:TR group: phase I: Meloxicam Suspension Injection (T) 7.5 mg, phase II: Mobi (R) 7.5 mg; RT group: phase I: R, phase II: T.;B:Meloxicam Suspension Injection 15 mg;C:Meloxicam Suspension Injection 30 mg;D:Meloxicam Suspension Injection 60 mg;	Center for Clinical Pharmacology, the Third Xiangya Hospital, Central South University		Recruiting			Both	A:12;B:12;C:12;D:12;	Phase 1	China
27	ChiCTR1900024261	2019-07-15	15 July 2019	Efficacy and safety of sirolimus in new-onset rheumatoid arthritis: a prospective, double-blinded, randomized, placebo-controlled, monocentric study in China	Efficacy and safety of sirolimus in new-onset rheumatoid arthritis: a prospective, double-blinded, randomized, placebo-controlled, monocentric study in China	rheumatoid arthritis	A:methotrexate (7.5~15 mg/week)+ placbo (1 mg/d);B:sirolimus (1 mg/d) + methotrexate (7.5~15 mg/week);	The Second Hospital of Shanxi Medical University		Not Recruiting	18	65	Both	A:30;B:30;	Phase 4	China
28	NCT04018599	July 15, 2019	30 September 2019	Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS	A Phase I, Randomized, Open-label, Parallel-group Study to Determine the Pharmacokinetics, Safety, and Tolerability of MSB11022 (Proposed Adalimumab Biosimilar) Following a Single Subcutaneous Injection by an Auto-injector or by a Pre-filled Syringe in Healthy Subjects	Rheumatoid Arthritis;Polyarticular Juvenile Idiopathic Arthritis;Psoriatic Arthritis;Ankylosing Spondylitis;Crohn Disease;Ulcerative Colitis;Plaque Psoriasis;Pediatric Plaque Psoriasis;Pediatric Crohns Disease;Hidradenitis Suppurativa;Non-infectious Uveitis	Drug: 40 mg MSB11022	Fresenius Kabi SwissBioSim GmbH	PRA Health Sciences	Recruiting	18 Years	55 Years	All	216	Phase 1	United States
29	NCT03813199	July 4, 2019	29 July 2019	Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis	Phase IIa Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to an Anti- Tumor Necrosis Factor Alpha (Tnfa) Therapy, or Intolerance to Anti-Tnfa Therapy	Rheumatoid Arthritis	Drug: ABX464 50mg;Drug: Matching Placebo;Drug: ABX464 100mg;Drug: Methotrexate	Abivax S.A.		Recruiting	18 Years	75 Years	All	60	Phase 2	France
30	NCT03656627	June 27, 2019	22 October 2019	Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease	Safety, Activity, and Pharmacology of Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease	Autoimmune Diseases;Non-small Cell Lung Cancer;Rheumatoid Arthritis;Psoriasis;Giant Cell Arteritis;Polymyalgia Rheumatica;Systemic Lupus Erythematosus;Crohn Disease;Multiple Sclerosis;Ulcerative Colitis	Drug: Nivolumab	Alliance Foundation Trials, LLC.	Bristol-Myers Squibb	Recruiting	18 Years	N/A	All	72	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
31	NCT03912428	June 14, 2019	1 July 2019	Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis	Evaluation of Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis	Myositis	Drug: Celecoxib	National Institute of Mental Health (NIMH)		Recruiting	18 Years	99 Years	All	47	Phase 1	United States
32	NCT03970837	June 5, 2019	22 October 2019	Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)	A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs	Arthritis, Rheumatoid	Biological: GSK3196165;Drug: Tofacitinib;Drug: Placebo to GSK3196165;Drug: Placebo to Tofacitinib;Drug: csDMARDs	GlaxoSmithKline	Iqvia Pty Ltd	Recruiting	18 Years	N/A	All	1500	Phase 3	United States;Colombia
33	NCT03886038	June 1, 2019	1 April 2019	Subunit Vaccine Against Herpes Zoster in RA Patients Treated With JAK-inhibitors (VACCIMIL-ZOSTER)	The Immunogenicity and Efficacy of Subunit Vaccine Against Herpes Zoster in RA Treated With JAK-inhibitors (VACCIMIL-ZOSTER)	Rheumatoid Arthritis;Healthy Controls	Biological: Shingrix	Region Skane		Not recruiting	18 Years	N/A	All	150	Phase 4	Sweden
34	NCT03619876	June 2019	27 May 2019	Effects of Abatacept on Myocarditis in Rheumatoid Arthritis	Effects of Abatacept on Myocarditis in Rheumatoid Arthritis	Rheumatoid Arthritis;Myocardial Inflammation	Drug: Abatacept;Drug: Adalimumab	Columbia University	Bristol-Myers Squibb	Not recruiting	18 Years	N/A	All	20	Phase 4	United States
35	NCT04033809	May 30, 2019	29 July 2019	Effectiveness of Multigrain Supplementation Among the Rheumatoid Arthritis Patients	Effectiveness of High Fiber Multigrain Supplementation Among the Rheumatoid Arthritis Patients: A Randomized, Open Label Trial	Rheumatoid Arthritis	Dietary Supplement: Multigrain powder (S)	University of Science Malaysia		Not recruiting	21 Years	N/A	All	50	N/A	Malaysia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
36	NCT03980483	May 16, 2019	22 October 2019	Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate	A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate	Arthritis, Rheumatoid	Biological: GSK3196165;Drug: Tofacitinib 5 mg;Drug: Placebo to GSK3196165;Drug: Placebo to tofacitinib;Drug: Methotrexate;Drug: Folic (or folinic) acid	GlaxoSmithKline	Iqvia Pty Ltd	Recruiting	18 Years	N/A	All	1500	Phase 3	United States
37	NCT03823378	May 13, 2019	3 June 2019	A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib.	A Phase 2, Multicenter, Double-Blind, Parallel Group Long Term Extension Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial With ABBV-105 Given Alone or in Combination With Upadacitinib (ABBV-599)	Rheumatoid Arthritis (RA)	Drug: Upadacitinib;Drug: Upadacitinib placebo;Drug: ABBV-105 placebo;Drug: ABBV-105	AbbVie		Recruiting	18 Years	N/A	All	50	Phase 2	Belgium;Canada;Czechia;Hungary;Poland;Spain;United Kingdom
38	NCT03882008	April 25, 2019	29 April 2019	A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis	Phase IV Open-Label Study to Evaluate Biomarkers to Predict the Efficacy of Abatacept in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Abatacept	University of Washington	Bristol-Myers Squibb	Recruiting	18 Years	N/A	All	25	Phase 4	United States
39	NCT03915964	April 25, 2019	11 November 2019	A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis	A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Baricitinib;Drug: TNF Inhibitor	Eli Lilly and Company	Incyte Corporation	Recruiting	18 Years	N/A	All	2600	Phase 4	United States;Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom
40	EUCTR2018-003933-14-EE	09/04/2019	30 April 2019	A study evaluating the effect of filgotinib on sperm parameters in adult males with active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or non-radiographic axial spondyloarthritis.	A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males with active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis.	Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0 Level: PT Classification code 10002556 Term: Ankylosing spondylitis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0 Level: LLT Classification code 10037160 Term: Psoriatic arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0 Level: LLT Classification code 10076297 Term: Non-radiographic axial spondyloarthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Filgotinib Product Code: GLPG0634 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: FILGOTINIB Other descriptive name: FILGOTINIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Galapagos NV		Authorised			Female: no Male: yes	250	Phase 2	Estonia;Spain;Ukraine;Russian Federation;India;Czech Republic;Belgium;Poland;Romania;Bulgaria;Germany;Latvia;Moldova, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
41	NCT03938636	April 8, 2019	22 October 2019	Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging	Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging	Rheumatoid Arthritis	Drug: TC99m-tilmanocept	Navidea Biopharmaceuticals		Recruiting	18 Years	N/A	All	105	Phase 2	United States
42	NCT03816345	April 4, 2019	11 November 2019	Nivolumab in Treating Patients With Autoimmune Disorders or Advanced, Metastatic, or Unresectable Cancer	A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)	Advanced Malignant Neoplasm;Autoimmune Disease;Crohn Disease;Dermatomyositis;Inflammatory Bowel Disease;Metastatic Malignant Neoplasm;Multiple Sclerosis;Rheumatoid Arthritis;Sjogren Syndrome;Systemic Lupus Erythematosus;Systemic Scleroderma;Ulcerative Colitis;Unresectable Malignant Neoplasm	Biological: Nivolumab	National Cancer Institute (NCI)		Recruiting	18 Years	N/A	All	264	Phase 1	United States
43	NCT03669367	April 1, 2019	21 January 2019	EFFECTS OF ABATACEPT on the Progression to Rheumatoid Arthritis(PALABA Study)	EFFECTS OF ABATACEPT ON THE PROGRESSION TO RHEUMATOID ARTHRITIS IN PATIENTS WITH PALINDROMIC RHEUMATISM (PALABA)	Palindromic Rheumatism, Wrist	Drug: Abatacept Injection;Drug: hydroxycloroquina	Fundacion Clinic per a la Recerca Biomédica		Not recruiting	18 Years	N/A	All	98	Phase 4
44	NCT03700021	April 2019	4 February 2019	Response to Treatment With Intravenous Abatacept Adults With Rheumatoid Arthritis	Single-Open Label Study to Assess Changes in the Immune Profile in Response to Treatment With Intravenous Abatacept Adults With Rheumatoid Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs	Rheumatoid Arthritis	Drug: Abatacept + csDMARD	New York University School of Medicine		Not recruiting	18 Years	N/A	All	25	Phase 4	United States
45	NCT03823391	March 27, 2019	9 September 2019	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis	A Randomized, Double-Blind, Double-Dummy, Active Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Subjects With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis (RA)	Drug: ABBV-3373;Drug: Placebo for ABBV-3373;Drug: Adalimumab;Drug: Placebo for adalimumab	AbbVie		Recruiting	18 Years	75 Years	All	45	Phase 1	United States;Germany;Hungary;Israel;Netherlands;Poland;Puerto Rico
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
46	NCT03885037	March 20, 2019	4 November 2019	Infliximab Biosimilar for Intravenous Drip Infusion 100 mg Pfizer Drug Use Investigation (Rheumatoid Arthritis)	Infliximab BS for Intravenous Drip Infusion 100 mg Pfizer General Investigation (Rheumatoid Arthritis)	Rheumatoid Arthritis	Drug: Infliximab [infliximab biosimilar 3]	Pfizer		Recruiting	N/A	N/A	All	300	Phase 3	Japan
47	NCT04057118	March 20, 2019	4 November 2019	A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study to Evaluate the Efficacy and Safety of Oral SKI-O-703 in Patients With Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies	Rheumatoid Arthritis	Drug: SKI-O-703;Drug: Placebo	Oscotec Inc.		Recruiting	18 Years	N/A	All	148	Phase 2	United States;Czechia;Poland;Russian Federation;Ukraine
48	NCT03890302	March 14, 2019	8 April 2019	A Placebo-controlled Study to Evaluate the Safety, Movement Through, and Reaction of the Body to Single and Multiple Increasing Doses of FB704A	A Phase 1, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Single and Multiple Ascending Doses of FB704A	Rheumatoid Arthritis	Drug: FB704A;Drug: Placebo	Fountain Biopharma Inc.		Recruiting	18 Years	55 Years	All	41	Phase 1	United States
49	ChiCTR1900021808	2019-03-08	18 March 2019	A Phase 1, Randomized, Double-Blind and Paralle, Controlled Single-dose Clinical Trial of Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of QX003S and Tocilizumab in Chinese Health Male Subjects	A Phase 1, Randomized, Double-Blind and Paralle, Controlled Single-dose Clinical Trial of Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of QX003S and Tocilizumab in Chinese Health Male Subjects	Active rheumatoid arthritis	1:8 mg/kg QX003S ;2:Tocilizumab, 8 mg/kg;	JiangSu Qyuns Therapeutics Co., Ltd		Recruiting	18	50	Male	1:43;2:43;	Phase 1	China
50	NCT03813771	March 2019	4 February 2019	Targeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-naïve Early RA Patients Based on naïve T-cell Stratification	Targeted Treatment Early With Etanercept Plus Methotrexate Versus T2T Care for DMARD-naïve Early RA Patients. A Prospective, Longitudinal Cohort Study With Embedded Pilot Randomised Controlled Trial to Assess Treatment Rationalisation Based on naïve T-cell Stratification.	Rheumatoid Arthritis	Drug: Benepali;Drug: Sulfasalazine;Drug: Methotrexate;Drug: Hydroxychloroquine	University of Leeds	Samsung Bioepis Co., Ltd.	Not recruiting	18 Years	N/A	All	106	Phase 4	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
51	NCT03858725	February 26, 2019	18 March 2019	Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-374 5 mg in Healthy Volunteers	A Randomized, Open-label, Fasted, Single Dose, Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-374 5 mg in Healthy Volunteer	Rheumatoid Arthritis	Drug: D569 Tab.;Drug: CKD-374 5mg Tab.	Chong Kun Dang Pharmaceutical		Recruiting	19 Years	54 Years	All	36	Phase 1	Korea, Republic of
52	NCT03852355	February 25, 2019	1 April 2019	the Effectiveness of 3rd Occipital Radiofrequency Versus Systemic Steroid in Headache Management in Rheumatoid Arthritis	the Effectiveness of 3rd Occipital Radiofrequency Versus Systemic Steroid in Headache Management in Rheumatoid Arthritis; a Randomized Controlled Trial	Rheumatoid Arthritis;Headache	Drug: Radiofrequency;Drug: Steroids	Assiut University		Recruiting	18 Years	60 Years	All	60	N/A	Egypt
53	NCT03868072	February 22, 2019	18 March 2019	Study to Evaluate the Bioequivalence of Pfizer Korea Inc. XELJANZ 5Mg Tablet in Healthy Volunteers	An Open-label, Randomized, Fasted, Single Dose, Crossover Study to Evaluate the Bioequivalence of Chong Kun Dang Pharmaceutical Chong Kun Dang Tofacitinib Tablet and Pfizer Korea Inc. XELJANZ 5Mg Tablet in Healthy Volunteers	Rheumatoid Arthritis	Drug: XELJANZ 5Mg Tablet;Drug: Chong Kun Dang Tofacitinib Tablet	Chong Kun Dang Pharmaceutical		Recruiting	19 Years	N/A	All	40	Phase 1	Korea, Republic of
54	NCT03737708	February 13, 2019	18 March 2019	A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)	Compare Efficacy and Safety Between Biologics + Methotrexate (MTX) vs Biologics + Tacrolimus (TAC) (Switched From Biologics + Methotrexate (MTX)) in the Patients With Rheumatoid Arthritis (RA): Randomized, Interventional, Open, Active Controlled, Parallel Group, Multicenter-designed, Phase 4 Clinical Trial	Rheumatoid Arthritis (RA)	Drug: tacrolimus;Drug: methotrexate;Biological: adalimumab;Biological: tocilizumab;Biological: abatacept	Astellas Pharma Korea, Inc.		Recruiting	19 Years	75 Years	All	148	Phase 4	Korea, Republic of
55	NCT03729349	January 15, 2019	22 October 2019	Golimumab for Adherence in Rheumatoid Arthritis	Golimumab for Adherence in Rheumatoid Arthritis	Arthritis, Rheumatoid	Biological: Golimumab	Janssen Inc.		Recruiting	18 Years	85 Years	All	300	Early Phase 1	Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
56	NCT03863405	January 9, 2019	3 June 2019	Metformin Use in Rheumatoid Arthritis	The Effect of Metformin on the Clinical Outcome of Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Placebo Oral Tablet;Drug: Conventional DMARDs;Drug: Metformin	Ain Shams University	Future University in Egypt	Recruiting	18 Years	N/A	All	60	Phase 2	Egypt
57	NCT03981900	January 4, 2019	22 July 2019	IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis	IDentification of Predictive Factors of Continuation of Treatment With Tofacitinib in Patients With Rheumatoid Arthritis in Common Practice and the Impact of the Patient's Behavioural Strategies on Clinical Parameters: The DeFacTo Study.	Arthritis, Rheumatoid	Drug: Tofacitinib	Pfizer		Recruiting	18 Years	N/A	All	500	Phase 1	France
58	EUCTR2018-000666-10-HU	03/01/2019	28 February 2019	A Phase 2 study to investigate the safety and efficacy of ABBV-105 given alone or in combination with ABT-494 (Upadacitinib) in patients with active rheumatoid arthritis who have failed prior treatment with biologic therapy	A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 Given Alone or in Combination with Upadacitinib (ABBV-599 Combination) with a Background of Conventional Synthetic DMARDs in Subjects with Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs	Rheumatoid Arthritis MedDRA version: 20.0 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000004870 ;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Code: ABBV-105 Pharmaceutical Form: Capsule CAS Number: 1643570-24-4 Current Sponsor code: ABBV-105 Other descriptive name: ABBV-105, A-1519938.0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Code: ABBV-105 Pharmaceutical Form: Capsule CAS Number: 1643570-24-4 Current Sponsor code: ABBV-105 Other descriptive name: ABBV-105, A-1519938.0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Upadacitinib Product Code: ABT-494 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Upadacitinib CAS Number: 1310726-60-3 Current Sponsor code: ABT-494 Other descriptive name: ABT-494 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	AbbVie Deutschland GmbH & Co. KG		Authorised			Female: yes Male: yes	240	Phase 2	United States;Czech Republic;Hungary;Puerto Rico;Canada;Poland;Belgium;Spain;Germany;United Kingdom
59	NCT03896594	December 24, 2018	15 April 2019	A Multiple Dose of HL237 in Healthy Male Subject	A Dose Block-randomized, Double-blind, Placebo Controlled, Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Oral Dose of HL237 in Healthy Male Subject	Rheumatoid Arthritis	Drug: HL237;Drug: Placebo Oral Tablet	Hanlim Pharm. Co., Ltd.		Recruiting	20 Years	45 Years	Male	36	Phase 1	Korea, Republic of
60	NCT03652961	December 21, 2018	14 January 2019	Rheumatoid Arthritis Memory B Cells and Abatacept (RAMBA)	Rheumatoid Arthritis Memory B Cells and Abatacept (RAMBA)	Rheumatoid Arthritis	Drug: Abatacept	Dartmouth-Hitchcock Medical Center	New York University School of Medicine	Recruiting	18 Years	N/A	All	25	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
61	NCT03574545	December 19, 2018	4 November 2019	Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis	A Randomized, Open Label, Multiple Dose, Parallel Group Study to Assess the Safety and Pharmacokinetic Comparability of Two VAY736 Drug Products in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: VAY736	Novartis Pharmaceuticals		Recruiting	18 Years	65 Years	All	50	Phase 1	Germany;Jordan
62	NCT03830203	December 19, 2018	25 February 2019	Comparative Study of BAT1806 to RoActemra® in Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate	A Randomized, Double-Blind, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of BAT1806 to RoActemra® in Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: BAT1806;Drug: Actemra(EU-licensed)	Bio-Thera Solutions		Recruiting	18 Years	N/A	All	612	Phase 3	China
63	EUCTR2018-001690-25-PL	11/12/2018	7 January 2019	Evaluating efficacy and safety between CT-P17 and Humira when Co-administered with Methotrexate in Patients with Moderate to Severe Active Rheumatoid Arthritis	A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P17 with Humira when Co-administered with Methotrexate in Patients with Moderate to Severe Active Rheumatoid Arthritis	Moderate to Severe Active Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Code: CT-P17 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Current Sponsor code: CT-P17 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Trade Name: Humira Product Name: Humira Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100-	Celltrion, Inc		Authorised			Female: yes Male: yes	564	Phase 3	Hungary;Poland;Ukraine;Lithuania;Peru;Russian Federation;Bulgaria;Bosnia and Herzegovina
64	NCT03729674	November 26, 2018	3 December 2018	Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs	Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs	Rheumatoid Arthritis;Ankylosing Spondylitis;Ulcerative Colitis;Crohn's Disease	Drug: Biosimilar;Drug: Originator (legacy) drug	McGill University Health Center	Université de Sherbrooke;Institut de rhumatologie de Montréal;Hospital for Special Surgery, New York;University of Manitoba;University of Toronto;University of Alberta;University of British Columbia;Alberta Health Services;McMaster University;The Arthritis Program Research Group	Not recruiting	18 Years	N/A	All	800	Phase 3
65	NCT03789292	November 26, 2018	8 April 2019	A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis	A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P17 With Humira When Co-administered With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: CT-P17 SC;Biological: Humira SC	Celltrion		Not recruiting	18 Years	75 Years	All	564	Phase 3	Bulgaria
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
66	NCT03755466	November 21, 2018	10 December 2018	Examination of Efficacy and Safety of Baricitinib in RA Patients	Efficacy and Safety of Baricitinib in Rheumatoid Arthritis Patients Compared With Those Treated by Biologics or Tofacitinib	Rheumatoid Arthritis	Drug: Baricitinib, olumiant®;Drug: Biologics;Drug: Tofacitinib 5 MG [Xeljanz]	Shinshu University		Recruiting	20 Years	N/A	All	90	Phase 2	Japan
67	NCT03980639	November 20, 2018	24 June 2019	Abatacept and the Risk of Cancer: a Case Non-case Analysis in VigiBase	Abatacept and the Risk of Cancer: a Case Non-case Analysis in VigiBase	Rheumatoid Arthritis	Drug: patient treated with DMARD	University Hospital, Toulouse		Recruiting	18 Years	N/A	All	594226	N/A	France
68	NCT03852888	November 14, 2018	11 March 2019	Kinetics of Elimination of Methotrexate and Its Major Metabolite 7-OH-methotrexate for Observant Patients	Kinetics of Elimination of Methotrexate and Its Major Metabolite 7-OH-methotrexate for Observant Patients	Rheumatoid Arthritis	Biological: Urine samples taken to measure methotrexate and its major metabolite 7-OH-methotrexate level	CHU de Reims		Recruiting	18 Years	N/A	All	60	N/A	France
69	EUCTR2018-001690-25-HU	13/11/2018	19 November 2018	Evaluating efficacy and safety between CT-P17 and Humira when Co-administered with Methotrexate in Patients with Moderate to Severe Active Rheumatoid Arthritis	A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P17 with Humira when Co-administered with Methotrexate in Patients with Moderate to Severe Active Rheumatoid Arthritis	Moderate to Severe Active Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Code: CT-P17 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Current Sponsor code: CT-P17 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Trade Name: Humira Product Name: Humira Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100-	Celltrion, Inc		Authorised			Female: yes Male: yes	564	Phase 3	Hungary;Poland;Ukraine;Lithuania;Peru;Russian Federation;Bulgaria;Bosnia and Herzegovina
70	NCT03707535	November 12, 2018	29 April 2019	To Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis	A Randomized, Controlled, Double-Blind, Phase 3 Study to Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: CT-P13;Biological: Remicade	Celltrion		Recruiting	18 Years	75 Years	All	270	Phase 3	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
71	ChiCTR1800019277	2018-11-01	5 November 2018	The Zoledronic Acidameliorate theSecondary Osteoporosis in Rheumatoid Arthritis patients	The Zoledronic Acidameliorate theSecondary Osteoporosis in Rheumatoid Arthritis patients	Rheumatoid Arthritis	Control group:MTX;Treatment group 1:Zoledronate Acid(ZA);Treatment group 2:MTX+Zoledronate Acid;	Shanghai Traditional Medicine University Affiliated Guanghua Hospital		Recruiting	18	65	Both	Control group:22;Treatment group 1:22;Treatment group 2:22;	Other	China
72	EUCTR2017-004226-15-DK	26/10/2018	26 November 2018	Can-Art Effect and safety of using Canabis derivatives for the treatment of pain in patients with inflammatory Arthritis, such as reumatoid arthritis and ankylosing spondylitis, the latter being a type of arthritis that causes a long term inflammation of the joints of the spine. A randomized, double blinded, placebo controlled trial, i.e. in this drug trial, a control group is given a placebo while another group is given the Cannabis derivative being studied.	CAN-ART The efficacy and safety of using cannabis derivatives cannabidiol (CBD) and tetrahydrocannabinol (THC) for the treatment of pain in patients with inflammatory arthritis (RA, AS). A randomized, double blinded, placebo controlled trial - Can-Art	Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS) MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0 Level: PT Classification code 10002556 Term: Ankylosing spondylitis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Cannabidiol tablet 10 mg Pharmaceutical Form: Tablet CAS Number: 13956-29-1 Other descriptive name: CANNABIDIOL Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Dronabinol capsule 2.5. mg Pharmaceutical Form: Capsule INN or Proposed INN: DRONABINOL CAS Number: 1972-08-3	King Christian 10th Hospital for Rheumatology		Authorised			Female: yes Male: yes	180	Phase 2	Denmark
73	ChiCTR1900026079	2018-10-25	30 September 2019	Wangbi capsule combined methotrexate tablets for treatment of Rheumatoid Arthritis: A Randomized,Double-blind,Single analog,Positive Drug Parallel-group controlled clinical study	Wangbi capsule combined methotrexate tablets for treatment of Rheumatoid Arthritis: A Randomized,Double-blind,Single analog,Positive Drug Parallel-group controlled clinical study	Rheumatoid Arthritis	Experimental group:Wangbi capsule combined methotrexate tablets;Control group:Simulation of Wangbi capsule combined methotrexate tablets;	Longhua Hospital Shanghai University of Traditional Chinese Medicine		Recruiting	18	70	Both	Experimental group:60;Control group:60;	Phase 4	China
74	NCT03718611	October 22, 2018	22 July 2019	To Evaluate the Pharmacokinetics and Safety of Oral Administration of BR9001 Compared With BR900A in Healthy Subjects	A Randomized, Open-label, Single-dose, Crossover Study to Evaluate the Pharmacokinetics and Safety of Oral Administration of BR9001 Compared With BR900A in Healthy Subjects	Rheumatoid Arthritis	Drug: BR9001;Drug: BR900A	Boryung Pharmaceutical Co., Ltd		Not recruiting	19 Years	50 Years	All	36	Phase 1	Korea, Republic of
75	NCT03682705	October 8, 2018	14 October 2019	A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis.	A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 Given Alone or in Combination With Upadacitinib (ABBV-599 Combination) With a Background of Conventional Synthetic DMARDs in Subjects With Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs	Rheumatoid Arthritis (RA)	Drug: Upadacitinib;Drug: ABBV-105;Drug: Upadacitinib placebo;Drug: ABBV-105 placebo	AbbVie		Recruiting	18 Years	N/A	All	240	Phase 2	United States;Belgium;Canada;Czechia;Hungary;Poland;Puerto Rico;Spain;United Kingdom;Germany;Ireland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
76	JPRN-JapicCTI-184031	02/10/2018	7 October 2019	A Phase III Study of TS-152 in Patients with Active Rheumatoid Arthritis (RA) Without Methotrexate (MTX) Therapy	A Phase III Study of TS-152 in Patients with Active Rheumatoid Arthritis (RA) Without Methotrexate (MTX) Therapy	Rheumatoid Arthritis (RA)	Intervention name : TS-152 INN of the intervention : ozoralizumab Dosage And administration of the intervention : Subcutaneous injection every 4 weeks Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : -	Taisho Pharmaceutical co., LTD		Not Recruiting	20		BOTH	135	Phase 3	Japan
77	NCT03511625	October 2, 2018	7 October 2019	The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis	The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis: A Pilot Study	Rheumatoid Arthritis	Drug: Acthar Injectable Product;Drug: Depo medrol	Attune Health Research, Inc.	Mallinckrodt	Recruiting	18 Years	N/A	All	6	Phase 3	United States
78	NCT03546335	October 1, 2018	22 October 2018	Zr-89 Cimzia PET Imaging Rheumatoid Arthritis	Zirconium-89 Certolizumab PET Imaging in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: 89Zr-DFO-CZP	University of California, San Francisco		Recruiting	18 Years	N/A	All	10	Phase 1	United States
79	NCT03593837	October 1, 2018	20 August 2018	Efficacy and Safety of HQGZWWT Patients With Rheumatoid Arthritis	A Multicenter, Randomized, Double-blind,Placebo-controlled Trial Evaluating the Efficacy and Safety of Huang Qi GuiZhi Wu Wu Tang Granulesin Patients With Rheumatoid Arthritis	Huang Qi Gui Zhi Wu Wu Granule;Rheumatoid Arthritis	Drug: Huang qi gui zhi wu wu granule;Drug: Huang qi gui zhi wu wu granule placebo	Cui xuejun		Not recruiting	18 Years	80 Years	All	100	Phase 2/Phase 3
80	NCT03770702	October 1, 2018	18 December 2018	Statins and ARBs on Rheumatoid Activity	Investigational and Comparative Study Between the Anti-inflammatory Effectof Both Angiotensin Reeptor Blockers and Statins on Rheumatoid Arthritis Disease Activity on Egyptian Patients	Rheumatoid Arthritis	Drug: Angiotensin receptor blockers;Drug: Statins	Sherief Abd-Elsalam		Recruiting	18 Years	65 Years	All	45	Phase 3	Egypt
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
81	NCT03770923	October 1, 2018	18 December 2018	Effect of Some Drugs on Rheumatoid Arithritis Activity	Clinical Study Evaluating the Effect of Histamine 1 Receptor Antagonist and Leukotreine Receptor Antagonist on Patients With Rheumatoid Arithritis	Rheumatoid Arthritis	Drug: Rupatadine;Drug: Montelukast	Sherief Abd-Elsalam		Recruiting	18 Years	N/A	All	75	Phase 3	Egypt
82	NCT03660059	September 27, 2018	16 September 2019	A Study to Assess Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)	A Randomized, Double-Blind, Placebo-Controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to MTX	Rheumatoid Arthritis (RA)	Drug: Peficitinib;Drug: Plaebo;Drug: Disease-modifying antirheumatic drugs (DMARDs)	Astellas Pharma China, Inc.		Recruiting	18 Years	N/A	All	375	Phase 3	China;Korea, Republic of;Taiwan
83	ChiCTR1800018637	2018-09-26	10 October 2018	Correlation between Human epididymis protein 4 and interstitial lung disease in patients with rheumatoid arthritis	Correlation between Human epididymis protein 4 and interstitial lung disease in patients with rheumatoid arthritis	rheumatoid arthritis	Gold Standard:Clinical outcome, meet the 2010 ACR/EULAR rheumatoid arthritis classification criteria.;Index test:Human epididymis protein 4,anti-cyclic citrullinated peptide, creatinine, rheumatoid factor;	Affiliated Hospital of North Sichuan Medical College		Recruiting			Both	Target condition:150;Difficult condition:100	Diagnostic New Technique Clincal Study	China
84	NCT03691909	September 25, 2018	2 September 2019	A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Rheumatoid Arthritis	A Phase 1/2a Clinical Trial to Assess Safety of a Single IV Infusion of Autologous Adipose-derived Mesenchymal Stem Cells in Adults With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: HB-adMSC	Hope Biosciences		Not recruiting	18 Years	65 Years	All	15	Phase 1/Phase 2	United States
85	NCT03699293	September 22, 2018	15 October 2018	NSAIDs vs. Coxibs in the Presence of Aspirin	NSAIDs vs. Coxibs in the Presence of Aspirin: Effects on Platelet Function, Endothelial Function, and Biomarkers of Inflammation in Subjects With Rheumatoid Arthritis and Increased Cardiovascular Risk or Cardiovascular Disease	Rheumatoid Arthritis;Cardiovascular Diseases	Drug: celecoxib 200mg capsule;Drug: naproxen sodium 550mg tablet;Drug: Aspirin 81mg tablet	Inova Health Care Services		Recruiting	18 Years	75 Years	All	30	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
86	EUCTR2018-001114-15-NL	18/09/2018	28 February 2019	Predicting the risk for rheumatoid arthritis with the help of a PET scan.	Positron emission tomography with macrophage targeting to select individuals at risk for rheumatoid arthritis. - Early diagnostics in RA	Rheumatoid arthritis;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: [18F]PEG-Folate Pharmaceutical Form: Solution for injection	VU Medical Center, department of Rheumatology		Authorised			Female: yes Male: yes	60	Phase 4	Netherlands
87	JPRN-JapicCTI-184229	12/9/2018	16 July 2019	Investigation of the Risk of Hypocalcemia in Patients With Rheumatoid Arthritis Who Were Treated for the First Time With Pralia Subcutaneous Injection 60 mg Syringe -Medical Information Database Network-based Cohort Study-	Investigation of the Risk of Hypocalcemia in Patients With Rheumatoid Arthritis Who Were Treated for the First Time With Pralia Subcutaneous Injection 60 mg Syringe -Medical Information Database Network-based Cohort Study-	Rheumatoid Arthritis	Intervention name : PRALIA 60mg Subcutaneous Injection Syringe(denosumab) Dosage And administration of the intervention : For adults under normal conditions, 60 mg of denosumab (genetic recombination) is injected subcutaneously every six months. If bone erosion progression occurs when denosumab is injected once every 6 months, denosumab can be injected subcutaneously once every 3 months.	DAIICHISANKYO Co., Ltd.		Not Recruiting			BOTH	2000	NA
88	NCT03701789	September 11, 2018	22 October 2019	Effect of Baricitinib Treatment on Peripheral Bone in RA	Evaluation of Bone Quality in Patients With Rheumatoid Arthritis Treated With Baricitinib: Single Centre, Mode of Action Study (BARE BONE)	Rheumatoid Arthritis;Bone Density;Finger Joints	Drug: Baricitinib	University of Erlangen-Nürnberg Medical School		Recruiting	18 Years	74 Years	All	15	Phase 3	Germany
89	JPRN-JapicCTI-184029	04/9/2018	7 October 2019	A Phase II/III Study of TS-152 in Patients with Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response to Methotrexate (MTX) Therapy	A Phase II/III Study of TS-152 in Patients with Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response to Methotrexate (MTX) Therapy	Rheumatoid Arthritis (RA)	Intervention name : TS-152 INN of the intervention : ozoralizumab Dosage And administration of the intervention : Subcutaneous injection every 4 weeks Control intervention name : Placebo INN of the control intervention : Placebo Dosage And administration of the control intervention : Usage: Subcutaneous injection every 4 weeks, Dosage: No active ingredients contain	Taisho Pharmaceutical co., LTD		Not Recruiting	20	75	BOTH	370	Phase 2-3	Japan
90	NCT04079374	September 3, 2018	22 October 2019	Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel	Open, Randomized, Comparative, Multicenter Study in Parallel Groups of the Efficacy, Safety, Immunogenicity of Etanercept and Enbrel, Lyophilisates for Solution for Subcutaneous Injection, in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Etanercept;Drug: Enbrel	Joint Stock Company Farmak	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	Recruiting	18 Years	75 Years	All	160	Phase 3	Ukraine
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
91	EUCTR2015-004386-91-PL	26/08/2018	7 January 2019	Study to explore and compare the effects of a new drug in combination with methotrexate therapy in people with early and established rheumatoid arthritis.	A Phase IIa, Double-Blind, Mechanistic Study of GSK3196165 in Combination with Methotrexate Therapy in Subjects with Active Rheumatoid Arthritis Despite Treatment with DMARDs	Rheumatoid Arthritis MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Code: GSK3196165 Pharmaceutical Form: Solution for injection INN or Proposed INN: INN not available CAS Number: 1638332-55-4 Current Sponsor code: GSK3196165 Other descriptive name: Anti human granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	GlaxoSmithKline Research & Development Limited		Not Recruiting			Female: yes Male: yes	40	Phase 2	United States;Poland;Germany
92	NCT03636984	August 24, 2018	27 August 2018	Efficacy and Safety Study of Anbainuo in Chinese Patients With RA/AS in the Real World	Efficacy and Safety Study of Anbainuo in Chinese Patients With Rheumatoid Arthritis/ Ankylosing Spondylitis in the Real World: a Prospective, Open-label, Multi-center Observational Study	Rheumatoid Arthritis;Ankylosing Spondylitis	Drug: recombinant TNF-a receptor: IgG Fc fusion protein	Zhejiang Hisun Pharmaceutical Co. Ltd.		Not recruiting	18 Years	N/A	All	1000	Phase 2/Phase 3
93	NCT03535519	August 7, 2018	26 August 2019	Rheumatoid Arthritis Response to Methotrexate	Rheumatoid Arthritis Ultrasound Response to Methotrexate	Rheumatoid Arthritis	Drug: Methotrexate	Juan Carlos Nieto	Nordic Pharma SAS	Recruiting	18 Years	N/A	All	50	Phase 4	Spain
94	NCT04066803	August 1, 2018	2 September 2019	Optimal MTX Dose With Folic Acid Randomized Case-control Trial	Safety and Efficacy of Optimal Methotrexate With Folic Acid in Patients With Rheumatoid Arthritis in Meizhou, Guangdong: a Randomized Case-control Study	Rheumatoid Arthritis	Drug: DMARDs;Drug: Folic Acid;Drug: MTX	Sun Yat-sen University	Shanghai Pharmaceuticals Holding Co., Ltd	Recruiting	18 Years	70 Years	All	160	Phase 4	China
95	EUCTR2018-002368-18-ES	25/07/2018	20 August 2018	Phase IV, open, low-level intervention, clinical trial to compare the immunogenicity in immunosuppressed patients of an adjuvanted anti-hepatitis B vaccine with an anti-hepatitis B vaccine with increased antigenic load	Phase IV, open, low-level intervention, clinical trial to compare the immunogenicity in immunosuppressed patients of an adjuvanted anti-hepatitis B vaccine with an anti-hepatitis B vaccine with increased antigenic load	1. Autoinmune rheumatic diseases undertreated by rituximab or infliximab. 2. breast and lung cancer undertreated by chemotherapy 3. HIV 4. Haematopoietic progenitor cell transplantation (TCPH). MedDRA version: 20.0 Level: PT Classification code 10006187 Term: Breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000004870 MedDRA version: 20.0 Level: PT Classification code 10058467 Term: Lung neoplasm malignant System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.1 Level: PT Classification code 10020161 Term: HIV infection System Organ Class: 10021881 - Infections and infestations MedDRA version: 20.0 Level: PT Classification code 10063581 Term: Stem cell transplant System Organ Class: 10042613 - Surgical and medical procedures ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Fendrix suspension for injection Product Code: Fendrix Pharmaceutical Form: Suspension for injection INN or Proposed INN: Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed). Other descriptive name: HEPATITIS B VACCINE (RDNA) Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 20- Trade Name: HBVAXPRO 5 micrograms/0.5 ml Product Code: HBVAXPRO® 40 micrograms Pharmaceutical Form: Suspension for injection INN or Proposed INN: HBVAXPRO 5 micrograms/0.5 ml Suspension for injection Hepatitis B vaccine (rDNA) Other descriptive name: HEPATITIS B VIRUS SURFACE ANTIGEN RECOMBINANT (S PROTEIN) Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 5-	FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR)		Authorised			Female: yes Male: yes	740	Phase 4	Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
96	NCT03618784	July 11, 2018	26 August 2019	Safety and Efficacy of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis	A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Phase I/2a Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-RA Inj. for Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: FURESTEM-RA Inj;Other: sterile saline	Kang Stem Biotech Co., Ltd.		Not recruiting	19 Years	80 Years	All	33	Phase 1/Phase 2	Korea, Republic of
97	EUCTR2017-004079-30-ES	10/07/2018	23 July 2018	Stratification of biologic Therapies for Rheumatoid Arthritis by Pathobiology	Stratification of Biologic Therapies for RA by Pathobiology (STRAP)-EU: A randomised, open-labelled biopsy-driven stratification trial in DMARD inadequate responder patients randomised to Etanercept, Tocilizumab or Rituximab. - STRAP-EU	Rhuematoid Arthritis MedDRA version: 20.0 Level: LLT Classification code 10003268 Term: Arthritis rheumatoid System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: MabThera Product Name: MabThera Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Rituximab Other descriptive name: Rituximab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: RoActmera Product Name: RoActmera Pharmaceutical Form: Solution for injection Trade Name: Enbrel Product Name: Enbrel Pharmaceutical Form: Solution for injection in pre-filled pen	Joint Research & Development Office (QMUL)		Authorised			Female: yes Male: yes	207	Phase 3	Portugal;Belgium;Spain;Italy
98	NCT03445871	July 2, 2018	29 July 2019	Association Between Methotrexate Erythrocyte Polyglutamate Concentration and Clinical Response in Rheumatoid Arthritis Patients Treated With Subcutaneous Injectable Methotrexate	Association Between Methotrexate Erythrocyte Polyglutamate Concentration and Clinical Response in Rheumatoid Arthritis Patients Treated With Subcutaneous Injectable Methotrexate	Rheumatoid Arthritis	Biological: Blood sample;Diagnostic Test: CRQ	Centre Hospitalier Universitaire de Saint Etienne		Recruiting	18 Years	N/A	All	60	Phase 4	France
99	NCT03605251	July 1, 2018	11 February 2019	Efficacy and Safety Study of TAS5315 Compared With Placebo in Participants With Rheumatoid Arthritis.	An Early Phase-II, Randomized, Double-blind, Study of TAS5315 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: TAS5315 low dose;Drug: TAS5315 high dose;Drug: Placebos	Taiho Pharmaceutical Co., Ltd.		Recruiting	20 Years	64 Years	All	90	Phase 2	Japan
100	NCT02885597	July 2018	23 July 2018	Juanbi Pill for Rheumatoid Arthritis	Juanbi Pill Combined With Methotrexate for Rheumatoid Arthritis: Multi-center Random Controlled Clinical Trials	Juanbi Pill;Rheumatoid Arthritis	Drug: Juanbi pill;Drug: Juanbi pill placebo;Drug: Methotrexate	Cui xuejun	Shanghai Yueyang Integrated Medicine Hospital;Longhua Hospital;Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine	Recruiting	18 Years	80 Years	All	120	Phase 2/Phase 3	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
101	NCT03173040	July 2018	23 July 2018	The Efficacy of the Traditional Chinese Medicine Niubang Pill Combined With Methotrexate on Active Rheumatoid Arthritis	The Efficacy of the Traditional Chinese Medicine Niubang Pill Combined With Methotrexate on Active Rheumatoid Arthritis: a Study Protocol for a Multicenter, Randomized, Controlled Clinical Trial	Niu Bang Zi Pill;Rheumatoid Arthritis	Drug: NiuBangZi pill or NiuBangZi pill placebo	Cui xuejun	Shanghai Yueyang Integrated Medicine Hospital;Longhua Hospital;Shanghai Seventh People's Hospital	Recruiting	18 Years	80 Years	All	100	Phase 2/Phase 3	China
102	NCT03589833	July 2018	20 August 2018	Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA	Effectiveness and Safety of Tumor Necrosis Factor Receptor Fusion Protein(Yisaipu) Combined With Tripterygium Wilfordii for Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Tripterygium Wilfordii;Drug: Methotrexate;Drug: Yisaipu	Peking Union Medical College Hospital		Recruiting	18 Years	65 Years	All	504	Phase 2	China
103	NCT03084419	June 26, 2018	29 July 2019	APRIL (AbatacePt in Rheumatoid Arthritis-ILD)	Safety of Abatacept in Rheumatoid Arthritis Associated Interstitial Lung Disease: A Feasibility Trial	Rheumatoid Arthritis;Interstitial Lung Disease	Drug: Abatacept	Cambridge University Hospitals NHS Foundation Trust	Bristol-Myers Squibb	Recruiting	18 Years	N/A	All	30	Phase 2	United Kingdom
104	JPRN-UMIN000033059	2018/06/20	23 April 2019	The impact of including corticosteroid in a periarticular injection for pain control after total hip arthroplasty: a double blind randomized controlled trial	The impact of including corticosteroid in a periarticular injection for pain control after total hip arthroplasty: a double blind randomized controlled trial - The impact of including corticosteroid in a periarticular injection for pain control after total hip arthroplasty: a double blind randomized controlled trial	Osteoarthritis of the hip, rheumatoid arthritis, avascular necrosis of the femoral head, femoral neck fracture	A periarticular injection including methylprednisolone, ropivacaine, morphine, bosmin, and ketoprofen for pain after total hip arthroplasty A periarticular injection including ropivacaine, morphine, bosmin, and ketoprofen for pain after total hip arthroplasty	Hokusuikai Kinen Hospital		Not Recruiting	18years-old	Not applicable	Male and Female	120	Not selected	Japan
105	NCT03550833	June 13, 2018	30 September 2019	Impact of Life Events and Psychological Stress in Rheumatoid Arthritis Set-up : Case-control Study Within a Multifactorial and Integrative Psychological Model	Impact of Life Events and Psychological Stress in Rheumatoid Arthritis Set-up : Case-control Study Within a Multifactorial and Integrative Psychological Model	Arthritis, Rheumatoid;Stress Disorder	Behavioral: Questionnaire;Biological: blood sample	University Hospital, Bordeaux		Not recruiting	18 Years	N/A	All	152	Phase 3	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
106	NCT03606876	June 13, 2018	28 January 2019	Comparative Study to Evaluate the Pharmacokinetics of BAT1806 vs Actemra® in Healthy Subjects	A Randomized, Double-blinded, Single-dose, 3-arm Parallel, Comparative Study to Evaluate the Pharmacokinetics and Safety of BAT1806 Injection vs Actemra® in Healthy Chinese Male Subjects	Rheumatoid Arthritis	Drug: BAT1806 injection	Bio-Thera Solutions		Not recruiting	18 Years	55 Years	Male	138	Phase 1	China
107	NCT03535402	June 1, 2018	15 July 2019	Measurement of the Structural Efficacy in Active RA Patients Treated With Sarilumab in Combination With MTX and Naive to Biologics	Measurement of the Structural Efficacy in Active Rheumatoid Arthritis (RA) Patients Treated With Sarilumab in Combination With Methotrexate (MTX) and Naive to Biologics as Measured by Low-field MRI Using a Modified OMERACT-RAMRIS Score.	Rheumatoid Arthritis	Drug: Sarilumab	Gaylis, Norman B., M.D.		Recruiting	18 Years	N/A	All	20	Phase 3	United States
108	NCT03559686	May 30, 2018	15 July 2019	Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Aarthritis (RA)	Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Arthritis (RA) Who Participated in Open Label Studies C87015, C87028 and C87051	Rheumatoid Arthritis	Drug: Certolizumab Pegol	UCB Biopharma S.P.R.L.		Not recruiting	18 Years	N/A	All		Phase 3
109	NCT03522415	May 28, 2018	23 July 2018	Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid Arthritis	A Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of HLX01 (Recombinant Human-mouse Chimeric Anti-CD20 Monoclonal Antibody Injection) Combined With MTX Therapy in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate	Moderately to Severely Active Rheumatoid Arthritis	Drug: HLX01;Drug: Methotrexate(MTX)	Shanghai Henlius Biotech		Recruiting	18 Years	75 Years	All	267	Phase 3	China
110	NCT03410056	May 22, 2018	4 November 2019	Safety and Efficacy of AMG 592 in Subjects With Active Rheumatoid Arthritis	A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects With Active Rheumatoid Arthritis With Inadequate Response to Standard of Care Therapy	Rheumatoid Arthritis RA	Drug: AMG 592;Drug: Placebo	Amgen		Not recruiting	18 Years	70 Years	All	153	Phase 1/Phase 2	United States;Bulgaria;Germany;Poland;Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
111	EUCTR2017-001944-36-ES	21/05/2018	18 June 2018	Safety and Efficacy of AMG 592 in Subjects with Active Rheumatoid Arthritis	A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects with Active Rheumatoid Arthritis With Inadequate Response to Standard of Care Therapy	Rheumatoid Arthritis MedDRA version: 20.0 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000004870 ;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: AMG592 Pharmaceutical Form: Solution for injection INN or Proposed INN: AMG 592 Current Sponsor code: AMG 592 Other descriptive name: RECOMBINANT FACTOR FC FUSION PROTEIN Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Amgen Inc		Authorised			Female: yes Male: yes	137	Phase 1;Phase 2	United States;Czech Republic;Mexico;Poland;Spain;Romania;Australia;Bulgaria;Germany;New Zealand;United Kingdom
112	NCT03378219	May 18, 2018	26 August 2019	An Observational Study on Sarilumab-exposed Pregnancies	Kevzara® (Sarilumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study	Rheumatoid Arthritis -Exposure During Pregnancy	Drug: Sarilumab SAR153191 (REGN88)	Sanofi	Regeneron Pharmaceuticals	Recruiting	N/A	N/A	Female	300	N/A	United States;Canada
113	NCT03508713	May 13, 2018	11 June 2018	Long-term Prognosis and Quality of Life in Early Rheumatoid Arthritis Patients Treated by 2015 ACR Guideline (LELAND)	Long-term Prognosis and Quality of Life in Early Rheumatoid Arthritis Patients Treated by 2015 ACR Guideline (LELAND): a Multicenter Prospective Observational Study in Southern China	Rheumatoid Arthritis	Drug: disease modified antirheumatic drugs or biological agents	Nanfang Hospital of Southern Medical University	Southern Medical University, China	Not recruiting	18 Years	N/A	All	200	Phase 3
114	EUCTR2017-004054-41-BE	07/05/2018	3 September 2018	COBRA-Slim with or without fast access to TNF blockade for remission induction in early RA	CareRA2020: Effectiveness of a combination of Methotrexate and a step down glucocorticoid regimen (COBRA-Slim) for remission induction in patients with early Rheumatoid Arthritis (RA), with or without fast access to 24 weeks of Tumor Necrosis Factor (TNF) blockade in insufficient responders, a randomized, multicenter, pragmatic trial. - CareRA2020	early active Rheumatoid Arthritis, previously untreated with DMARDs MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: etanercept Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical Form: Coated tablet INN or Proposed INN: LEFLUNOMIDE CAS Number: 75706-12-6 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 10-20	University Hospitals Leuven		Authorised			Female: yes Male: yes	440	Phase 4	Belgium
115	EUCTR2016-002569-68-GB	04/05/2018	28 May 2018	Safety of abatacept in Rheumatoid Arthritis associated Interstitial Lung Disease	Safety of abatacept in Rheumatoid Arthritis associated Interstitial Lung Disease: A feasibility study - APRIL	Rheumatoid-associated Interstitial Lung Disease (RA-ILD) MedDRA version: 20.0 Level: PT Classification code 10022611 Term: Interstitial lung disease System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 20.0 Level: LLT Classification code 10003268 Term: Arthritis rheumatoid System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Orencia Product Name: Orencia Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: ABATACEPT CAS Number: 3 332348-12 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: up to Concentration number: 10-	Cambridge University Hospitals NHS Foundation Trust		Authorised			Female: yes Male: yes	30	Phase 2	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
116	NCT03492658	May 2018	11 June 2018	Abatacept to Silence Anti-citrullinated Protein Antibody-expressing B Cells in Rheumatoid Arthritis (ASCARA)	Abatacept to Silence Anti-citrullinated Protein Antibody-expressing B Cells in Rheumatoid Arthritis (ASCARA).	Rheumatoid Arthritis;Rheumatic Diseases	Drug: Abatacept;Drug: Methotrexate	Leiden University Medical Center		Not recruiting	18 Years	N/A	All	46	Phase 4
117	NCT03435601	April 18, 2018	11 June 2018	A Study to Target the Type I IFN Receptor by Administrating Anifrolumab in RA Patients With a High IFN Signature (TarIFNiRA)	A Randomised, Double-blind, Placebo-controlled Phase II Study to Target the Type I IFN Receptor by Administrating Anifrolumab in RA Patients With a High IFN Signature (TarIFNiRA)	Rheumatoid Arthritis	Drug: Anifrolumab;Drug: Placebos	Josef Smolen, Univ. Prof. Dr.		Recruiting	18 Years	70 Years	All	24	Phase 2	Austria
118	NCT03493269	April 16, 2018	22 October 2019	A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Rheumatoid Arthritis (RA) or Psoriasis	A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Exploratory Pharmacodynamics of Multiple Oral Doses of BAY1834845 in Healthy Male Subjects and in Female and Male Patients With Rheumatoid Arthritis or Psoriasis Over an Extended Treatment Duration	Healthy Volunteers	Drug: BAY1834845;Other: Matching Placebo;Drug: Midazolam	Bayer		Recruiting	18 Years	65 Years	All	88	Phase 1	Germany
119	JPRN-UMIN000030575	2018/03/31	22 July 2019	Comparative study of the inhibitory effect on bone erosion progression with Denosumab treatment and conventional treatment in rheumatoid arthritis patients. An open label randomized controlled trial by HR-pQCT.	Comparative study of the inhibitory effect on bone erosion progression with Denosumab treatment and conventional treatment in rheumatoid arthritis patients. An open label randomized controlled trial by HR-pQCT. - Comparative study of the inhibitory effect on bone erosion progression with Denosumab treatment and conventional treatment in rheumatoid arthritis patients. An open label randomized controlled trial by HR-pQCT.	Rheumatoid arthritis	Patients of the group that starts treatment of Denosumab will be treated with Denosumab at the time of visit on Month 0 and Month 6. Patients of the group that continues conventional treatment will be not treated with Denosumab as a rule.	Daiichi Sankyo Company, Limited		Recruiting	20years-old	Not applicable	Male and Female	44	Not applicable	Japan
120	NCT03478111	March 30, 2018	30 September 2019	CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis	A Randomized, Double-blind, Methotrexate (MTX) Based, Parallel-group, Multicenter Phase III Study to Evaluate Efficacy and Safety of CMAB008 in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis, Compared to Remicade	Rheumatoid Arthritis	Drug: CMAB008;Drug: MTX;Drug: Remicade	Shanghai Biomabs Pharmaceutical Co., Ltd.		Not recruiting	18 Years	N/A	All	390	Phase 3	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
121	JPRN-UMIN000031890	2018/03/21	2 April 2019	Triple-masked randomized comparison of 5mL or 20nL levobupivacaine to femoral triangle block for total knee arthroplasty		knee osteoarthritis or knee rheumatoid arthritis	Group LV(Low volume): preoperative femoral triangle block with 0.5% levobupivacaine 5mL Group HV(High volume): preoperative femoral triangle block with 0.125% levobupivacaine 20mL	Daiyukai General Hospital		Recruiting	20years-old	100years-old	Male and Female	120	Phase 3	Japan
122	NCT03449758	March 9, 2018	9 September 2019	Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis	Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis and With Inadequate Response or Intolerance to Current Conventional Synthetic DMARDs or Tumor Necrosis Factor Inhibitors	Rheumatoid Arthritis	Drug: SARILUMAB;Drug: Azathioprine;Drug: Chloroquine;Drug: Hydroxychloroquine;Drug: Leflunomide;Drug: Methotrexate;Drug: Sulfasalazine	Sanofi	Regeneron Pharmaceuticals	Not recruiting	18 Years	N/A	All	84	Phase 4	France
123	ChiCTR1800014584	2018-03-01	29 January 2018	Clinical efficacy of small dose aspirin in the prevention of deep venous thrombosis and pulmonary embolism after total knee arthroplasty.	Clinical efficacy of small dose aspirin in the prevention of deep venous thrombosis and pulmonary embolism after total knee arthroplasty.	Knee osteoartritis;Rheumatoid arthritis	Experimental group:Asprin;Controlled group:Rivaroxaban;	Department of Orthopaedics, West China Hospital, Sichuan University		Not Recruiting	70	100	Both	Experimental group:90;Controlled group:30;	Other	China
124	ChiCTR1800014872	2018-03-01	19 February 2018	Role of parecoxib sodium in the multimodal analgesia after total knee arthroplasty	Safety and efficacy of parecoxib sodium in the multimodal analgesia after total knee arthroplasty: a prospective randomized controlled trial	osteoarthritis or rheumatoid arthritis	Experimental group:Preoperative intravenous injection of parecoxib sodium and postoperative intravenous patient-controlled analgesia;Control group:Preoperative normal saline injection and postoperative intravenous patient-controlled analgesia;	Peking Union Medical College Hospital		Not Recruiting			Both	Experimental group:50;Control group:50;	Post-market	China
125	JPRN-UMIN000031692	2018/03/01	7 October 2019	Efficacy and Safety of repeated administration of intravenous acetaminophen injection for pain management after total knee arthroplasty	Efficacy and Safety of repeated administration of intravenous acetaminophen injection for pain management after total knee arthroplasty - Efficacy of intravenous acetaminophen injection for pain management after TKA	knee osteoarthritis rheumatoid arthritis	Study group:Fentanyl sustained intravenous administration given after operation end. And use the Intravenous acetaminophen 4 times per 6 hour.Dosage is 15 mg/kg for the patient less than 50 kg in weight and 1000 mg for the patient more than 50 kg in weight. Control group:Fentanyl sustained intravenous administration given after operation end.	Yamaguchi University		Recruiting	20years-old	Not applicable	Male and Female	60	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
126	NCT03100253	March 1, 2018	30 September 2019	Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation	Open-label, Randomized Controlled Trial Comparing Tocilizumab to Anti-TNF Treatment and Discovery of Biomarkers for Treatment Selection in Rheumatoid Arthritis Patients With Inadequate Response to a First Anti-TNF	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: Etanercept;Drug: Infliximab;Drug: Adalimumab;Drug: Golimumab;Drug: Certolizumab Pegol	Mario Negri Institute for Pharmacological Research		Recruiting	18 Years	N/A	All	400	Phase 4	Italy
127	NCT03470688	March 1, 2018	11 June 2018	Investigating the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents	An Observational Study Designed to Investigate the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents in Australian Rheumatology	Rheumatoid Arthritis;Psoriatic Arthritis;Ankylosing Spondylitis	Biological: Originator;Biological: Biosimilar	Opal Rheumatology Ltd.	Merck Sharp & Dohme Corp.	Recruiting	18 Years	N/A	All	5000	Phase 4	Australia
128	NCT03480529	March 1, 2018	16 September 2019	Monitoring the IMmUological TOXicity of Drugs	Monitoring the IMmUological TOXicity of Drugs	Arthritis;Systemic Lupus Erythematosus;Rheumatoid Arthritis;Capillary Leak Syndrome;Hepatitis	Drug: drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom	Groupe Hospitalier Pitie-Salpetriere	Institut National de la Santé Et de la Recherche Médicale, France	Not recruiting	18 Years	N/A	All	662	Early Phase 1	France
129	EUCTR2017-004079-30-BE	19/02/2018	30 April 2019	Stratification of biologic Therapies for Rheumatoid Arthritis by Pathobiology	Stratification of Biologic Therapies for RA by Pathobiology (STRAP)-EU: A randomised, open-labelled biopsy-driven stratification trial in DMARD inadequate responder patients randomised to Etanercept, Tocilizumab or Rituximab. - STRAP-EU	Rheumatoid Arthritis MedDRA version: 20.0 Level: LLT Classification code 10003268 Term: Arthritis rheumatoid System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: MabThera Product Name: MabThera Pharmaceutical Form: Concentrate for solution for infusion Trade Name: RoActmera Product Name: RoActmera Pharmaceutical Form: Solution for injection Trade Name: Enbrel Product Name: Enbrel Pharmaceutical Form: Solution for injection in pre-filled pen	Joint Research & Development Office (QMUL)		Authorised			Female: yes Male: yes	219	Phase 3	Portugal;Spain;Belgium;Italy
130	EUCTR2017-002878-38-NL	07/02/2018	5 March 2018	Abatacept to Silence anti-Citrullinated protein Antibody-expressing B cells in Rheumatoid Arthritis	Abatacept to Silence anti-Citrullinated protein Antibody-expressing B cells in Rheumatoid Arthritis - ASCARA	Patients with early, methotrexate-naïve, ACPA-positive rheumatoid arthritis MedDRA version: 20.0 Level: LLT Classification code 10003268 Term: Arthritis rheumatoid System Organ Class: 100000018818 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Orencia 125 mg Pharmaceutical Form: Solution for infusion in pre-filled syringe INN or Proposed INN: ABATACEPT CAS Number: 332348-12-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 125-	Leiden University Medical Center		Authorised			Female: yes Male: yes	46	Phase 4	Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
131	NCT03455842	February 1, 2018	11 February 2019	The BCD-089 (aIL6R) in Patients With Active Rheumatoid Arthritis	International Multicenter Comparative Randomized Double-blind Placebo-controlled Clinical Study of Efficacy and Safety of BCD-089 in Different Dosing Regimens in Patients With Active Rheumatoid Arthritis	Seropositive RA	Drug: placebo;Biological: BCD-089, 162 mg, s/c, q2w;Biological: BCD-089, 162 mg, s/c, qw	Biocad		Not recruiting	18 Years	80 Years	All	105	Phase 2	Belarus;Russian Federation
132	NCT04022525	February 1, 2018	29 July 2019	Assessment of Leflunomide Efficacy and Hepatotoxicity in Patients With Rheumatoid Arthritis Through Pharmacokinetic and Genetic Approaches	Assessment of Leflunomide Efficacy and Hepatotoxicity in Patients With Rheumatoid Arthritis Through Pharmacokinetic and Genetic Approaches	Rheumatoid Arthritis	Drug: Leflunomide 20Mg Tab	Assiut University		Not recruiting	18 Years	N/A	All	80	Phase 1/Phase 2	Egypt
133	NCT01694693	January 31, 2018	16 December 2017	Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study	Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study	Rheumatoid Arthritis	Drug: Orencia	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	0	N/A
134	NCT03430388	January 31, 2018	6 May 2019	Yellow Fever Vaccine in Patients With Rheumatic Diseases	Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area	Systemic Lupus;Rheumatoid Arthritis;Spondyloarthritis;Inflammatory Myopathy;Systemic Sclerosis;Mixed Connective Tissue Disease;Takayasu Arteritis;Granulomatosis With Polyangiitis;Sjogren's Syndrome;Juvenile Idiopathic Arthritis;Juvenile Dermatomyositis	Biological: Yellow Fever vaccine (17D)	University of Sao Paulo General Hospital		Not recruiting	2 Years	60 Years	All	600	N/A	Brazil
135	EUCTR2017-002753-11-FI	25/01/2018	30 April 2019	The effect of the new anti-rheumatic drug tofacitinib on cytokine-induced inflammatory pathways in patients with rheumatoid arthritis	The effect of tofacitinib on the activity of JAK-STAT pathways in patients with rheumatoid arthritis (RA) - TofaSTAT17	Rheumatoid arthritis;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Xeljanz Product Name: Xeljanz Product Code: PRD4862257 Pharmaceutical Form: Tablet CAS Number: 540737-29-9 Other descriptive name: TOFACITINIB CITRATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Trade Name: Tofacitinib Product Code: PRD4862257	Tampere University Hospital		Authorised			Female: yes Male: yes	24	Phase 4	Finland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
136	NCT03227419	January 22, 2018	3 September 2018	Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders	Abatacept Versus Tocilizumab by Subcutaneous Administration for the Treatment of Rheumatoid Arthritis in TNF Alpha Inhibitor Inadequate Responder Patients: A Randomized, Open-labeled, Superiority Trial	Arthritis, Rheumatoid	Drug: Tocilizumab Prefilled Syringe;Drug: Abatacept Prefilled Syringe	Lille Catholic University		Recruiting	18 Years	N/A	All	224	Phase 4	France
137	NCT03368235	January 18, 2018	4 November 2019	Early Phase Study to Assess Efficacy and Safety of AZD9567 Versus Prednisolone in Patients With Rheumatoid Arthritis	A Phase 2a, Randomised, Double-blind, Parallel Study to Assess the Efficacy, Safety and Tolerability of AZD9567 Compared to Prednisolone 20 mg in Patients With Active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: AZD9567;Drug: Prednisolone	AstraZeneca		Recruiting	18 Years	80 Years	All	40	Phase 2	Denmark;Netherlands;Sweden
138	JPRN-UMIN000030828	2018/01/15	2 April 2019	The preventive effect for new vertebral fractures of zoledronic acid and denosumab combined with vitamin D in patients with rheumatoid arthritis.		Rheumatoid Arthritis Osteoporosis	zoledronic acid denosumab	Osaka City University Graduate School of Medicine		Recruiting	20years-old	Not applicable	Male and Female	500	Not selected	Japan
139	EUCTR2017-003259-40-ES	04/01/2018	8 January 2018	Periodontitis treatment in patients with reumatoid arthritis and high clinical activity in the. Randomized clinical trial.	Periodontitis treatment in patients with reumatoid arthritis and high clinical activity in the. Randomized clinical trial.	Patients with rheumatoid arthritis with high clinical activity and chronical peirodontitis moderate-severe. MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: amoxicilina Pharmaceutical Form: Buccal tablet INN or Proposed INN: AMOXICILLIN CAS Number: 26787-78-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- Product Name: metronidazol Pharmaceutical Form: Buccal tablet INN or Proposed INN: METRONIDAZOLE Other descriptive name: metronidazol Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250-	Dra Beatriz Lozano-Hospital Universitario de Canarias		Authorised			Female: yes Male: yes	120	Phase 4	Spain
140	NCT02955212	January 3, 2018	30 September 2019	A Study With Upatacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)	Rheumatoid Arthritis (RA)	Drug: Upadacitinib;Drug: Placebo	AbbVie		Not recruiting	18 Years	N/A	All	338	Phase 3	Brazil;China;Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
141	JPRN-UMIN000030237	2018/01/01	2 April 2019	Additional postoperative intravenous tranexamic acid administration versus placebo administration for patients treated with intraoperative combined intravenous and intra-articular tranexamic acid in total knee arthroplasty: a randomized, double-blind, placebo-controlled trial		Osteoarthritis of the knee, rheumatoid arthritis, avascular necrosis	Additional postoperative intravenous tranexamic acid group: Patients received 1000 mg of tranexamic acid administered intravenously just before skin incision and 1000 mg of tranexamic acid administered intra-articularly after closure of the capsule and retinaculum. In addition, patients received 1000mg/100mL of tranexamic acid administered intravenously 6 hours after the first intravenous administration of tranexamic acid, and 08:00 and 20:00 one day after surgery. Placebo group: Patients received 1000 mg of tranexamic acid administered intravenously just before skin incision and 1000 mg of tranexamic acid administered intra-articularly after closure of the capsule and retinaculum. Patients received 100 mL of normal saline administered intravenously 6 hours after the first intravenous administration of tranexamic acid, and 08:00 and 20:00 one day after surgery.	Hokusuikai Kinen Hospital		Not Recruiting	20years-old	Not applicable	Male and Female	100	Not selected	Japan
142	NCT02795299	January 2018	23 July 2018	Study Evaluating Gerilimzumab´s Safety/Efficacy for Patients MTX or TNFa Antagonist Failed in Rheumatoid Arthritis	Phase 2, Rand, Placebo-Controlled, Double-Blind, Dose Ranging Study to Evaluating Safety/Efficacy of Gerilimzumab in Patients With Moderately to Severely Active Rheumatoid Arthritis Inadequately Treated With Methotrexate or TNFa Antagonist	Rheumatoid Arthritis	Drug: Gerilimzumab;Drug: Methotrexate;Drug: Folic Acid;Drug: Placebo	Bird Rock Bio, Inc.	Techtrials Pesquisa e Tecnologia Ltda;Pharmagenix	Not recruiting	18 Years	80 Years	All	0	Phase 2
143	JPRN-jRCTs031180050	26/12/2017	10 September 2019	Hydroxychloroquine for Japanese patients with rheumatoid arthritis	Efficacy and safety of hydroxychloroquine for Japanese patients with rheumatoid arthritis	Rheumatoid arthritis;D001172	Treatment with hydroxychloroquine for 24 weeks	Yuko Kaneko		Recruiting	>= 18age old	Not applicable	Both	120	Phase 2-3	None
144	NCT03798028	December 26, 2017	21 January 2019	The Safety and Effects of Mesenchymal Stem Cell (MSCs) in the Treatment of Rheumatoid Arthritis	The Effects and Safety of Mesenchymal Stem Cells in the Treatment of Moderate/Severe Rheumatoid Arthritis, a Multicenter Randomized Controlled Clinical Study	Rheumatoid Arthritis	Biological: UC-MSCs	Xijing Hospital	Changhai Hospital;Southwest Hospital, China	Recruiting	18 Years	70 Years	All	250	N/A	China
145	EUCTR2017-001970-41-DK	21/12/2017	24 September 2018	Dose reduction and withdrawal of biological therapy in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: Protocol for a 18 months multi-centre trial	Dose reduction and discontinuation of biological therapy in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: Protocol for a 18 months randomised, open label, parallel-group, multi-centre trial - The BIODOPT trial (BIOlogical Dose OPTimisation)	Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis MedDRA version: 20.0 Level: LLT Classification code 10040107 Term: Seropositive rheumatoid arthritis System Organ Class: 100000004859 MedDRA version: 20.0 Level: LLT Classification code 10062719 Term: Seronegative rheumatoid arthritis System Organ Class: 100000004859 MedDRA version: 20.0 Level: LLT Classification code 10037160 Term: Psoriatic arthritis System Organ Class: 100000004859 MedDRA version: 20.0 Level: LLT Classification code 10076297 Term: Non-radiographic axial spondyloarthritis System Organ Class: 100000004859 MedDRA version: 20.0 Level: LLT Classification code 10041672 Term: Spondylitis ankylosing System Organ Class: 100000004859 MedDRA version: 20.0 Level: LLT Classification code 10002557 Term: Ankylosing spondylitis and other inflammatory spondylopathies System Organ Class: 100000004859 MedDRA version: 20.0 Level: LLT Classification code 10045966 Term: Unspecified inflammatory spondylopathy System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Orencia Product Name: Abatacept Product Code: L04AA24 Pharmaceutical Form: Concentrate for solution for injection INN or Proposed INN: ABATACEPT CAS Number: 332348-12-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 125 - Trade Name: Orencia Product Name: Abatacept Product Code: L04AA24 Pharmaceutical Form: Concentrate and solvent for solution for infusion INN or Proposed INN: ABATACEPT CAS Number: 332348-12-6 Concentration unit: mg/kg milligram(s)/kilogram Concentration type: up to Concentration number: 10 - Trade Name: Humira Product Name: Adalimumab Product Code: L04AB04 Pharmaceutical Form: Concentrate and solvent for solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40 - Trade Name: Cimzia Product Name: Certolizumab pegol Product Code: L04AB05 Pharmaceutical Form: Concentrate and solvent for solution for injection INN or Proposed INN: CERTOLIZUMAB PEGOL CAS Number: 428863-50-7 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 200 -400 Trade Name: Enbrel Product Name: Etanercept Product Code: L04AB01 Pharmaceutical Form: Concentrate and solvent for solution for injection INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 25 -50 Trade Name: Benepali Product Name: Etanercept Product Code: L04AB01 Pharmaceutical Form: Concentrate and solvent for suspension for injection INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 25 -50 Trade Name: Simponi Product Name: Golimumab Product Code: L04AB06 Pharmaceutical Form: Concentrate and solvent for solution for injection INN or Proposed INN: GOLIMUMAB CAS Number: 476181-74-5 Concentration unit: mg milligram(s) Concentration type: equal	MD, PhD Salome Kristensen		Authorised			Female: yes Male: yes	180	Phase 4	Denmark
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
146	NCT03457792	December 19, 2017	11 June 2018	A Study of Abatacept in Participants That Only Recently Started to Develop Rheumatoid Arthritis	Abatacept in Early-Stage Rheumatoid Arthritis Patients: Longterm Experience and Efficacy in Routine Clinical Practice	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb		Recruiting	18 Years	N/A	All	400	N/A	Germany
147	NCT03186417	December 15, 2017	22 July 2019	Mesenchymal Stem Cells in Early Rheumatoid Arthritis	Cell-Based Therapy in Rheumatoid Arthritis: Proof of Concept Phase 1 Trial	Rheumatoid Arthritis	Biological: 2 million hMSC/kg;Biological: 4 million hMSC/kg;Biological: 6 million hMSC/kg;Biological: placebo	MetroHealth Medical Center	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Recruiting	18 Years	80 Years	All	20	Phase 1	United States
148	EUCTR2017-001717-92-AT	11/12/2017	7 January 2019	A randomised, double-blind, placebo-controlled Phase II study to target the type I IFN receptor by administrating Anifrolumab in patients with rheumatoid arthritis who have a high interferon signature (TarIFNiRA)	A randomised, double-blind, placebo-controlled Phase II study to target the type I IFN receptor by administrating Anifrolumab in RA patients with a high IFN signature (TarIFNiRA) - TarIFNiRA	High IFN siganture in patients with rheumatoid arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Anifrolumab (MEDI-546) Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ANIFROLUMAB Other descriptive name: ANIFROLUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use	Medical University of Vienna		Authorised			Female: yes Male: yes	24	Phase 2	Austria;Italy;Switzerland
149	EUCTR2017-001944-36-PL	23/11/2017	15 October 2018	Safety and Efficacy of AMG 592 in Subjects with Active Rheumatoid Arthritis	A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects with Active Rheumatoid Arthritis With Inadequate Response to Standard of Care Therapy	Rheumatoid Arthritis MedDRA version: 20.0 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000004870 ;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: AMG 592 Pharmaceutical Form: Solution for injection INN or Proposed INN: AMG592 Current Sponsor code: AMG592 Other descriptive name: AMG592 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Amgen Inc		Authorised			Female: yes Male: yes	137	Phase 1;Phase 2	United States;Czech Republic;Mexico;Spain;Poland;Romania;Australia;Bulgaria;Germany;New Zealand;United Kingdom
150	NCT03334851	November 17, 2017	30 September 2019	Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis	A PHASE 1, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, SPONSOR OPEN, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS	Systemic Lupus Erythematosus;Rheumatoid Arthritis	Drug: PF-06835375;Drug: Placebo	Pfizer		Recruiting	18 Years	70 Years	All	112	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
151	NCT03911830	November 11, 2017	23 April 2019	Aerobic Exercise Program Followed by Cold Water Immersion: Effects on Arthritis Patients Arterial Stiffness	Effects of an Aerobic Exercise Program on Cycloergometer Followed by Cold Water Immersion Recovery in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis;Cryotherapy Effect;Physical Activity	Other: Exercise followed cold water immersion	Centre Hospitalier Universitaire de Besancon		Not recruiting	20 Years	80 Years	All	18	N/A	France
152	EUCTR2017-003425-15-DK	10/11/2017	11 December 2017	Patients with rheumatoid arthritis and synovitis treated with ultrasound guided intraarticular or intramuscular glucocorticoid injection - A randomised, double-blind, controlled study (Panguian)	Patients with rheumatoid arthritis and synovitis treated with ultrasound guided intraarticular or intramuscular glucocorticoid injection - A randomised, double-blind, controlled study (Panguian)	Treatment of synovitis among rheumatoid arthritis patients MedDRA version: 20.0 Level: PT Classification code 10042868 Term: Synovitis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Diprofos Depot Pharmaceutical Form: Solution for injection INN or Proposed INN: BETAMETHASONE ACIBUTATE CAS Number: 5534-05-4 Current Sponsor code: Glucococorticoid Other descriptive name: Binyrebsrkhormon Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 3.5-14 Pharmaceutical form of the placebo: Solution for injection/infusion Route of administration of the placebo: Intraarticular use Pharmaceutical form of the placebo: Solution for injection/infusion Route of administration of the placebo: Intramuscular use	Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet		Authorised			Female: yes Male: yes	100	Phase 4	Denmark
153	NCT03357471	November 3, 2017	10 September 2018	Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease	A Multicenter, Open-Label Study to Evaluate the Safe and Effective Use of an Electro-Mechanical Injection Device (E-Device) for the Subcutaneous Self-Injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease	Moderate and Severe Active Rheumatoid Arthritis;Active Psoriatic Arthritis;Active Ankylosing Spondylitis;Moderately to Severely Active Crohn's Disease	Drug: e-Device	UCB Biopharma S.P.R.L.		Not recruiting	18 Years	N/A	All	70	Phase 3	United States
154	EUCTR2017-000384-32-BG	02/11/2017	30 April 2019	Phase IIb in Rheumatoid Arthritis	A Phase IIb, Randomized, Double blind Study in Subjects with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Subjects with an Inadequate Response to Methotrexate - N/A	Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Evobrutinib Product Code: M2951 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Evobrutinib CAS Number: N/A Current Sponsor code: M2951 Other descriptive name: M2951 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Merck KGaA		Authorised			Female: yes Male: yes	363	Phase 2	Serbia;United States;Ukraine;Russian Federation;Chile;Colombia;Czech Republic;Mexico;Argentina;Brazil;Poland;Bulgaria;South Africa;Germany;Japan
155	JPRN-UMIN000029797	2017/11/02	23 April 2019	Intravenous versus combined intravenous and intra-articular tranexamic acid for simultaneous bilateral total hip arthroplasty: randomized controlled trial	Intravenous versus combined intravenous and intra-articular tranexamic acid for simultaneous bilateral total hip arthroplasty: randomized controlled trial - Intravenous versus combined intravenous and intra-articular tranexamic acid for simultaneous bilateral total hip arthroplasty: randomized controlled trial	Osteoarthritis of the hip, Avascular necrosis of the femoral head, Rheumatoid arthritis	The combined tranexamic acid group received 1000 mg of tranexamic acid administered intravenously just before skin incision of the first hip. After closure of fascia, 1000 mg of tranexamic acid (10 mL of 100 mg/mL tranexamic acid) was administered intra-articularly for each hip. Five hours after the first intravenous administration of tranexamic acid, 1000 mg of tranexamic acid was again given intravenously. The intravenous tranexamic acid group received 1000 mg of tranexamic acid administered intravenously just before skin incision of the first hip. After closure of the fascia, 10 mL of normal saline was administered intra-articularly for each hip. Five hours after the first intravenous administration of tranexamic acid, 1000 mg of tranexamic acid was again given intravenously.	Hokusuikai Kinen Hospital		Not Recruiting	18years-old	Not applicable	Male and Female	40	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
156	NCT03329885	November 2, 2017	20 August 2018	A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Patients and Patients With Average to Very Serious Psoriasis	A Double-Blind Randomized Placebo-Controlled Single and Multiple Ascending Doses Study of the Safety and Tolerability, Pharmacokinetics (Including Bioavailability Comparison and Food Effect) and Pharmacodynamics of Oral BMS-986251 Administration in Healthy Subjects, With Efficacy Assessment of Multiple Doses in Patients With Moderate-to-Severe Psoriasis	Rheumatoid Arthritis;Psoriasis;Ankylosing Spondylitis;Inflammatory Bowel Diseases;Nonalcoholic Steatohepatitis	Other: Placebo;Drug: BMS-986251	Bristol-Myers Squibb		Not recruiting	18 Years	70 Years	All	38	Phase 1/Phase 2	Netherlands
157	NCT03387423	November 2, 2017	11 November 2019	Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis	ESCALATE-RA A NON-INTERVENTIONAL STUDY OF CRITICAL FACTORS FOR ESCALATING DRUG TREATMENT IN PATIENTS TREATED WITH TOFACITINIB FOR MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS	Arthritis, Rheumatoid	Drug: Tofacitinib	Pfizer		Recruiting	18 Years	N/A	All	1500	N/A	Germany
158	JPRN-JapicCTI-173747	01/11/2017	16 July 2019	Specific Use Result Survey of PRALIA 60 mg Subcutaneous Injection Syringe - A Long-term Use Survey in Patients with Rheumatoid Arthritis -	Specific Use Result Survey of PRALIA 60 mg Subcutaneous Injection Syringe - A Long-term Use Survey in Patients with Rheumatoid Arthritis -	Rheumatoid Arthritis	Intervention name : PRALIA 60 mg Subcutaneous Injection Syringe(denosumab) Dosage And administration of the intervention : For adults under normal conditions, 60 mg of denosumab (genetic recombination) is injected subcutaneously every six months. If bone erosion progression occurs when denosumab is injected once every 6 months, denosumab can be injected subcutaneously once every 3 months.	DAIICHISANKYO Co., Ltd.		Recruiting			BOTH	1000	NA
159	JPRN-UMIN000029759	2017/11/01	2 April 2019	Percutaneous periarticular analgesic injection at one day after simultaneous bilateral total knee arthroplasty as a component of multimodal pain management: a randomized control trial		Osteoarthritis, Avascular necrosis of femoral condyle, Rheumatoid arthritis	Percutaneous periarticular analgesic injection including methylprednisolone 80 mg [2 mL], ropivacaine 150 mg [20 mL], and epinephrine 0.2 mg [0.2 mL] at one day after simultaneous bilateral total knee arthroplasty No percutaneous periarticular analgesic injection at one day after simultaneous bilateral total knee arthroplasty	Nekoyama Miyao Hospital		Not Recruiting	20years-old	Not applicable	Male and Female	32	Not selected	Japan
160	NCT03440892	November 1, 2017	18 March 2019	Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients	Longitudinal Observational Study on Rheumatoid Arthritis Patients: Effects of Antirheumatic Treatment on Serum Levels of Survivin	Rheumatoid Arthritis	Drug: methotrexate;Drug: sulfasalazine;Drug: abatacept;Drug: tocilizumab;Drug: tofacitinib/baricitinib	Vastra Gotaland Region		Recruiting	20 Years	N/A	All	2500	N/A	Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
161	NCT02647762	October 30, 2017	14 October 2019	CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis	A Phase 3, Randomized, Double-Blind, Active- and Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of CF101 Compared to Methotrexate in the Treatment of Early Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CF101 1 mg;Drug: CF101 2 mg;Drug: Placebo;Drug: MTX	Can-Fite BioPharma		Recruiting	18 Years	75 Years	All	525	Phase 3	Bosnia and Herzegovina;Canada;Israel;Moldova, Republic of;Poland;Romania;Serbia
162	NCT03324412	October 28, 2017	16 December 2017	Efficacy and Safety of TwHF and MTX in Patients With Rheumatoid Arthritis	A 24-Week, Multicenter ,Double Blind, Randomized Study to Determine the Effects and Security of TwHF and MTX Treating Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Treatment of MTX;Drug: Treatment of MTX and TwHF	Guang'anmen Hospital of China Academy of Chinese Medical Sciences		Not recruiting	45 Years	70 Years	All	216	Phase 2/Phase 3
163	NCT03337815	October 28, 2017	16 December 2017	A Specification Clinical Application Research of Tripterygium Wilfordii Treating Rheumatoid Arthritis	A 24-Week, Multicenter ,Double Blind, Randomized Study to Determine the Effects and Security of Tripterygium Wilfordii Treating Rheumatoid Arthritis and Establish A Prediction Model	Rheumatoid Arthritis	Drug: Treatment of MTX and TwHF placebo;Drug: Treatment of TwHF and MTX placebo	Guang'anmen Hospital of China Academy of Chinese Medical Sciences		Recruiting	45 Years	70 Years	All	264	Phase 2/Phase 3	China
164	NCT03163966	October 5, 2017	8 January 2018	A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis	A Randomized, Double Blind, Placebo-controlled, Dose Response, Phase II, Multicentre Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Oral CR6086 Administered at the Doses of 30, 90 or 180 mg Bid for 12 Weeks in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis	Rheumatoid Arthritis, DMARD-naive and Early Disease Patients	Drug: CR6086;Drug: Methotrexate;Drug: Placebo	Rottapharm Biotech		Recruiting	18 Years	N/A	All	240	Phase 2	Czechia
165	JPRN-UMIN000029003	2017/10/01	2 April 2019	Percutaneous periarticular analgesic injection at one day after total knee arthroplasty as a component of multimodal pain management: a randomized control trial		Osteoarthritis, Avascular necrosis of femoral condyle, Rheumatoid arthritis	Percutaneous periarticular analgesic injection including methylprednisolone 40 mg [1 mL], ropivacaine 150 mg [20 mL], and epinephrine 0.1 mg [0.1 mL] at one day after total knee arthroplasty No percutaneous periarticular analgesic injection at one day after total knee arthroplasty	Nekoyama Miyao Hospital		Not Recruiting	20years-old	Not applicable	Male and Female	40	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
166	NCT03254589	October 1, 2017	26 August 2019	Methotrexate, Blood Pressure and Arterial Function in Rheumatoid Arthritis	Methotrexate, Blood Pressure and Arterial Function in Rheumatoid Arthritis	Rheumatoid Arthritis;Stiffness, Aortic;Endothelial Dysfunction;Cardiovascular Risk Factor	Drug: Methotrexate;Drug: Sulfasalazine;Drug: Other DMARDs	Flinders University	University of South Australia;medac GmbH	Recruiting	18 Years	N/A	All	124	Phase 4	Australia
167	NCT03257852	September 29, 2017	11 November 2019	A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate	A Phase 2a, Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate	Rheumatoid Arthritis (RA)	Drug: ASP5094;Drug: Placebo;Other: Methotrexate therapy	Astellas Pharma Inc		Not recruiting	20 Years	N/A	All	66	Phase 2	Japan
168	EUCTR2016-004300-65-BE	26/09/2017	20 August 2018	Optimizing the Biologic Treatment Strategy in Rheumatoid Arthritis (RA) Patients that have failed a Tumor Necrosis Factor-alpha (TNFa) blocking Agent by immunoscintigraphy with Technetium-labeled Cimzia®).	Optimizing the Biologic Treatment Strategy in Rheumatoid Arthritis (RA) Patients that have failed a Tumor Necrosis Factor-alpha (TNFa) blocking Agent by immunoscintigraphy with Technetium-labeled Cimzia®). - SCINTRA TRIS	rheumatoid arthritis;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: 99mTc-S-HYNIC Certolizumab pegol Pharmaceutical Form: Solution for injection INN or Proposed INN: CERTOLIZUMAB PEGOL CAS Number: 428863-50-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.25-	Ghent University Hospital		Authorised			Female: yes Male: yes	120	Phase 4	Belgium
169	EUCTR2017-000384-32-CZ	26/09/2017	11 June 2018	Phase IIb in Rheumatoid Arthritis	A Phase IIb, Randomized, Double blind Study in Subjects with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Subjects with an Inadequate Response to Methotrexate - N/A	Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Evobrutinib Product Code: M2951 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Evobrutinib CAS Number: N/A Current Sponsor code: M2951 Other descriptive name: M2951 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Merck KGaA		Authorised			Female: yes Male: yes	363	Phase 2	Japan;Germany;Bulgaria;South Africa;Poland;Brazil;Argentina;Mexico;Czech Republic;Colombia;Chile;Russian Federation;Ukraine;United States;Serbia
170	NCT03233230	September 18, 2017	15 July 2019	Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis	A Phase IIb, Randomized, Double-blind Study in Subjects With Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared With Placebo in Subjects With an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: Evobrutinib;Drug: Placebo;Drug: Methotrexate	EMD Serono Research & Development Institute, Inc.	Merck KGaA, Darmstadt, Germany	Not recruiting	18 Years	75 Years	All	390	Phase 2	United States;Argentina;Brazil;Bulgaria;Chile;Colombia;Czechia;Mexico;Poland;Russian Federation;Serbia;South Africa;Ukraine;Germany;Hungary;Romania;Slovakia;Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
171	EUCTR2017-000838-64-SE	11/09/2017	16 October 2017	An early phase study in patients with active Rheumatoid Arthritis to compare the safety and efficacy of AZD9567 and prednisolone	A Phase 2a, Randomised, Double-blind, Parallel Study to Assess the Efficacy, Safety and Tolerability of AZD9567 compared to Prednisolone 20 mg in patients with active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]	Product Name: AZD9567 Product Code: AZD9567 monohydrate Pharmaceutical Form: Oral suspension INN or Proposed INN: N/A CAS Number: 1893415-64-9 Current Sponsor code: ADZ9567 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 0.5-10 Pharmaceutical form of the placebo: Oral suspension Route of administration of the placebo: Oral use Trade Name: PredniHEXAL Pharmaceutical Form: Capsule, hard INN or Proposed INN: Prednisolone CAS Number: - Current Sponsor code: - Other descriptive name: - Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	AstraZeneca AB		Authorised			Female: yes Male: yes	40	Phase 2	Denmark;Netherlands;Sweden
172	NCT03262740	September 11, 2017	12 March 2018	The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients	The Effect of BMS-986195 on the Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Subjects	Rheumatoid Arthritis	Drug: BMS-986195;Drug: Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol)	Bristol-Myers Squibb		Not recruiting	18 Years	40 Years	Female	58	Phase 1	United States
173	EUCTR2016-004834-11-BG	04/09/2017	28 February 2019	A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of oral CR6086 administered at the doses of 30, 90 or 180 mg bid for 12 weeks in combination with methotrexate, in DMARD-naïve patients with early rheumatoid arthritis	A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of oral CR6086 administered at the doses of 30, 90 or 180 mg bid for 12 weeks in combination with methotrexate, in DMARD-naïve patients with early rheumatoid arthritis	Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: CR6086 Product Code: CR6086Z Pharmaceutical Form: Capsule INN or Proposed INN: see D.3.9.3 'Other descriptive name' below CAS Number: 1417742-86-9 Current Sponsor code: CR6086Z Other descriptive name: CR6086 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: CR6086 Product Code: CR6086Z Pharmaceutical Form: Capsule INN or Proposed INN: see D.3.9.3 'Other descriptive name' below CAS Number: 1417742-86-9 Current Sponsor code: CR6086Z Other descriptive name: CR6086 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: Methotrexate® 2.5 mg tablets Pharmaceutical Form: Tablet INN or Proposed INN: Methotrexate CAS Number: 59-05-2 Other descriptive name: METHOTREXATE 2.5 mg tablets Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5-	Rottapharm Biotech S.r.l.		Not Recruiting			Female: yes Male: yes	240	Phase 2	Moldova, Republic of;United Kingdom;Bulgaria;Denmark;Romania;Poland;Argentina;Czech Republic
174	NCT03241446	September 2017	15 October 2018	Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)	A Phase I, Open-Label Study to Investigate the Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Tilmanocept	Navidea Biopharmaceuticals		Not recruiting	30 Years	65 Years	All	0	Phase 1
175	NCT03254966	September 2017	16 December 2017	Study of SHR0302 Tablets (SHR0302) as Monotherapy in Active Rheumatoid Arthritis (RA) Patients	Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Assess the Safety and Efficacy of SHR0302 in Patients With Moderate to Severe Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: SHR0302;Drug: Placebo	Jiangsu HengRui Medicine Co., Ltd.		Not recruiting	18 Years	70 Years	All	170	Phase 2	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
176	EUCTR2017-000947-41-FR	18/08/2017	16 October 2017	ORENCIA VERSUS ROACTEMRA BY SUBCUTANEOUS ADMINISTRATION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN TNF ALPHA INHIBITOR INADEQUATE RESPONDER PATIENTS.	ABATACEPT VERSUS TOCILIZUMAB BY SUBCUTANEOUS ADMINISTRATION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN TNF ALPHA INHIBITOR INADEQUATE RESPONDER PATIENTS: A RANDOMIZED, OPEN-LABELED, SUPERIORITY TRIAL. - SUNSTAR	Adults patients suffering from rheumatoid arthritis and in adequate response to a first line of treatment with a TNF alpha inhibitor. MedDRA version: 20.0 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000004870 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: ORENCIA 125 mg, solution injectable en seringue préremplie Pharmaceutical Form: Solution for injection/infusion in pre-filled syringe Trade Name: RoActemra 162 mg solution injectable en seringue préremplie Pharmaceutical Form: Solution for injection	Groupement des Hôpitaux de l’Institut Catholique de Lille		Authorised			Female: yes Male: yes		Phase 4	France
177	NCT03160001	August 15, 2017	18 December 2018	Niclosamide With Etanercept in Rheumatoid Arthritis	Adjuvant Use of Niclosamide With Etanercept in Rheumatoid Arthritis: Experimental and Clinical Study	Rheumatoid Arthritis (RA)	Drug: Placebo;Drug: Niclosamide;Drug: Etanercept	Faiq Gorial		Not recruiting	18 Years	N/A	All	110	Phase 1/Phase 2	Iraq
178	NCT03245515	August 15, 2017	18 January 2018	A Study of BMS-986195 in Healthy Male Subjects	Pharmacokinetics and Metabolism of [14C] BMS-986195 in Healthy Male Subjects	Rheumatoid Arthritis	Drug: BMS-986195	Bristol-Myers Squibb		Not recruiting	18 Years	55 Years	Male	24	Phase 1	Netherlands
179	NCT03156023	August 14, 2017	4 November 2019	Multiple Ascending Doses of AMG 570 in Subjects With Rheumatoid Arthritis	A Randomized, Double Blind Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of AMG 570 in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: AMG 570;Drug: Placebo	Amgen		Not recruiting	18 Years	75 Years	All	34	Phase 1	United States;Germany
180	NCT03327454	August 10, 2017	5 November 2018	Benepali® PEN Patient Satisfaction Survey	Non-Interventional Observational Study on Patient Satisfaction With the Benepali® Pre-Filled Pen	Rheumatoid Arthritis;Spondyloarthropathies	Biological: Benepali	Biogen		Not recruiting	18 Years	N/A	All	500	N/A	Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
181	NCT03188081	August 4, 2017	23 July 2018	A Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in Italian Real Life Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous (SC) Abatacept	A Prospective, Multicentric, Observational Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in Italian Real Life RA Patients Treated With Abatacept SC	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb		Recruiting	18 Years	N/A	All	300	N/A	Italy
182	NCT03155347	August 2, 2017	4 November 2019	An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy	A Randomized, Multi-Center, Double Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Subcutaneous (SC) Tocilizumab (TCZ) in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Patients With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current DMARD Therapy	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: MTX;Drug: Placebo Matched to MTX;Drug: Placebo Matched to Tocilizumab	Hoffmann-La Roche		Recruiting	18 Years	70 Years	All	300	Phase 3	China
183	NCT03215407	August 1, 2017	16 December 2017	The Comparative Study of Intra-articular Injection of Tocilizumab and Compound Betamethasone	The Comparative Study of Safety and Effectiveness of Intra-articular Injection of Tocilizumab and Compound Betamethasone in Rheumatoid Arthritis of the Knee	Rheumatoid Arthritis of Knee	Drug: Intra-articular Tocilizumab;Drug: Intra-articular Compound Betamethasone	Chinese PLA General Hospital		Not recruiting	18 Years	65 Years	All	60	Phase 4
184	NCT03250767	August 1, 2017	30 September 2019	Clinical Evaluation of the Integra® Titan™ Modular Shoulder System Generation 2.5 for Primary Shoulder Joint Replacement	A Post-Market, Prospective, Multi-Center, Open-Label, Single Arm Clinical Evaluation of the Integra® Titan™ Modular Shoulder System Generation 2.5 for Primary Shoulder Joint Replacement	Osteo Arthritis Shoulders;Traumatic Arthritis;Rheumatoid Arthritis	Device: Integra Titan Modular Shoulder System 2.5	Integra LifeSciences Corporation		Recruiting	18 Years	N/A	All	140	Phase 1/Phase 2	United States
185	JPRN-UMIN000028376	2017/07/26	2 April 2019	Study of ultrasound detected residual synovitis treated with combination of anti-rheumatic therapy and denosumab in rheumatoid arthritis		rheumatoid arthritis	Combination of anti-rheumatic therapy and denosumab Anti-rheumatic therapy alone	Hokkaido Medical Center for Rheumatic Diseases		Recruiting	20years-old	75years-old	Male and Female	30	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
186	NCT02541955	July 20, 2017	9 September 2019	Use of Acthar in Rheumatoid Arthritis (RA) Related Flares	Use of Acthar in Rheumatoid Arthritis Related Flares	Rheumatoid Arthritis (RA)	Drug: Acthar	Dr. Veena Ranganath		Recruiting	18 Years	N/A	All	40	Phase 4	United States
187	EUCTR2016-004834-11-DK	06/07/2017	30 April 2019	A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of oral CR6086 administered at the doses of 30, 90 or 180 mg bid for 12 weeks in combination with methotrexate, in DMARD-naïve patients with early rheumatoid arthritis	A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of oral CR6086 administered at the doses of 30, 90 or 180 mg bid for 12 weeks in combination with methotrexate, in DMARD-naïve patients with early rheumatoid arthritis	Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: CR6086 Product Code: CR6086Z Pharmaceutical Form: Capsule INN or Proposed INN: see D.3.9.3 'Other descriptive name' below CAS Number: 1417742-86-9 Current Sponsor code: CR6086Z Other descriptive name: CR6086 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: CR6086 Product Code: CR6086Z Pharmaceutical Form: Capsule INN or Proposed INN: see D.3.9.3 'Other descriptive name' below CAS Number: 1417742-86-9 Current Sponsor code: CR6086Z Other descriptive name: CR6086 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: Methotrexate® 2.5 mg tablets Pharmaceutical Form: Tablet INN or Proposed INN: Methotrexate CAS Number: 59-05-2 Other descriptive name: METHOTREXATE 2.5 mg tablets Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5-	Rottapharm Biotech S.r.l.		Not Recruiting			Female: yes Male: yes	240	Phase 2	Czech Republic;Argentina;Poland;Romania;Denmark;Bulgaria;Moldova, Republic of;United Kingdom
188	NCT03120949	July 4, 2017	18 December 2018	Evaluation of the Long Term Safety, Tolerability and Efficacy of Two Dosing Regimens of Olokizumab (OKZ), in Subjects With Rheumatoid Arthritis (RA) Who Previously Completed 24 Weeks of Blinded Treatment in One of the Core Studies - CREDO 1, 2 or 3.	A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Olokizumab 64 mg SC q4w;Drug: Olokizumab 64 mg SC q2w;Drug: Methotrexate	R-Pharm	Quintiles, Inc.;OCT Clinical Trials;Mene Research	Recruiting	18 Years	N/A	All	1880	Phase 3	United States;Argentina;Brazil;Bulgaria;Colombia;Czechia;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom
189	NCT03189017	July 3, 2017	26 August 2019	A Phase I Study of ICP-022 in Healthy Subjects	A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ICP-022 Following Single and Multiple Escalating Dose	Systemic Lupus Erythematosus;Rheumatoid Arthritis	Drug: ICP-022;Drug: Placebos	Innocare Pharma Australia Pty Ltd		Not recruiting	18 Years	55 Years	Male	64	Phase 1	Australia
190	NCT03285191	July 3, 2017	27 August 2018	Subject Insights to Understand Rheumatoid Arthritis (RA)	Patient Interviews to Better Understand Disease Experience and Unmet Treatment Needs in Rheumatoid Arthritis	Arthritis, Rheumatoid	Other: Numerical rating scale;Other: Real-time data capture app	GlaxoSmithKline		Not recruiting	18 Years	N/A	All	30	Phase 1/Phase 2	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
191	ChiCTR-IPR-17011566	2017-07-01	12 June 2017	The efficacy and safety of sirolimus in refractory rheumatoid arthritis: A multi-center randomized controlled trial in China	The efficacy and safety of sirolimus in refractory rheumatoid arthritis: A multi-center randomized controlled trial in China	Rheumatoid Arthritis;M05.901	Sirolimus group: Sirolimus; Non-Sirolimus group:Glucocorticoids and Immunosuppressant;	the Second Hospital of Shanxi Medical University		Recruiting	18	65	Both	Sirolimus group:200; Non-Sirolimus group:100;	Post-market	China
192	NCT03394131	July 1, 2017	23 July 2018	?Efficacy of Insulin Versus Hyalase Hydro-dissection of Median Nerve in Rheumatoid Arthritis Patients	Treatment of Carpal Tunnel in Rheumatoid Arthritis	Treatment Resistant Carpal Tunnel in RA Patients	Drug: Hylase;Drug: Insulin;Other: saline	Assiut University		Recruiting	20 Years	80 Years	All	90	N/A	Egypt
193	ChiCTR-INR-17011772	2017-06-27	3 July 2017	The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of rheumatoid arthritis with poor response to immunosuppressive agents	The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of rheumatoid arthritis with poor response to immunosuppressive agents	Rheumatoid Arthritis	test group:Metformin tablets, 0.25g, 3 / day, oral, atorvastatin tablets 10mg, 1 / night, oral;;Control group:Traditional DMARDs group;	Inner Mongolia University of Science and Technology Baotou Medical College First Affiliated Hospital		Recruiting	18	65	Both	test group:80;Control group:40;	New Treatment Measure Clinical Study	China
194	NCT03278470	June 26, 2017	27 August 2018	A Single Ascending Dose Clinical Trial to Find the Maximum Tolerable Dose of HL237 in Healthy Male Subject	A Dose Block-randomized, Double Blinded, Placebo Controlled, Dose-escalation Clinical Trial to Find the Maximum Tolerable Dose After Single Oral Dose of HL237 in Healthy Male Subject	Rheumatoid Arthritis	Drug: HL237;Drug: Placebo Oral Tablet	Hanlim Pharm. Co., Ltd.		Not recruiting	20 Years	45 Years	Male	57	Phase 1	Korea, Republic of
195	NCT03239080	June 19, 2017	11 February 2019	Effect of Denosumab in Erosion Healing in RA	Effect of RANKL Inhibition on Healing of Bone Erosion in Rheumatoid Arthritis Using HR-pQCT	Rheumatoid Arthritis	Drug: Denosumab;Other: Placebo	Chinese University of Hong Kong		Not recruiting	18 Years	N/A	All	110	Phase 2	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
196	EUCTR2015-005309-35-GB	16/06/2017	28 February 2019	Study of the Efficacy and Safety of Olokizumab in Patients with Moderately to Severely Active Rheumatoid Arthritis	A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis - Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4	Moderately to Severely Active Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Olokizumab Product Code: (CDP6038; L04041) Pharmaceutical Form: Solution for injection INN or Proposed INN: Olokizumab Other descriptive name: CDP6038 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 160- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	R-Pharm		Authorised			Female: yes Male: yes	1880	Phase 3	United States;Belarus;Taiwan;Estonia;Lithuania;Turkey;Russian Federation;Colombia;United Kingdom;Czech Republic;Hungary;Mexico;Argentina;Poland;Brazil;Romania;Bulgaria;Latvia;Germany;Korea, Republic of
197	JPRN-UMIN000027719	2017/06/12	2 April 2019	Effect of tapering methotrexate in rheumatoid arthritis patients after add-on iguratimod therapy.		rheumatoid arthritis/remission	add-on iguratimod tapering MTX continuing the treatment	Osaka Medical College		Recruiting	20years-old	100years-old	Male and Female	100	Not selected	Japan
198	EUCTR2016-000569-21-FR	08/06/2017	28 February 2019	Filgotinib in Combination With Conventional Anti-rheumatic Drugs in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD treatment.	A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 weeks in Combination with Conventional Synthetic Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment	Moderately to severely active rheumatoid arthritis MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Filgotinib Product Code: GS-6034 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: FILGOTINIB Other descriptive name: FILGOTINIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Filgotinib Product Code: GS-6034 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: FILGOTINIB Other descriptive name: FILGOTINIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Gilead Sciences, Inc.		Not Recruiting			Female: yes Male: yes	423	Phase 3	United States;Spain;Israel;Switzerland;United Kingdom;Italy;France;Hungary;Mexico;Argentina;Poland;Belgium;Australia;Netherlands;Germany;Japan;Korea, Republic of
199	NCT03100734	June 1, 2017	15 July 2019	Observational Study to Evaluate the Real-Life Effectiveness of Benepali Following Transition From Enbrel	A Multicentre Observational Study to Evaluate the Real-Life Effectiveness of Benepali® Following Transition From Enbrel® in Patients With Rheumatoid Arthritis (RA) and Axial Spondyloarthritis (axSpA) - The BENEFIT Study	Rheumatoid Arthritis;Axial Spondyloarthritis	Biological: Benepali;Biological: Enbrel	Biogen	Samsung Bioepis Co., Ltd.	Not recruiting	18 Years	N/A	All	585	N/A	Germany
200	NCT03139136	May 30, 2017	26 August 2019	Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis	A 12-Week, Double-Blind, Placebo-Controlled, Phase 2a Study to Investigate the Safety, Tolerability and Efficacy of MBS2320 in Patients With Active Rheumatoid Arthritis Receiving Methotrexate	Rheumatoid Arthritis	Drug: MBS2320;Drug: Placebo	Modern Biosciences plc		Not recruiting	18 Years	75 Years	All	121	Phase 2	Georgia;Moldova, Republic of;Romania
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
201	NCT03193957	May 15, 2017	16 December 2017	An Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in Subjects With Rheumatoid Arthritis	An Open-label, Single-arm, Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Etanercept;Device: Autoinjector	Samsung Bioepis Co., Ltd.		Not recruiting	18 Years	55 Years	All	50	Phase 2	Poland
202	NCT03131973	May 13, 2017	8 January 2018	Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin	Effects of Concomitant Administration of BMS-986195 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates for Cytochrome P450 1A2, 2C8, 2C9, 2C19, 3A4, Organic Anion Transporter Polypeptide 1B1 and P-glycoprotein in Healthy Participants	Rheumatoid Arthritis	Drug: BMS-986195;Drug: Methotrexate;Drug: Leucovorin;Drug: Caffeine;Drug: Montelukast;Drug: Flurbiprofen;Drug: Omeprazole;Drug: Midazolam;Drug: Digoxin;Drug: Pravastatin	Bristol-Myers Squibb		Not recruiting	18 Years	50 Years	All	26	Phase 1	United States
203	EUCTR2016-005017-45-HU	12/05/2017	18 June 2018	A study to explore the effect of a new antibody to treat patients with Rheumatoid Arthritis	A Randomized, Placebo-Controlled, Double Blind, Multicenter Phase 2 Study to Explore Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Intravenous Multiple Infusions of NI-0101, an anti-Toll Like Receptor 4 Monoclonal Antibody in Patients with Rheumatoid Arthritis	Rheumatoid Arthritis MedDRA version: 19.1 Level: LLT Classification code 10040107 Term: Seropositive rheumatoid arthritis System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: NI-0101 Product Code: NI-0101 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: N/A CAS Number: N/A Current Sponsor code: NI-0101 Other descriptive name: Humanized immunoglobulin gamma 1 (IgG1) kappa monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use	NovImmune S.A.		Not Recruiting			Female: yes Male: yes	81	Phase 2	Bosnia and Herzegovina;United Kingdom;Moldova, Republic of;Bulgaria;Georgia;Poland;Hungary;Serbia
204	EUCTR2016-005017-45-BG	11/05/2017	28 February 2019	A study to explore the effect of a new antibody to treat patients with Rheumatoid Arthritis	A Randomized, Placebo-Controlled, Double Blind, Multicenter Phase 2 Study to Explore Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Intravenous Multiple Infusions of NI-0101, an anti-Toll Like Receptor 4 Monoclonal Antibody in Patients with Rheumatoid Arthritis	Rheumatoid Arthritis MedDRA version: 20.0 Level: LLT Classification code 10040107 Term: Seropositive rheumatoid arthritis System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: NI-0101 Product Code: NI-0101 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: N/A CAS Number: N/A Current Sponsor code: NI-0101 Other descriptive name: Humanized immunoglobulin gamma 1 (IgG1) kappa monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use	NovImmune S.A.		Not Recruiting			Female: yes Male: yes	81	Phase 2	Serbia;Hungary;Poland;Georgia;Bulgaria;Moldova, Republic of;United Kingdom;Bosnia and Herzegovina
205	NCT03241108	May 10, 2017	27 August 2018	Study of an Anti-TLR4 mAb in Rheumatoid Arthritis	Randomized, Placebo-Controlled, Double Blind, Multicenter Phase 2 Study to Explore Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Intravenous Multiple Infusions of NI-0101, an Anti-Toll Like Receptor 4 Monoclonal Antibody in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Other: Placebo;Drug: NI-0101	NovImmune SA		Not recruiting	18 Years	N/A	All	90	Phase 2	Bosnia and Herzegovina;Bulgaria;Georgia;Hungary;Moldova, Republic of;Poland;Serbia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
206	NCT03086343	May 9, 2017	22 October 2019	A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )	A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)	Rheumatoid Arthritis (RA)	Drug: Abatacept;Drug: Upadacitinib;Drug: Abatacept matching placebo;Drug: Upadacitinib matching placebo	AbbVie		Not recruiting	18 Years	N/A	All	657	Phase 3	United States;Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Czechia;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;Chile;Colombia
207	EUCTR2016-001825-15-BE	08/05/2017	28 February 2019	A PHASE 3B/4 STUDY OF METHOTREXATE (MTX) WITHDRAWAL IN SUBJECTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH TOFACITINIB 11MG	A PHASE 3B/4 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF METHOTREXATE (MTX) WITHDRAWAL IN SUBJECTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH TOFACITINIB 11MG MODIFIED RELEASE (MR) FORMULATION	Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: tofacitinib Product Code: CP 690,550 Pharmaceutical Form: Modified-release tablet INN or Proposed INN: tofacitinib CAS Number: 540737-29-9 Current Sponsor code: CP 690,550 Other descriptive name: TOFACITINIB CITRATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 11- Trade Name: Methotrexate 2.5mg Tablets BP Product Name: methotrexate Pharmaceutical Form: Capsule INN or Proposed INN: METHOTREXATE Other descriptive name: METHOTREXATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Pfizer Inc., 235 East 42nd Street, New York, New York		Not Recruiting			Female: yes Male: yes	680	Phase 3;Phase 4	United States;Philippines;Slovakia;Spain;Russian Federation;Italy;United Kingdom;Czech Republic;Hungary;Mexico;Poland;Belgium;Australia;South Africa;Bulgaria;Germany;Korea, Republic of
208	NCT02808871	April 7, 2017	7 October 2019	Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)	Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients With Rheumatoid Arthritis Interstitial Lung Disease (TRAIL1)	Rheumatoid Arthritis Interstitial Lung Disease	Drug: Pirfenidone;Drug: Placebo	Ivan O. Rosas		Recruiting	18 Years	85 Years	All	270	Phase 2	United States;Australia;Canada;United Kingdom
209	NCT02908490	April 1, 2017	25 February 2019	Does Sildenafil Improve Endothelial Dysfunction in Rheumatoid Arthritis?	Does Sildenafil Improve Endothelial Dysfunction in Rheumatoid Arthritis?	Arthritis, Rheumatoid;Atherosclerosis	Drug: Sildenafil;Other: Placebo	Kimberly Liang		Recruiting	18 Years	N/A	All	60	Phase 2	United States
210	NCT03275025	April 1, 2017	22 July 2019	A Phase 2 Study to Evaluate the Safety and Efficacy of YRA-1909 in Patients With Rheumatoid Arthritis	A Multicenter, Randomized, Double-blind, Placebo-controlled, Therapeutic Exploratory, Phase II Clinical Trial for the Efficacy Investigation and Safety Evaluation of YRA-1909 in Patients With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)	Rheumatoid Arthritis	Drug: YRA-1909 low dose;Drug: YRA-1909 mid dose;Drug: YRA-1909 high dose;Drug: Placebo	Yungjin Pharm. Co., Ltd.		Recruiting	19 Years	80 Years	All	200	Phase 2	Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
211	NCT03291457	March 30, 2017	22 October 2019	A Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical Practice	A Prospective Non-Interventional Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical Practice	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: Glucocorticoid Agent	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	101	Phase 3	Belgium
212	NCT03178955	March 27, 2017	24 June 2019	Circadian RA Study in Rheumatoid Arthritis Subjects	The Effects of Biologic Therapy With Disease Activity and Circadian Rhythm	Rheumatoid Arthritis	Drug: Etanercept	University of California, Davis		Not recruiting	18 Years	80 Years	All	0	Phase 1	United States
213	NCT03348046	March 23, 2017	12 March 2018	Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan	Post-Authorization Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan	Rheumatoid Arthritis	Drug: Biosimilar Infliximab	Hikma Pharmaceuticals LLC	INC Research	Recruiting	18 Years	N/A	All	40	N/A	Jordan
214	NCT03245320	March 20, 2017	4 February 2019	Clinical Evaluation of the TITAN™ Total Shoulder System	A Post-Market Observational Study to Evaluate Performance and Safety of the TITAN™ Total Shoulder System	Arthritis;Arthritis, Degenerative;Rheumatoid Arthritis;Post-traumatic Arthrosis of Other Joints, Shoulder Region;Rotator Cuff Syndrome of Shoulder and Allied Disorders;Fracture;Avascular Necrosis;Joint Instability;Joint Trauma;Dislocation, Shoulder;Pain, Shoulder	Device: Integra TITAN™ Total Shoulder Generation 1.0	Integra LifeSciences Corporation		Not recruiting	18 Years	N/A	All	50	Phase 1	United States
215	NCT03755258	March 16, 2017	10 December 2018	Trial of Ginsenoside Compound K (GCK) Tablet in Patients With Rheumatoid Arthritis	A Phase Ib Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GCK in Rheumatoid Arthritis Patients	Early Rheumatoid Arthritis	Drug: GCK 100 mg + Placebo 200 mg;Drug: GCK 200 mg + Placebo 100 mg;Drug: GCK 300 mg;Drug: Placebo 300mg	Zhejiang Hisun Pharmaceutical Co. Ltd.		Recruiting	18 Years	65 Years	All	128	Phase 1	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
216	NCT03110094	March 13, 2017	11 June 2018	Investigation of Immunological and Pharmacological Factors for Response to Adalimumab in Rheumatoid Arthritis	Investigation of Immunological and Pharmacological Factors for Response to Adalimumab in Rheumatoid Arthritis, With Analysis of CD4 + Follicular Helper T Subpopulations	Rheumatoid Arthritis	Other: Adalimumab;Other: Healthy volunteers	Rennes University Hospital		Recruiting	18 Years	N/A	All	60	N/A	France
217	EUCTR2015-005307-83-LV	03/03/2017	30 April 2019	Study of the Efficacy and Safety of Olokizumab in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy	A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy - Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 2	Moderately to Severely Active Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Olokizumab Product Code: (CDP6038; L04041) Pharmaceutical Form: Solution for injection INN or Proposed INN: Olokizumab Other descriptive name: CDP6038 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 160- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Humira 40 mg solution for injection in pre-filled syringe Product Name: Adalimumab (Humira®) Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Humira 40 mg solution for injection in pre-filled syringe Product Name: Adalimumab (Humira®) Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-	R-Pharm		Authorised			Female: yes Male: yes	1575	Phase 3	United States;Taiwan;Estonia;Lithuania;Russian Federation;Colombia;United Kingdom;Czech Republic;Hungary;Mexico;Argentina;Poland;Brazil;Romania;Bulgaria;Georgia;Latvia;Germany;Korea, Republic of
218	NCT03082573	March 3, 2017	16 December 2017	Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel	Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Were Treated With H.P. Acthar Gel After an Incomplete Response to Combinations of DMARDs and Biologic DMRADs	Rheumatoid Arthritis	Drug: H.P. Acthar gel	Iraj Sabahi Research Inc.	Mallinckrodt	Recruiting	21 Years	N/A	All	30	Phase 4	United States
219	EUCTR2016-002126-36-AT	01/03/2017	10 December 2018	A Study to Evaluate the Safety and Efficacy of RO7123520 as Adjunct Treatment in Patients With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to TNF-a Inhibitors	A randomized, double-blind, placebo-controlled, multi-center, three-part phase II study to evaluate the safety and efficacy of RO7123520 as adjunct treatment in patients with moderately to severely active rheumatoid arthritis and an inadequate response to TNF-a inhibitors	Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: RO7123520 Product Code: RO7123520/F03-01 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Not available Current Sponsor code: RO7123520/F03-01 Other descriptive name: RO7123520 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	F. Hoffmann-La Roche Ltd		Not Recruiting			Female: yes Male: yes	204	Phase 2	United States;Spain;Guatemala;Austria;Chile;Colombia;United Kingdom;Italy;Czech Republic;Mexico;Argentina;Poland;Brazil;Peru;Germany
220	NCT03025308	February 28, 2017	4 November 2019	Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis	A Multicenter, Double-blind, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects With Rheumatoid Arthritis	RheumatoId Arthritis	Drug: Filgotinib;Drug: Placebo to match filgotinib	Gilead Sciences	Galapagos NV	Not recruiting	18 Years	N/A	All	2731	Phase 3	United States;Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
221	NCT03161457	February 27, 2017	23 July 2018	A Study of JHL1101 Versus MabThera® in Subjects With Severe Rheumatoid Arthritis	A Randomised, Double-blind, Parallel Group, Multicentre Study to Compare the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Efficacy of JHL1101 Versus EU-sourced MabThera® in Anti TNF Inadequate Responder Patients With Moderate to Severe Rheumatoid Arthritis (RA) on Background Methotrexate (MTX) Therapy	Rheumatoid Arthritis;Arthritis, Rheumatoid	Biological: JHL1101;Biological: MabThera	JHL Biotech, Inc.		Recruiting	18 Years	80 Years	All	150	Phase 1	Bosnia and Herzegovina;Bulgaria;Czechia;Germany;Hungary;Lithuania;Poland;Russian Federation;Taiwan;Ukraine;United Kingdom
222	JPRN-UMIN000026137	2017/02/15	5 November 2019	Intravenous versus combined intravenous and intra-articular tranexamic acid for simultaneous bilateral total knee arthroplasty: randomized controlled trial	Intravenous versus combined intravenous and intra-articular tranexamic acid for simultaneous bilateral total knee arthroplasty: randomized controlled trial - Intravenous versus combined intravenous and intra-articular tranexamic acid for simultaneous bilateral TKA: randomized controlled trial	Osteoarthritis of the knee Rheumatoid arthritis	The combined tranexamic acid group received 1000 mg of tranexamic acid administered intravenously just before skin incision of the first knee. After closure of the capsule and retinaculum, 1000 mg of tranexamic acid (10 mL of 100 mg/mL tranexamic acid) was administered intra-articularly for each knee. Six hours after the first intravenous administration of tranexamic acid, 1000 mg of tranexamic acid was again given intravenously. The intravenous tranexamic acid group received 1000 mg of tranexamic acid administered intravenously just before skin incision of the first knee. After closure of the capsule and retinaculum, 10 mL of normal saline was administered intra-articularly for each knee. Six hours after the first intravenous administration of tranexamic acid, 1000 mg of tranexamic acid was again given intravenously.	Hokusuikai Kinen Hospital		Not Recruiting	20years-old	Not applicable	Male and Female	32	Not selected	Japan
223	NCT03667131	February 13, 2017	26 November 2018	Enalapril Maleate on Arterial Stiffness in Rheumatoid Arthritis.	Effect of Prophylactic Treatment With Enalapril Maleate on Arterial Stiffness in Rheumatoid Arthritis Patients.	Rheumatoid Arthritis	Drug: Enalapril Maleate;Drug: Placebo	University of Guadalajara		Not recruiting	18 Years	80 Years	Female	59	Phase 2	Mexico
224	ChiCTR-IPR-17010325	2017-01-31	18 April 2017	The efficacy and safety of Metformin combined with coenzyme Q10 in refractory rheumatoid arthritis: A multi-center randomized controlled trial	The efficacy and safety of Metformin combined with coenzyme Q10 in refractory rheumatoid arthritis: A multi-center randomized controlled trial	rheumatic disease;M05.901	Metformin Group:Metformin combined Glucocorticoids and DMARDs;Non-Metformin Group:Glucocorticoids and DMARDs;Metformin combined with Coenzyme Q10 Group:Metformin and Coenzyme Q10 combined Glucocorticoids and DMARDs;	the Second Hospital of Shanxi Medical University		Not Recruiting	18	65	Both	Metformin Group:100;Non-Metformin Group:100;Metformin combined with Coenzyme Q10 Group:100;	Post-market	China
225	NCT02997605	January 31, 2017	4 February 2019	Comparison of Two Strategies of Glucocorticoid Withdrawal in Rheumatoid Arthritis Patients	Comparison of Two Strategies of Glucocorticoid Withdrawal in Rheumatoid Arthritis Patients in Low Disease Activity or Remission.	RheumatoId Arthritis	Drug: GlucoCorticoid	University Hospital, Toulouse		Recruiting	18 Years	N/A	All	122	Phase 4	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
226	NCT03052322	January 31, 2017	1 July 2019	MSB11022 in Moderate to Severe Rheumatoid Arthritis	A Multicenter, Randomized, Double-blind, Phase III Trial to Evaluate the Safety, Immunogenicity, and Efficacy of MSB11022 Compared With Humira® in Patients With Moderately to Severely Active Rheumatoid Arthritis	Moderate to Severe Rheumatoid Arthritis	Drug: MSB11022;Drug: EU-Humira	Fresenius Kabi SwissBioSim GmbH		Not recruiting	18 Years	N/A	All	288	Phase 3	Czech Republic;United Kingdom;Poland;Hungary;Germany;Czechia;Bulgaria
227	EUCTR2013-003413-18-NL	30/01/2017	12 March 2018	Arthritis prevention with abatacept	Arthritis Prevention In the Pre-clinical Phase of RA with Abatacept. - APIPPRA	The target population for therapeutic intervention will be subjects who carry serum autoantibodies (antibodies to citrullinated protein antigens – ACPA; rheumatoid factor – RF) and who have joint pains (arthralgia) but no joint swelling. These subjects are deemed to be at highest risk of developing rheumatoid arthritis. MedDRA version: 20.0 Level: PT Classification code 10003239 Term: Arthralgia System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: ORENCIA 125 mg solution for injection Pharmaceutical Form: Solution for infusion in pre-filled syringe Pharmaceutical form of the placebo: Solution for infusion in pre-filled syringe Route of administration of the placebo: Subcutaneous use	Leiden University Medical Center		Authorised			Female: yes Male: yes	206	Phase 2	Netherlands;United Kingdom
228	NCT03028467	January 24, 2017	27 August 2018	Evaluation of Pharmacokinetics and Safety of GSK3196165 in Combination With Methotrexate in Japanese Subjects With Rheumatoid Arthritis	A Phase 1/2, Double-Blind, Placebo-Controlled Study of the Pharmacokinetics, Safety and Tolerability of GSK3196165 in Combination With Methotrexate Therapy, in Japanese Subjects With Active Moderate-Severe Rheumatoid Arthritis Despite Treatment With Methotrexate	Arthritis, Rheumatoid	Drug: GSK3196165 Dose 1;Drug: GSK3196165 Dose 2;Drug: GSK3196165 Dose 3;Drug: Methotrexate;Drug: Placebo;Drug: Folic acid	GlaxoSmithKline		Not recruiting	20 Years	N/A	All	15	Phase 2	Japan
229	NCT03085940	January 20, 2017	16 December 2017	Role of Hydroxychloroquine to Improve Endothelial Dysfunction in Patients With Rheumatoid Arthritis	Role of Hydroxychloroquine to Improve Endothelial Dysfunction in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Hydroxychloroquine;Drug: Placebo	Indonesia University		Not recruiting	18 Years	N/A	All	37	N/A	Indonesia
230	NCT02984943	January 19, 2017	4 November 2019	The Effects of Hyperbaric Oxygen on Rheumatoid Arthritis	The Effects of Hyperbaric Oxygen on Rheumatoid Arthritis: A Pilot Study	RheumatoId Arthritis	Device: Hyperbaric Oxygen	David Grant U.S. Air Force Medical Center		Not recruiting	18 Years	N/A	All	14	N/A	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
231	NCT03112213	January 12, 2017	18 December 2018	Characterization of Non-Steroidal Anti-Inflammatory Drug (NSAID) Intake in Rheumatoid Arthritis (RA) Participants on Tocilizumab (RoACTEMRA®) Treatment	CONIFER (Characterization of NSAID Intake for Established Rheumatoid Arthritis)	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: NSAIDs	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	135	Phase 3	Germany
232	EUCTR2015-003140-39-PL	09/01/2017	10 September 2018	A Study to EValuate the Efficacy and Safety of JTE-051 on Subjects with Active Rheumatoid Arthritis (MOVE-RA)	A Multicenter, Randomized, Double-blind, PlacebO-controlled, Parallel-group Study to EValuate the Efficacy and Safety of JTE-051 Administered for 12 Weeks to Subjects with Active Rheumatoid Arthritis (MOVE-RA) - MOVE-RA	Rheumatoid Arthritis (RA) MedDRA version: 20.0 Level: LLT Classification code 10040107 Term: Seropositive rheumatoid arthritis System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: JTE-051 Product Code: JTE-051 Pharmaceutical Form: Tablet INN or Proposed INN: No proposed INN available CAS Number: 1309784-13-1 Current Sponsor code: JTE-051 Other descriptive name: JTE-051 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Akros Pharma Inc.		Not Recruiting			Female: yes Male: yes	250	Phase 2	United States;Mexico;Argentina;Poland;Ukraine;Romania;Peru;Russian Federation;Bulgaria;Colombia
233	ChiCTR-IPR-17010307	2017-01-01	18 April 2017	The efficacy and safety of rapamycin in refractory rheumatoid arthritis: A multi-center randomized controlled trial in China	The efficacy and safety of rapamycin in refractory rheumatoid arthritis: A multi-center randomized controlled trial in China	Rheumatoid Arthritis;M05.901	Rapamycin group:Rapamycin;Non-rapamycin group :conventional glucocorticoids and DMARDs;	the Second Hospital of Shanxi Medical University		Recruiting	18	65	Both	Rapamycin group:200;Non-rapamycin group :100;	Post-market	China
234	NCT03855007	January 1, 2017	11 March 2019	The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment	Prospective Clinical Study to Observe the Efficacy and Safety of Iguratimod in Rheumatoid Arthritis and Early Rheumatoid Arthritis Patients for 6 Months Treatment in China	Arthritis, Rheumatoid	Drug: Iguratimod;Drug: MTX;Drug: HCQ;Drug: Pred	Qilu Hospital of Shandong University		Recruiting	16 Years	90 Years	All	200	Phase 4	China
235	NCT02865434	January 2017	1 April 2019	Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA	An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection and Skeletal Joint Imaging With SPECT in Subjects With Active Rheumatoid Arthritis (RA) and Healthy Controls	Arthritis, Rheumatoid	Drug: Tc99m-tilmanocept;Procedure: SPECT Imaging (60 Minutes post-injection);Procedure: SPECT Imaging (180 Minutes post-injection);Procedure: Whole body planar SPECT imaging (15 Minutes post-injection);Procedure: Whole body planar SPECT imaging (60 Minutes post-injection);Procedure: Whole body planar SPECT imaging (180 Minutes post-injection);Procedure: Whole body planar SPECT imaging (18-20 Hours post-injection);Procedure: Blood Collection for PK Testing (15 Mins Before Injection);Procedure: Blood Collection for PK Testing (after injection);Procedure: Blood Collection for PK Testing (15 minutes post injection);Procedure: Blood Collection for PK Testing (60 minutes post injection);Procedure: Blood Collection for PK Testing (180 minutes post injection);Procedure: Blood Collection for PK Testing (18-20 hours post injection);Procedure: Planar Image with both Hands in Field of View	Navidea Biopharmaceuticals		Not recruiting	18 Years	N/A	All	39	Phase 1/Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
236	NCT03016884	January 2017	5 February 2018	Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients	Safety and Tolerability of Herpes Zoster Vaccine in Patients With Rheumatoid Arthritis Immunized Prior to Biologics and Tofacitinib Therapy Initiation	Herpes Zoster	Biological: Zostavax vaccine	HaEmek Medical Center, Israel		Recruiting	50 Years	N/A	All	250	Phase 4	Israel
237	NCT03288584	January 2017	16 July 2018	Effects of Interleukin-6 Inhibition on Vascular, Endothelial and Left Ventricular Function in Rheumatoid Arthritis	The Effect of Inhibition of Interleukin-6 Activity on Vascular, Endothelial and Left Ventricular Function in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis;Inflammation	Drug: Tocilizumab (Actemra®);Drug: Other biological agent;Drug: Corticosteroid and non-biological agents.	University of Athens		Recruiting	18 Years	80 Years	All	60	Phase 1	Greece
238	NCT02965599	December 27, 2016	8 April 2019	Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Rheumatoid Arthritis	A Randomised, Multi-center, Double Blind (Sponsor Open), Placebo-controlled Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Severe, Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Placebo;Drug: GSK3117391	GlaxoSmithKline		Not recruiting	18 Years	N/A	All	3	Phase 1/Phase 2	Mexico;Poland;Romania
239	EUCTR2016-000569-21-GB	23/12/2016	28 February 2019	Filgotinib in Combination With Conventional Anti-rheumatic Drugs in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD treatment.	A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 weeks in Combination with Conventional Synthetic Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment	Moderately to severely active rheumatoid arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Filgotinib Product Code: GS-6034 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: FILGOTINIB Other descriptive name: FILGOTINIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Filgotinib Product Code: GS-6034 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: FILGOTINIB Other descriptive name: FILGOTINIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Gilead Sciences, Inc.		Not Recruiting			Female: yes Male: yes	423	Phase 3	United States;Spain;Israel;United Kingdom;Switzerland;Italy;France;Hungary;Mexico;Argentina;Poland;Belgium;Australia;Netherlands;Germany;Japan;Korea, Republic of
240	NCT02969044	December 20, 2016	29 January 2018	Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate	A Phase 2a, Randomized, Double-blind, Parallel Group, Placebo-controlled, Multi-center Study To Assess The Efficacy And Safety Profile Of Pf-06651600 In Subjects With Moderate To Severe Active Rheumatoid Arthritis With An Inadequate Response To Methotrexate	Rheumatoid Arthritis	Drug: Placebo;Drug: PF-06651600	Pfizer		Not recruiting	18 Years	75 Years	All	74	Phase 2	United States;Bulgaria;Czechia;Georgia;Germany;Hungary;Poland;Serbia;Slovakia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
241	EUCTR2014-004704-29-CZ	15/12/2016	1 October 2018	This trial is designed to determine what effects the human body has on the investigational medicine, ABP 710, and what effects the body has on the investigational medicine after you have been given it, and if this is comparable to what is seen for the licensed medicine, infliximab, in patients with moderate or severe rheumatoid arthritis (RA). This study will assess if the investigational medicine is safe and effective in treating moderate or severe RA compared to the licensed medicine.	A Randomized, Double-Blind Phase 3 Study to Assess the Efficacy and Safety of ABP 710 Compared to Infliximab in Subjects with Moderate to Severe Rheumatoid Arthritis - Not applicable	Rheumatoid arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: ABP 710 Product Code: ABP 710 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ABP 710 Current Sponsor code: ABP 710 Other descriptive name: ABP 710 - Biosimilar to infliximab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: Remicade Product Name: infliximab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Amgen Inc.		Not Recruiting			Female: yes Male: yes	550	Phase 3	United States;Hungary;Czech Republic;Canada;Poland;Spain;Romania;Australia;Bulgaria;Germany
242	NCT02862574	December 15, 2016	16 December 2017	Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis	Evaluation of the Efficacy and Safety of GS-5745 as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Subjects With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Andecaliximab;Drug: Placebo;Drug: Methotrexate;Drug: TNF Inhibitor	Gilead Sciences		Not recruiting	18 Years	80 Years	All	15	Phase 2	United States;Australia;Hungary;Taiwan
243	EUCTR2016-002852-26-CZ	07/12/2016	17 September 2018	MSB11022 in moderately to severely active rheumatoid arthritis	A multicenter, randomized, double-blind, Phase III trial to evaluate the safety, immunogenicity, and efficacy of MSB11022 compared with Humira® in patients with moderately to severely active rheumatoid arthritis - AURIEL-RA	moderately to severely active rheumatoid arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: adalimumab Product Code: MSB11022 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Current Sponsor code: MSB11022 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Humira Product Name: Humira Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-	Merck KGaA		Not Recruiting			Female: yes Male: yes	260	Phase 3	Hungary;Czech Republic;Poland;Lithuania;Bulgaria;Germany;United Kingdom
244	EUCTR2015-003140-39-BG	05/12/2016	20 August 2018	A Study to EValuate the Efficacy and Safety of JTE-051 in Subjects with Active Rheumatoid Arthritis (MOVE-RA)	A Multicenter, Randomized, Double-blind, PlacebO-controlled, Parallel-group Study to EValuate the Efficacy and Safety of JTE-051 Administered for 12 Weeks to Subjects with Active Rheumatoid Arthritis (MOVE-RA) - MOVE-RA	Rheumatoid Arthritis (RA) MedDRA version: 20.0 Level: LLT Classification code 10040107 Term: Seropositive rheumatoid arthritis System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: JTE-051 Product Code: JTE-051 Pharmaceutical Form: Tablet INN or Proposed INN: No proposed INN available CAS Number: 1309784-13-1 Current Sponsor code: JTE-051 Other descriptive name: JTE-051 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Akros Pharma Inc.		Not Recruiting			Female: yes Male: yes	250	Phase 2	United States;Mexico;Argentina;Poland;Ukraine;Romania;Peru;Russian Federation;Bulgaria;Colombia
245	NCT02760433	December 2016	18 December 2018	Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Have Active Disease	A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-a) Inhibitor Therapy	Rheumatoid Arthritis	Drug: Olokizumab q4w;Drug: Olokizumab q2w;Drug: Placebo q2w	R-Pharm	Quintiles, Inc.;OCT Clinical Trials;Mene Research	Recruiting	18 Years	N/A	All	350	Phase 3	United States;Argentina;Brazil;Colombia;Czechia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Turkey;Czech Republic
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
246	NCT02982083	December 2016	12 December 2016	Clinical Trial on the Efficacy of Raloxifene on Disease Activity in Rheumatoid Arthritis	Clinical Trial on the Efficacy of Raloxifene on Disease Activity and Glucocorticoid-induced Osteoporosis in Postmenopausal Women With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Placebo Oral Tablet;Drug: Raloxifene hydrochloride	Sara Saeidi Shahri		Not recruiting	50 Years	N/A	Female	40	N/A
247	NCT02990806	December 2016	11 November 2019	A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)	A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis	Rheumatoid Arthritis (RA)	Biological: NI-071;Biological: Infliximab	Nichi-Iko Pharmaceutical Co., Ltd.		Not recruiting	18 Years	75 Years	All	683	Phase 3	United States;Czechia;Poland;Puerto Rico;Russian Federation;Spain;Ukraine;United Kingdom
248	NCT03016260	December 2016	16 December 2017	RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFa BIologicals in Rheumatoid Arthritis	Proof-of-Performance Study of RABIOPRED Assay as an In Vitro Diagnostic Test to Identify Patients With Rheumatoid Arthritis Who Are Unlikely to Show Response to 1st Treatment With Anti-TNFa and Methotrexate Combination.	RheumatoId Arthritis	Biological: Infliximab;Biological: Adalimumab;Biological: Etanercept;Biological: Golimumab;Biological: Certolizumab Pegol;Biological: Infliximab biosimilar;Biological: Etanercept biosimilar	TcLand Expression S.A.	European Commission	Recruiting	18 Years	N/A	All	720	N/A	Czechia;France;Israel;Netherlands;Turkey;Czech Republic
249	NCT03337165	December 2016	30 September 2019	Autologous Tolerogenic Dendritic Cells for Treatment of Patients With Rheumatoid Arthritis	Safety/Efficacy of Intra-articular Administration of Autologous Tolerogenic Dendritic Cells for Treatment of Patients With Rheumatoid Arthritis	Musculoskeletal Diseases;Joint Disease;Arthritis;Arthritis, Rheumatoid;Rheumatic Diseases;Connective Tissue Diseases;Autoimmune Diseases;Immune System Diseases	Biological: tolerogenic dendritic cells	Russian Academy of Medical Sciences		Not recruiting	18 Years	75 Years	All	10	Phase 1	Russian Federation
250	NCT02983227	November 30, 2016	4 November 2019	A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350 (NCT02833350)	A Phase II Open-Label Extension Study of Patients Previously Enrolled in Study GA29350 to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Rheumatoid Arthritis	RheumatoId Arthritis	Drug: GDC 0853	Genentech, Inc.		Not recruiting	18 Years	76 Years	All	497	Phase 2	United States;Argentina;Brazil;Bulgaria;Colombia;Mexico;Poland;Russian Federation;Serbia;Ukraine;Chile;Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
251	NCT02986139	November 29, 2016	22 July 2019	Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis	A Multicenter, Randomized, Double-blind, Crossover Study to Assess the Injection Site Pain Associated With a Modified Etanercept Formulation in Adult Subjects With Either Rheumatoid Arthritis or Psoriatic Arthritis	Arthritis, Rheumatoid; Arthritis, Psoriatic	Drug: Commercial Formulation Etanercept;Drug: New Formulation Etanercept	Amgen		Not recruiting	18 Years	N/A	All	111	Phase 3	United States;Puerto Rico
252	NCT02960490	November 26, 2016	28 October 2019	A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics	A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics	Rheumatoid Arthritis	Drug: E6011;Drug: Placebo	Eisai Co., Ltd.		Not recruiting	18 Years	75 Years	All	64	Phase 2	Japan
253	EUCTR2016-000933-37-HU	24/11/2016	22 May 2017	Study to Compare ABT-494 to Abatacept in Subjects with Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response or Intolerance to Biologic DMARDs (SELECT-CHOICE)	A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)	Moderately to Severely Active Rheumatoid Arthritis (RA) MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: ABT-494 Pharmaceutical Form: Tablet INN or Proposed INN: ABT-494 CAS Number: 1310726-60-3 Other descriptive name: ABT-494 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: ORENCIA 250mg powder for concentrate for solution for infusion Product Name: Abatacept Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: ABATACEPT CAS Number: 332348-12-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	AbbVie Deutschland GmbH & Co. KG		Authorised			Female: yes Male: yes	313	Phase 3	Portugal;Belarus;United States;Slovakia;Greece;Spain;Ireland;Russian Federation;Chile;Israel;Colombia;Switzerland;Italy;France;Puerto Rico;Australia;Netherlands;Latvia;Korea, Democratic People's Republic of;Turkey;United Kingdom;Hungary;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Belgium;Romania;Bulgaria;Norway;Germany;New Zealand;Sweden
254	EUCTR2014-005368-13-DE	22/11/2016	23 July 2018	A Study Comparing SAIT101 to MabThera® or Rituxan® in Patients with Rheumatoid Arthritis (RA)	A Randomized, Double-blind, Parallel Group, Multicenter Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of SAIT101 versus MabThera® versus Rituxan® in Patients with Rheumatoid Arthritis (RA).	Severe Rheumatoid Arthritis (RA) MedDRA version: 20.0 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000004870 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: SAIT101 (proposed rituximab biosimilar) Product Code: SAIT101 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Current Sponsor code: SAIT101 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: MabThera® Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: Rituxan® Pharmaceutical Form: Concentrate and solvent for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Archigen Biotech Limited		Authorised			Female: yes Male: yes	282	Phase 1;Phase 3	United States;Spain;Russian Federation;Italy;India;Czech Republic;Hungary;Mexico;Poland;Bulgaria;Germany;Bosnia and Herzegovina;Korea, Republic of
255	JPRN-UMIN000026819	2016/11/21	23 April 2019	A randomized controlled trial of low-dose Enoxaparin versus low-dose Edoxavan for prevention of venous thromboembolism after total hip arthroprasty in elderly or underweight or moderate renal insufficient patients.	A randomized controlled trial of low-dose Enoxaparin versus low-dose Edoxavan for prevention of venous thromboembolism after total hip arthroprasty in elderly or underweight or moderate renal insufficient patients. - A RCT of anticoagulant agents for prevention of VTE after THA in elderly or underweight or moderate renal insufficient patients.	osteoarthritis of the hip, osteonecrosis of the femoral head, femoral neck fracture, rheumatoid arthritis, rapidly destructive coxarthropathy, septic arthritis of the hip	Dose: Edoxaban group; Edoxaban 15mg per day Enoxaparin gropu; Enoxaparin 2000 IU per day Intervention period: for 10 days after the surgery	Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences		Recruiting	20years-old	Not applicable	Male and Female	80	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
256	NCT02874092	November 15, 2016	22 July 2019	Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis	Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: MTX therapy;Drug: Ticagrelor	NYU Langone Health		Not recruiting	18 Years	N/A	All	9	Phase 4	United States
257	EUCTR2015-005800-27-PL	08/11/2016	5 March 2018	Study of a new drug’s effect in people with severe rheumatoid arthritis who have not responded sufficiently well to treatment with DMARDs	A randomised, multi-center, double blind (sponsor open), placebo-controlled study to assess the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of GSK3117391 in subjects with moderate to severe, active rheumatoid arthritis	Rheumatoid Arthritis (RA) MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: GSK3117391 Product Code: GSK3117391 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Not applicable CAS Number: 1018673-42-1 Current Sponsor code: GSK3117391 Other descriptive name: GSK3117391 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	GlaxoSmithKline Research & Development Ltd		Not Recruiting			Female: yes Male: yes	40	Phase 2	Poland;Romania;Russian Federation
258	EUCTR2016-002908-15-NL	08/11/2016	18 April 2017	REDO study: Research into the effects of lower doses rituximab in patients with rheumatoid arthritis	REDO study: RhEumatoid arthritis REtreatment with ultra-low dose Rituximab: Disease Outcome after Dose Optimization - REDO	Rheumatoid arthritis MedDRA version: 19.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: MabThera Pharmaceutical Form: Infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7	Sint Maartenskliniek		Authorised			Female: yes Male: yes		Phase 4	Netherlands
259	NCT02919761	November 7, 2016	11 November 2019	Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis	A Multicenter, 2 Part Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Rheumatoid Arthritis With Persistently Active Disease	Arthritis, Rheumatoid	Drug: Acthar;Drug: Placebo	Mallinckrodt		Not recruiting	18 Years	N/A	All	259	Phase 4	United States;Argentina;Mexico;Peru;Puerto Rico;Colombia
260	NCT02960438	November 2, 2016	28 October 2019	A Dose Response Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Methotrexate	A Dose Response Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Methotrexate	Rheumatoid Arthritis	Drug: E6011;Drug: Placebo	Eisai Co., Ltd.		Not recruiting	18 Years	75 Years	All	190	Phase 2	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
261	ChiCTR-INR-16009546	2016-11-01	18 April 2017	The Efficacy and Safety of Low Dose IL-2 Conbined IL-6 Antagonist Therapy in Chinese Over-treated Patients with Rheumatoid Arthritis	The Efficacy and Safety of Low Dose IL-2 Conbined IL-6 Antagonist Therapy in Chinese Over-treated Patients with Rheumatoid Arthritis	rheumatoid arthritis;M05.901	IL-2 group:lL-2;IL-2 + IL-6 antagonist group:Tocilizumab;non IL-2 or IL-6 antagonist group:glucocorticoids and DMARDs;	the Second Hospital of Shanxi Medical University		Recruiting	18	65	Both	IL-2 group:15;IL-2 + IL-6 antagonist group:15;non IL-2 or IL-6 antagonist group:15;	New Treatment Measure Clinical Study	China
262	ChiCTR-IPR-16009029	2016-11-01	18 April 2017	Clinical Study of the Bone Protection Effect of Biqi Capsule for Treatment of Rheumatoid Arthritis	Clinical Study of the Bone Protection Effect of Biqi Capsule for Treatment of Rheumatoid Arthritis	Rheumatoid arthritis	RA:the experimental group:MTX 10-15mg po qw+BiQi Capsule, 1.2g po bid;RA:the control group:MTX 10-15mg po qw+LEF, 10mg, po, bid;OA:The traditional Chinese group:BiQi Capsule, 1.2g po bid+Celecoxib capsules 0.2g po take as needed;OA:The western medicine control group:Calcitriol Soft Capsules 0.25ug, po, bid+Celecoxib capsules 0.2g po take as needed;	Guangdong Provincial Hospital of Chinese Medicine		Not Recruiting	18	65	Both	RA:the experimental group:60;RA:the control group:60;OA:The traditional Chinese group:60;OA:The western medicine control group:60;	Post-market	China
263	NCT02996500	November 2016	12 November 2018	Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate	A 12 Week Randomized, Double-blind, Double Dummy, Parallel Group, Active And Placebo-controlled, Multicenter Study To Assess The Efficacy And Safety Profile Of Pf-06650833 In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To Methotrexate	Rheumatoid Arthritis	Drug: PF-06650833;Drug: Placebo;Drug: Tofacitinib	Pfizer		Not recruiting	18 Years	75 Years	All	269	Phase 2	United States;Australia;Bosnia and Herzegovina;Bulgaria;Croatia;Czechia;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine
264	NCT03011281	November 2016	16 December 2017	Effectiveness and Safety of Tofacitinib in Korean Patients With Rheumatoid Arthritis	Effectiveness and Safety of Tofacitinib in Korean Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Tofacitinib	Hanyang University		Recruiting	19 Years	N/A	All	378	N/A	Korea, Republic of
265	NCT03067870	November 2016	18 June 2018	Transplantation of Autologous Bone Marrow Derived Stem Cells in Patients With Rheumatoid Arthritis	Transplantation of Autologous Purified Bone Marrow Derived Specific Populations of Stem Cells and Mesenchymal Stem Cells in Patients With Rheumatoid Arthritis	RheumatoId Arthritis;Osteoarthritis, Knee;Osteoarthritis, Hip	Biological: Stem Cell Transplantation	Stem Cells Arabia		Not recruiting	17 Years	75 Years	All	100	Phase 1
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
266	NCT02819726	October 31, 2016	18 December 2018	PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis	A Randomized, Double-blind, Parallel Group, Multicenter Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Biological: SAIT101;Biological: MabThera;Biological: Rituxan;Biological: Rituxan/SAIT101	Archigen Biotech Limited		Not recruiting	18 Years	80 Years	All	294	Phase 1	United States;Bosnia and Herzegovina;Bulgaria;Czechia;Germany;Hungary;India;Korea, Republic of;Mexico;Poland;Spain
267	NCT03061838	October 27, 2016	29 July 2019	Safety, Tolerability, PK and PD of Biosimilar Drug Ritumax® Compared to Original Drug MabThera®	Multicenter Double-blind Randomized Clinical Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Biosimilar Drug Ritumax® Compared to Original Drug MabThera® in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: MabThera®;Drug: Ritumax®	Biointegrator LLC		Not recruiting	18 Years	N/A	All	8	Phase 1	Russian Federation
268	NCT02858492	October 17, 2016	26 November 2018	Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Repeat Doses of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)	A Multicenter, Randomized, Double-blind (Sponsor-unblinded), Placebo-controlled Study to Investigate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: GSK2982772 60 mg;Drug: Placebo	GlaxoSmithKline		Not recruiting	18 Years	75 Years	All	52	Phase 1/Phase 2	Germany;Italy;Poland;Russian Federation;Spain;United Kingdom
269	EUCTR2016-000498-19-BG	13/10/2016	10 December 2018	A Study of Patients Previously Enrolled in Study GA29350 to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Patients with Moderate to Severe Rheumatoid Arthritis	A PHASE II OPEN-LABEL EXTENSION STUDY OF PATIENTS PREVIOUSLY ENROLLED IN STUDY GA29350 TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS	Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: GDC-0853 Product Code: RO7010939 Pharmaceutical Form: Tablet INN or Proposed INN: not available Other descriptive name: GDC-0853 RO7010939 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-	Genentech, Inc.		Authorised			Female: yes Male: yes	580	Phase 2	Serbia;United States;Mexico;Argentina;Poland;Brazil;Ukraine;Russian Federation;Chile;Bulgaria;Colombia;Korea, Republic of
270	EUCTR2016-002061-54-IT	13/10/2016	7 January 2019	Switch between originator infliximab (Remicade®) and biosimilar infliximab (Remsima®) in the treatment of rheumatoid arthritis, spondyloarthritis and chronic inflammatory bowel diseases.	Switch between originator infliximab (Remicade®) and biosimilar infliximab (Remsima®) in the treatment of rheumatoid arthritis, spondyloarthritis and chronic inflammatory bowel diseases. Evaluation of immunogenicity and clinical response - Switch between originator infliximab (Remicade®) and biosimilar infliximab (Remsima®)	Rheumatoid arthritis, seronegative spondylo arthritis, Crohn's Disease, Ulcerative Colitis MedDRA version: 20.0 Level: PT Classification code 10002556 Term: Ankylosing spondylitis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 20.0 Level: PT Classification code 10075634 Term: Acute haemorrhagic ulcerative colitis System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: REMSIMA - 100 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLANCONCINO (VETRO) - 1 FLACONCINO Product Name: Remsima Product Code: 42942019 Pharmaceutical Form: Powder for solution for infusion	UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI		Not Recruiting			Female: yes Male: yes	250	Phase 4	Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
271	JPRN-jRCTs041180071	13/10/2016	7 October 2019	T-ReX study	Tocilizumab treatment with Reducing and stopping methotreXate in patients with rheumatoid arthritis in stable low disease activity-state - T-ReX study	Rheumatoid arthritis	At week 0, the dosing frequency of MTX was decreased from weekly to biweekly without a change in dose, regardless of the initial dose. At week 12, MTX was discontinued if low disease activity was maintained. TCZ and csDMARDs other than MTX were continued at a stable dose and interval throughout the course of the study. Glucocorticoids were continued at a stable dose up to week 36, and allowed to taper after week 36. The use of oral analgesics (non-steroidal anti-inflammatory drugs, acetaminophen, pregabalin, and tramadol) was not prohibited during the study period. One or more of the following rescue treatments were performed if the CDAI score was >10 and at the discretion of the investigator and/or upon patient request: changing the dosing frequency back to weekly administration, restarting, or increasing doses of MTX; increasing doses of or adding csDMARDs other than MTX or glucocorticoids; and administering an intraarticular injection of corticosteroids, hyaluronic acid, or lidocaine.	Toshihisa Kojima		Not Recruiting	>= 20age old	Not applicable	Both	51	N/A	none
272	NCT02937701	October 10, 2016	21 January 2019	Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab	A Randomized, Double-Blind Phase 3 Study to Assess the Efficacy and Safety of ABP 710 Compared to Infliximab in Subjects With Moderate to Severe Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: ABP 710;Drug: Infliximab	Amgen		Not recruiting	18 Years	80 Years	All	558	Phase 3	United States;Australia;Bulgaria;Canada;Czechia;Germany;Hungary;Poland;Spain;Czech Republic
273	NCT03403140	October 6, 2016	29 January 2018	Long Term Efficacy, Safety and Immunogenicity of Enerceptan in Rheumatoid Arthritis ( GEMENE002 )	Multicenter Extension Study To 104 Weeks To Asses The Efficacy, Safety And Immunogenicity Of Enerceptan® In Combination With Methotrexate For The Treatment Of Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Etanercept	Gema Biotech S.A.	QUID-Quality in Drugs and Devices Latin American Consulting SRL	Not recruiting	19 Years	99 Years	All	141	Phase 3	Argentina
274	EUCTR2015-004858-17-NL	05/10/2016	10 October 2016	REMission INDuction in very early Rheumatoid Arthritis	REMission INDuction in very early Rheumatoid Arthritis - REMINDRA	Very early Rheumatoid arthritis MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Methotrexate Product Name: Methotrexate Product Code: MTX Pharmaceutical Form: INN or Proposed INN: Methotrexate Other descriptive name: METHOTREXATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 7.5-25 Trade Name: Golimumab Product Name: Golimumab Product Code: GOL Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: GOLIMUMAB CAS Number: 476181-74-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-	University Medical Center Utrecht (UMCU)		Authorised			Female: yes Male: yes		Phase 4	Netherlands
275	NCT03364088	October 1, 2016	4 February 2019	Outcome After Total Knee Arthroplasty Under General or Spinal Anesthesia	Outcome After Total Knee Arthroplasty Under General or Spinal Anesthesia, a Randomized Controlled Trial	Knee Osteoarthritis;Arthropathy of Knee Joint;Knee Pain Chronic;Rheumatoid Arthritis;Anesthesia	Procedure: Spinal anesthesia with tourniquet;Procedure: Spinal anesthesia without tourniquet;Procedure: General anesthesia with tourniquet;Procedure: General anesthesia without tourniquet;Drug: Oxycodone by patient-controlled analgesia (PCA)	Riku Antero Palanne	Helsinki University Central Hospital;Helsinki University;Finland	Not recruiting	18 Years	75 Years	All	402	N/A	Finland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
276	NCT02805010	October 2016	12 December 2016	Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously	A Randomized, Double-blind, Placebo-controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Single Dose of Abatacept 125mg Administered Subcutaneously in Chinese Healthy Subjects	Rheumatoid Arthritis (RA)	Drug: Abatacept;Other: Placebo	Jiangsu Simcere Pharmaceutical Co., Ltd.	Bristol-Myers Squibb	Not recruiting	18 Years	45 Years	Both	22	Phase 1
277	NCT02881307	October 2016	9 September 2019	Ultrasound Assessment of Rheumatoid Arthritis Patients Who Changed Diet	Ultrasound Assessment of Rheumatoid Arthritis Patients Who Changed Diet	Rheumatoid Arthritis;Overweight	Dietary Supplement: Whey Protein&Prebiotic Supplement;Behavioral: Dietary Counseling;Behavioral: Dietary recommendations	Dr. Veena Ranganath		Recruiting	18 Years	N/A	All	60	N/A	United States
278	NCT02927522	October 2016	17 October 2016	Donepezil Attenuate Postoperative Cognitive Dysfunction	Donepezil Attenuate Postoperative Cognitive Dysfunction in Aged Patients- A Multi-center, Case Control, Randomized Clinical Trail	Osteoarthritis;Femoral Head Necrosis;Rheumatoid Arthritis	Drug: Donepezil;Drug: Placebo	RenJi Hospital	Shanghai Sixth Hospital;Shanghai Guanghua Hospital;Sanya People's Hospital;Shanghai Sixth Hospital;Shanghai Guanghua Hospital;Sanya People's Hospital	Not recruiting	65 Years	N/A	Both	550	Phase 3
279	NCT02936180	October 2016	27 August 2018	Standard Versus High Dose Inactivated Influenza Vaccine in RA	Improving Influenza Immunization Responses in Rheumatoid Arthritis: A Strategy To Enhance Protection Against A Preventable Cause Of Death In An At Risk Population?	Rheumatoid Arthritis	Biological: HD-TIV;Biological: SD-QIV	McGill University Health Center	The Arthritis Society, Canada	Not recruiting	18 Years	N/A	All	280	Phase 4	Canada
280	NCT02037737	September 30, 2016	19 February 2018	Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting	Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting in Patients With Inadequate Response to One or Several Conventional DMARDs Including Methotrexate in France. A Database Analysis Based on the ACTION Study	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	153	N/A
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
281	NCT02648035	September 22, 2016	8 April 2019	EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis	Multicenter, Post-Marketing, Non-Interventional, Observational Study to Evaluate Persistence to Tocilizumab SC as Monotherapy or in Combination With cDMARD Treatment in RA Patients in Greece: the EMBRACE-SC Study.	Rheumatoid Arthritis	Biological: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	200	Phase 1	Greece
282	EUCTR2014-004904-31-BE	21/09/2016	20 August 2018	A clinical study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission.	An open-label, multicentre, phase IV study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission.	Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA).;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Remsima (infliximab) Pharmaceutical Form: Powder for concentrate for solution for injection/infusion	Mundipharma Pharmaceuticals B.V.		Not Recruiting			Female: yes Male: yes	156	Phase 4	Belgium;Netherlands
283	NCT02885181	September 21, 2016	16 December 2017	Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate	A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Proof-of-Concept Study to Evaluate Safety, Tolerability, and Efficacy of GS-9876 in Subjects With Active Rheumatoid Arthritis on Background Therapy With Methotrexate	Rheumatoid Arthritis	Drug: GS-9876;Drug: Filgotinib;Drug: GS-9876 placebo;Drug: Filgotinib placebo;Drug: Methotrexate	Gilead Sciences		Not recruiting	18 Years	75 Years	All	83	Phase 2	United States;Bulgaria;Czechia;Georgia;Moldova, Republic of;Poland;Ukraine;Czech Republic;Hungary
284	NCT02919475	September 14, 2016	27 August 2018	Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis	A Multicenter, Randomized, Double-blind, PlacebO-controlled, Parallel-group Study to EValuate the Efficacy and Safety of JTE-051 Administered for 12 Weeks to Subjects With Active Rheumatoid Arthritis (MOVE-RA)	Rheumatoid Arthritis	Drug: Placebo;Drug: JTE-051	Akros Pharma Inc.		Not recruiting	18 Years	75 Years	All	260	Phase 2	United States;Argentina;Bulgaria;Colombia;Mexico;Peru;Poland;Romania;Russian Federation;Ukraine
285	NCT03147248	September 12, 2016	26 August 2019	A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA	A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety Between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients With Active RA	Rheumatoid Arthritis	Biological: Infliximab	Celltrion		Not recruiting	18 Years	75 Years	All	412	Phase 3	Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
286	NCT02833350	September 9, 2016	30 September 2019	Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)	A Two-Cohort Randomized Phase II, Double-Blind, Parallel Group Study in Patients With Active Rheumatoid Arthritis Evaluating the Efficacy and Safety of GDC-0853 Compared With Placebo and Adalimumab in Patients With an Inadequate Response to Previous Methotrexate Therapy (Cohort 1) and Compared With Placebo in Patients With an Inadequate Response or Intolerance to Previous TNF Therapy (Cohort 2)	Rheumatoid Arthritis	Drug: GDC-0853;Drug: Adalimumab;Drug: Folic Acid;Drug: MTX;Drug: Placebo	Genentech, Inc.		Not recruiting	18 Years	75 Years	All	578	Phase 2	United States;Argentina;Brazil;Bulgaria;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;Chile
287	NCT02831855	September 1, 2016	1 April 2019	Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis	A PHASE 3B/4 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF METHOTREXATE (MTX) WITHDRAWAL IN SUBJECTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH TOFACITINIB 11MG MODIFIED RELEASE (MR) FORMULATION	Rheumatoid Arthritis	Drug: Placebo;Drug: Methotrexate;Drug: CP-690,550	Pfizer		Not recruiting	18 Years	N/A	All	695	Phase 4	United States;Australia;Belgium;Bulgaria;Czechia;Germany;Hungary;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom
288	NCT02666443	September 2016	12 September 2016	Low Dose Dexamethasone in Supraclavicular Blocks	Low Dose Dexamethasone as an Adjuvant to Supraclavicular Brachial Plexus Blocks: A Prospective Randomized, Double Blinded, Control Study	Rheumatoid Arthritis;Osteoarthritis;Nerve Entrapment;Ligament Injury	Drug: Intravenous Dexamethasone 1 mg;Drug: Peri-neural Dexamethasone 1 mg;Drug: Control intervention (no dexamethasone)	University of Calgary		Recruiting	18 Years	80 Years	Both	306	N/A	Canada
289	NCT02897011	September 2016	7 November 2016	2-week dc of MTX and Influenza Vaccination in RA	Effect of Two-week Discontinuation of Methotrexate on Efficacy of Seasonal Influenza Vaccination in Patients With Rheumatoid Arthritis: A Randomized Clinical Trial	Rheumatoid Arthritis;Influenza;Methotrexate	Drug: Methotrexate	Seoul National University Hospital		Recruiting	18 Years	65 Years	Both	318	N/A	Korea, Republic of
290	NCT02930343	September 2016	14 October 2019	Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy	Comparison of Sulfasalazine Versus Leflunomide Based Combination Disease Modifying Anti-rheumatic Drug Therapy (DMARD) in Patients With Rheumatoid Arthritis Failing Methotrexate Monotherapy : A Randomized Control Trial	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Leflunomide;Drug: Hydroxychloroquine;Drug: Prednisolone;Drug: Folic Acid;Drug: Sulfasalazine	Jawaharlal Institute of Postgraduate Medical Education & Research		Not recruiting	18 Years	65 Years	All	136	Phase 3	India
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
291	NCT03016013	September 2016	10 September 2018	A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.	A Phase III Study of RC18,a Recombinant Human B Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein in Subjects With Poor Efficacy of MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.	Moderate and Severe RheumatoId Arthritis	Biological: Placebo plus MTX;Biological: RC18 160 mg plus MTX	RemeGen		Recruiting	18 Years	65 Years	All	480	Phase 3	China
292	JPRN-UMIN000027242	2016/08/31	2 April 2019	the effect of tofacitinib on bone mineral density in patients with rheumatoid arthritis		to determine the effect of tofacitinib on bone	tofacitinib	Division of rheumatology, hiroshima clinic	Hatta clinic Sky clinic Toyohira hospital	Not Recruiting	18years-old	90years-old	Male and Female	50	Phase 4	Japan
293	EUCTR2016-000912-13-DE	30/08/2016	12 November 2018	A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subjects with moderate to severe rheumatoid arthritis.	A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subjects with moderate to severe rheumatoid arthritis.	subjects with moderate to severe rheumatoid arthritis. MedDRA version: 20.0 Level: LLT Classification code 10039076 Term: Rheumatoid arthritis and other inflammatory polyarthropathies System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: GSK2982772 Product Code: GSK2982772 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Not Available CAS Number: Not Availabl Other descriptive name: GSK2982772A, where A denotes the free base Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	GlaxoSmithKline Research & Development Ltd		Not Recruiting			Female: yes Male: yes	36	Phase 2	Poland;Spain;Romania;Germany;Italy;United Kingdom
294	NCT02889796	August 30, 2016	15 July 2019	Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate	A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks in Combination With Methotrexate to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: Filgotinib;Drug: Placebo to match filgotinib;Drug: Adalimumab;Drug: Placebo to match adalimumab;Drug: MTX	Gilead Sciences	Galapagos NV	Not recruiting	18 Years	N/A	All	1759	Phase 3	United States;Argentina;Australia;Belgium;Bulgaria;Canada;Czechia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;Czech Republic;France
295	EUCTR2016-000335-40-BG	23/08/2016	20 August 2018	A Study examining the treatment effect and Safety of GDC-0853 when compared With Placebo and a biologic therapy (Adalimumab) in Rheumatoid Arthritis Patients who have not responded or intolerance to Previous therapies.	A TWO-COHORT RANDOMIZED PHASE II, DOUBLEBLIND, PARALLEL GROUP STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS EVALUATING THE EFFICACY AND SAFETY OF GDC-0853 COMPARED WITH PLACEBO AND ADALIMUMAB IN PATIENTS WITH AN INADEQUATE RESPONSE TO PREVIOUS METHOTREXATE THERAPY (COHORT 1) AND COMPARED WITH PLACEBO IN PATIENTS WITH AN INADEQUATE RESPONSE OR INTOLERANCE TO PREVIOUS TNF THERAPY (COHORT 2)	Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: GDC-0853 Product Code: RO7010939 Pharmaceutical Form: Tablet INN or Proposed INN: not available Current Sponsor code: GDC-0853 RO7010939 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Humira Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection/infusion in pre-filled syringe Route of administration of the placebo: Subcutaneous use	Genentech, Inc.		Not Recruiting			Female: yes Male: yes	600	Phase 2	Serbia;United States;Mexico;Argentina;Poland;Brazil;Ukraine;Russian Federation;Chile;Bulgaria;Colombia;Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
296	EUCTR2016-002125-11-LV	23/08/2016	29 August 2016	Evaluating efficacy, pharmacokinetics and safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis	A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis	Active Rheumatoid Arthritis MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Code: CT-P13 Pharmaceutical Form: Concentrate for solution for injection INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Current Sponsor code: CT-P13 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 90- Product Code: CT-P13 Pharmaceutical Form: Concentrate for solution for injection INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Current Sponsor code: CT-P13 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Trade Name: REMSIMA Product Code: CT-P13 Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Current Sponsor code: CT-P13 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	Celltrion, Inc		Authorised			Female: yes Male: yes	258	Phase 1;Phase 3	Hungary;Estonia;Czech Republic;Poland;Ukraine;Lithuania;Russian Federation;Bulgaria;South Africa;Latvia;Korea, Republic of;Bosnia and Herzegovina
297	NCT02628028	August 22, 2016	6 May 2019	A Study of LY3337641 in Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study to Evaluate the Safety and Efficacy of LY3337641 in Adult Subjects With Rheumatoid Arthritis: The RAjuvenate Study	Rheumatoid Arthritis	Drug: LY3337641;Drug: Placebo	Eli Lilly and Company		Not recruiting	18 Years	65 Years	All	286	Phase 2	United States;Argentina;Australia;Austria;Italy;Japan;Korea, Republic of;Mexico;Poland;Puerto Rico;Slovakia;South Africa;Spain;Germany
298	ChiCTR-IIR-16008693	2016-08-20	18 April 2017	Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously	A Randomized, Double-blind, Placebo-controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Single Dose of Abatacept 125mg Administered Subcutaneously in Chinese Healthy Subjects	Rheumatoid Arthritis	Abatacept Group:Single dose of abatacept;Placebo Group:Single dose of placebo;	The First Hospital, Jilin University		Not Recruiting	18	45	Both	Abatacept Group:20;Placebo Group:2;	Phase 1 study	China
299	NCT02705989	August 18, 2016	11 February 2019	Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects	A Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD), and Non-Randomized, Bioavailability(BA) Study of BMS-986195 in Healthy Subjects	Rheumatoid Arthritis	Drug: BMS-986195;Other: Placebo	Bristol-Myers Squibb		Not recruiting	18 Years	55 Years	All	439	Phase 1	Australia
300	EUCTR2016-000393-37-BG	08/08/2016	26 September 2016	A study to test the effectiveness of bimekizumab as a treatment for rheumatoid arthritis, to look for unwanted side effects and to measure how the drug is distributed, modified and cleared from the body.	A MULTICENTER, SUBJECT-BLIND, INVESTIGATOR-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY/TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE INTRAVENOUS DOSES OF BIMEKIZUMAB (UCB4940) ADMINISTERED TO SUBJECTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS	RHEUMATOID ARTHRITIS MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: Bimekizumab Product Code: UCB4940 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Bimekizumab CAS Number: 1418205-77-2 Current Sponsor code: CDP4940 Other descriptive name: UCB4940 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 160- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	UCB Biopharma Sprl		Not Recruiting			Female: yes Male: yes	60	Phase 2	Serbia;Hungary;Macedonia, the former Yugoslav Republic of;Poland;Romania;Russian Federation;Georgia;Bulgaria;Moldova, Republic of;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
301	EUCTR2016-001532-35-HU	08/08/2016	30 October 2017	A Phase II, Clinical Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of LNP1955 in Patients with Moderate to Severe Rheumatoid Arthritis.	A Phase II, Dose Ranging, Exploratory Clinical Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of LNP1955 in Patients with Moderate to Severe Rheumatoid Arthritis.	Moderate to Severe Rheumatoid Arthritis. MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Code: LNP1955 Pharmaceutical Form: Capsule, soft Current Sponsor code: LND400111 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use	Lupin Limited		Not Recruiting			Female: yes Male: yes	64	Phase 2	Hungary;Bulgaria
302	NCT02886728	August 8, 2016	3 June 2019	Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy	A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination With Methotrexate (MTX) to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are Naïve to MTX Therapy	Rheumatoid Arthritis	Drug: Filgotinib;Drug: Placebo to match filgotinib;Drug: MTX;Drug: Placebo to match MTX	Gilead Sciences	Galapagos NV	Not recruiting	18 Years	N/A	All	1252	Phase 3	United States;Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Czechia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;Czech Republic
303	NCT03775824	August 1, 2016	30 September 2019	Faecal Analyses in Rheumatoid Arthritis Therapy	Faecal Analyses in Rheumatoid Arthritis Therapy: An Prospective Observational Study of the Intestinal Microbiome in Patients With Rheumatoid Arthritis Receiving Immunosuppressive Therapy	Rheumatoid Arthritis	Drug: MTX start;Drug: TNF start	Region Skane		Not recruiting	18 Years	N/A	All	50	N/A
304	NCT02722694	August 2016	26 September 2016	A Phase 3 Study of Abatacept in Chinese Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate	A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Abatacept 125mg Administered Subcutaneously in Chinese Subjects With Active Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate	Rheumatoid Arthritis (RA)	Drug: Subcutaneous(SC) Abatacept;Other: Placebo;Drug: Methotrexate	Jiangsu Simcere Pharmaceutical Co., Ltd.	Bristol-Myers Squibb	Recruiting	18 Years	N/A	Both	360	Phase 3	China
305	NCT02892370	August 2016	19 September 2016	Effect of a High-fat Meal on the Pharmacokinetics of SHR0302 and Mass Balance Study in Healthy Subjects	An Open Label, Randomized, Two-period, Crossover Study to Assess the Effect of Food on SHR0302 and Mass Balance in Healthy Volunteers	Rheumatoid Arthritis	Drug: SHR0302	Jiangsu HengRui Medicine Co., Ltd.		Recruiting	18 Years	45 Years	Male	14	Phase 1	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
306	NCT02940561	August 2016	31 October 2016	BE Study in Patients - Methotrexate Tablets	A Multicenter, Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single-dose, Two-way, Crossover, Bioequivalence Study of Methotrexate Tablets USP, 2.5 mg Manufactured by Amneal Pharmaceuticals, With Methotrexate Tablets USP 2.5 mg Manufactured for DAVA Pharmaceuticals, Inc., Fort Lee, NJ 07024 USA in Patients With Mild to Severe Psoriasis or Rheumatoid Arthritis, Who Are Already on Established Regimens of 2.5 mg Every 12 Hours Under Fasting Condition.	Psoriasis;Rheumatoid Arthritis	Drug: Methotrexate - Amneal;Drug: Methotrexate - DAVA	Amneal Pharmaceuticals, LLC	Accutest Research Laboratories (I) Pvt. Ltd.	Recruiting	18 Years	65 Years	Both	48	Phase 1	India
307	NCT02784106	July 31, 2016	11 June 2018	Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis	Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of M2951 in Subjects With Rheumatoid Arthritis on Stable Methotrexate Therapy	Rheumatoid Arthritis	Drug: Placebo;Drug: M2951	EMD Serono Research & Development Institute, Inc.	Merck KGaA	Not recruiting	18 Years	75 Years	All	65	Phase 2	United States;Germany
308	JPRN-JapicCTI-163317	28/7/2016	16 July 2019	Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis	Phase 2, Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety/Pharmacokinetics of BMS-986142 in Subjects With Moderate to Severe Rheumatoid Arthritis With an Inadequate Response to Methotrexate With or Without TNF Inhibitors	Rheumatoid Arthritis	Intervention name : BMS-986142 INN of the intervention : - Dosage And administration of the intervention : BMS-986142 at dose level 1+ Methotrexate as specified. BMS-986142 at dose level 2 + Methotrexate as specified. Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : Placebo + Methotrexate dose as specified	Bristol-Myers Squibb K.K.		Not Recruiting	18	120	BOTH	408	Phase 2	Japan, Asia except Japan, North America, South America, Europe, Oceania
309	EUCTR2016-000064-42-SK	27/07/2016	31 October 2016	Safety and Efficacy study of M2951 in Subjects with Rheumatoid Arthritis	Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of M2951 in Subjects with Rheumatoid Arthritis on Stable Methotrexate Therapy - N/A	Rheumatoid Arthritis MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: M2951 Product Code: M2951 Pharmaceutical Form: Capsule INN or Proposed INN: N/A CAS Number: N/A Current Sponsor code: M2951 Other descriptive name: M2951 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Merck KGaA		Authorised			Female: yes Male: yes	64	Phase 2	Hungary;Estonia;Czech Republic;Slovakia;Poland;Ukraine;Romania;South Africa;Bulgaria
310	NCT02873936	July 27, 2016	25 March 2019	Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment	A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 Weeks in Combination With Conventional Synthetic Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment	Rheumatoid Arthritis	Drug: Filgotinib;Drug: Placebo to match filgotinib;Drug: csDMARDs	Gilead Sciences	Galapagos NV	Not recruiting	18 Years	N/A	All	449	Phase 3	United States;Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Mexico;Poland;Spain;Switzerland;United Kingdom;Italy;Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
311	NCT02867306	July 25, 2016	25 March 2019	A Study to Evaluate the Pharmacokinetics of ASP1707 and Methotrexate in Patients With Rheumatoid Arthritis	A Phase 1 Open-label, Single-sequence, Drug Interaction Study to Evaluate the Pharmacokinetics of ASP1707 and Methotrexate in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: ASP1707;Drug: methotrexate (MTX)	Astellas Pharma Global Development, Inc.		Not recruiting	18 Years	65 Years	All	10	Phase 1	Moldova, Republic of
312	ChiCTR-IPR-16008793	2016-07-15	18 April 2017	A multi center, randomized, double blind, positive parallel controlled clinical study of Zhengqing Fengtongning sustained release tablets in the treatment of rheumatoid arthritis	A multi center, randomized, double blind, positive parallel controlled clinical study of Zhengqing Fengtongning sustained release tablets in the treatment of rheumatoid arthritis	Rheumatoid arthritis	experimental group:ZHENGQING FENGTONGNING sustained release tablets; control group:methotrexate;The combined treatment group:ZHENGQING FENGTONGNING sustained release tablets combine methotrexate;	The First Affiliated Hospital of Third Military Medical University		Recruiting	18	75	Both	experimental group:80; control group:80;The combined treatment group:80;	Post-market	China
313	EUCTR2015-003433-10-GB	05/07/2016	18 April 2017	ADMYRA Trial: Clinical trial to compare treatment with GP2017 and Humira® in patients with Rheumatoid Arthritis	GP17-302 A randomized, double-blind, parallel-group, multicenter study to demonstrate similar efficacy and to compare safety and immunogenicity of GP2017 and Humira® in patients with moderate to severe active rheumatoid arthritis - ADMYRA trial	rheumatoid arthritis MedDRA version: 19.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Adalimumab Product Code: GP2017 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Current Sponsor code: GP2017 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Humira Product Name: Humira Product Code: L04AB04 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Hexal, AG		Authorised			Female: yes Male: yes	308	Phase 3	Serbia;United States;Spain;Turkey;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Mexico;Malaysia;Poland;Romania;Germany;Korea, Republic of
314	NCT02683421	July 2016	9 January 2017	Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging	Evaluation of Subcutaneous (SC) Injected Tc 99m Tilmanocept Localization in Active Rheumatoid Arthritis (RA) Subjects by SPECT and SPECT/CT Imaging	Rheumatoid Arthritis	Drug: tilmanocept	Navidea Biopharmaceuticals		Not recruiting	21 Years	N/A	Both	18	Phase 1	United States
315	NCT02585258	June 30, 2016	10 September 2018	The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study	The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study Comparing the Cost-effectiveness and Safety of Additional Low-dose Glucocorticoid in Treatment Strategies for Elderly Patients With Rheumatoid Arthritis	RheumatoId Arthritis	Drug: Prednisolone;Other: Placebo	VU University Medical Center	European Commission	Recruiting	65 Years	N/A	All	500	Phase 4	Finland;Germany;Hungary;Italy;Netherlands;Portugal;Romania;Slovakia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
316	NCT02765074	June 30, 2016	20 May 2019	Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of Subcutaneous Tocilizumab in Rheumatoid Arthritis	Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of 12 Months Subcutaneous Tocilizumab in Rheumatoid Arthritis Phase IV Prospective Multicentrique Study	Rheumatoid Arthritis	Drug: subcutaneous tocilizumab	Centre Hospitalier Régional d'Orléans	Rennes University Hospital	Recruiting	18 Years	85 Years	All	60	Phase 4	France
317	NCT03106259	June 29, 2016	19 February 2018	Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj	Observational Study to Evaluate the Safety of FURESTEM-RA Inj. in Moderate to Severe Rheumatoid Arthritis Patients Who Participated in Phase 1 Clinical Trial of FURESTEM-RA Inj	Rheumatoid Arthritis	Drug: FURESTEM-RA Inj.	Kang Stem Biotech Co., Ltd.		Not recruiting	19 Years	80 Years	All	9	N/A	Korea, Republic of
318	EUCTR2015-003376-75-ES	23/06/2016	4 July 2016	A Study Comparing ABT-494 Monotherapy to Methotrexate (MTX) Monotherapy in Subjects with Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)	A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 Monotherapy to Methotrexate (MTX) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to MTX	Moderately to Severely Active Rheumatoid Arthritis (RA) MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: ABT-494 Pharmaceutical Form: Tablet INN or Proposed INN: ABT-494 CAS Number: 1310726-60-3 Current Sponsor code: ABT-494 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Methotrexate Pharmaceutical Form: Capsule INN or Proposed INN: Methotrexate Other descriptive name: METHOTREXATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7.5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Methotrexate Pharmaceutical Form: Capsule INN or Proposed INN: Methotrexate Other descriptive name: METHOTREXATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: ABT-494 Pharmaceutical Form: Tablet INN or Proposed INN: ABT-494 CAS Number: 1310726-60-3 Current Sponsor code: ABT-494 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	AbbVie Deutschland GmbH & Co. KG		Authorised			Female: yes Male: yes	600	Phase 3	Serbia;United States;Spain;Ukraine;Turkey;Austria;Russian Federation;Chile;Israel;Colombia;European Union;Mexico;Puerto Rico;Argentina;Australia;Japan;New Zealand
319	NCT03333681	June 20, 2016	25 March 2019	Evaluation of Stem Cell Therapy Effects on the Immune Response in Rheumatoid Arthritis Patients	Evaluation of Mesenchymal Stem Cell Therapy Effects on the Cellular and Humoral Immune Responses and Additionally Study on the Effect of Chemokines in Homing of the Immune Cells in Refractory Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Biological: Autologous mesenchymal stem cells	Mashhad University of Medical Sciences		Not recruiting	35 Years	60 Years	Female	15	Phase 1
320	NCT02799472	June 15, 2016	15 July 2019	Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis	A Phase IIa, Double-Blind, Mechanistic Study of GSK3196165 in Combination With Methotrexate Therapy in Subjects With Active Rheumatoid Arthritis Despite Treatment With DMARDs	Arthritis, Rheumatoid	Drug: GSK3196165;Drug: Placebo;Drug: MTX;Drug: Folic (or folinic) acid	GlaxoSmithKline	Parexel	Not recruiting	18 Years	N/A	All	39	Phase 2	United States;Germany;Poland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
321	NCT03762824	June 14, 2016	18 December 2018	Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease	Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response.	Rheumatoid Arthritis;Systemic Lupus;Sjögren Syndrome;Systemic Vasculitis;Spondyloarthritis	Biological: 23-valent pneumococcal polysaccharide vaccine;Biological: 13-valent pneumococcal conjugate vaccine	Region Skane		Not recruiting	18 Years	N/A	All	300	Phase 4
322	EUCTR2015-005308-27-CZ	07/06/2016	27 August 2018	Study of the Efficacy and Safety of Olokizumab in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-a) Inhibitor Therapy	A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-a) Inhibitor Therapy - Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 3	Moderately to Severely Active Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Olokizumab Product Code: (CDP6038; L04041) Pharmaceutical Form: Solution for injection INN or Proposed INN: Olokizumab Other descriptive name: CDP6038 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 160- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	R-Pharm		Authorised			Female: yes Male: yes	350	Phase 3	United States;Hungary;Czech Republic;Mexico;Argentina;Poland;Brazil;Germany;Colombia;Korea, Republic of
323	JPRN-UMIN000021929	2016/06/01	7 October 2019	Optimization of Infliximab Withdrawal Strategy for Rheumatoid Arthritis	Optimization of Infliximab Withdrawal Strategy for Rheumatoid Arthritis - OPTIWIT Study	Rheumatoid arthritis	Discontinuation of infliximab	Chiba University		Not Recruiting	18years-old	Not applicable	Male and Female	200	Not selected	Japan
324	NCT02804204	June 2016	25 February 2019	Serum Biomarkers Analysis in Patients With AR Treated With Anti-TMF	Analysis of Circulant Rheumatoid Factor, Cyclic Citrullinated Anti-peptide Anti-bodies and Albumin as a Potential Predictor in the Response to the Treatment With Anti-TNF in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Anti-TNF	Hospital Universitari Vall d'Hebron Research Institute	UCB Pharma	Recruiting	18 Years	N/A	All	200	Phase 2	Spain
325	NCT02804581	June 2016	27 June 2016	Gum Arabic as Immunomodulator In Rheumatoid Arthritis Patients	Potential Role of Gum Arabic as Immunomodulator In Sudanese Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Dietary Supplement: Gum Arabic	Lamis Kaddam	University of Khartoum;Military hospital	Recruiting	20 Years	50 Years	Both	45	Phase 2	Sudan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
326	EUCTR2016-002035-15-FI	20/05/2016	13 June 2016	Outcome after total knee endoprosthesis under general or regional anesthesia, a randomized study	Outcome after total knee arthroplasty under general or spinal anesthesia, a randomized study - Outcome after total knee arthroplasty under general or spinal anesthesia	Patients undego total knee arthroplasty operation in general or spinal anaesthesia because of osteoarthritis, rheumatoid arthritis or other degenerative condition of the knee MedDRA version: 19.0 Level: LLT Classification code 10031174 Term: Osteoarthrosis System Organ Class: 100000004859 MedDRA version: 19.0 Level: LLT Classification code 10031158 Term: Osteo arthritis knees System Organ Class: 100000004859 ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]	Trade Name: Bicain spinal Pharmaceutical Form: Solution for injection INN or Proposed INN: bupivacaine hydrochloride Other descriptive name: BUPIVACAINE HYDROCHLORIDE Trade Name: Propolipid Pharmaceutical Form: Solution for injection INN or Proposed INN: propofol Other descriptive name: PROPOFOL	Helsinki University Central Hospital		Authorised			Female: yes Male: yes		Phase 4	Finland
327	NCT02659150	May 18, 2016	14 January 2019	Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis	A Multicenter, Open-Label, Proof-of-Activity Study of the Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: tocilizumab	Massachusetts General Hospital	Brigham and Women's Hospital	Recruiting	50 Years	75 Years	Female	21	Phase 4
328	NCT02792699	May 17, 2016	22 October 2018	Study to Assess if ABP798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Rituximab	A Randomized, Double-blind Study to Compare Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of ABP 798 With Rituximab in Subjects With Moderate to Severe Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: ABP 798;Drug: Rituximab	Amgen		Not recruiting	18 Years	80 Years	All	311	Phase 3	United States;Bulgaria;Estonia;Germany;Hungary;Poland;Canada
329	EUCTR2014-004719-36-BG	14/05/2016	9 January 2017	Study of the Efficacy and Safety of Olokizumab in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy	A Randomized, Double-Blind, Parallel-Group, Placebo Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy - Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 1	Moderately to Severely Active Rheumatoid Arthritis MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Olokizumab Product Code: CDP6038 Pharmaceutical Form: Solution for injection INN or Proposed INN: Olokizumab Current Sponsor code: CDP6038 Other descriptive name: CDP6038 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 160- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	R-Pharm		Authorised			Female: yes Male: yes	420	Phase 3	Belarus;Turkey;Russian Federation;Bulgaria
330	NCT02780388	May 12, 2016	10 September 2018	A Phase 1b Study of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis	A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis	Adult Onset Rheumatoid Arthritis	Biological: MEDI4920;Other: Placebo	MedImmune LLC		Not recruiting	18 Years	70 Years	All	57	Phase 1	United States;Poland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
331	JPRN-UMIN000022364	2016/05/10	2 April 2019	Treatment strategy of minodronate in osteoporotic patients with rheumatoid arthritis	Treatment strategy of minodronate in osteoporotic patients with rheumatoid arthritis - Effectiveness of minodronate in osteoporotic patients with rheumatoid arthritis	Osteoprotic patients with rheumatoid arthritis	The selection criteria is based on which treatment each patient wants to take Minodronate group: oral intake 50mg per month Minodronate plus active vitamin D group: oral intake 50mg minodronate per month and eldecalcitol 0.75ug per day after breakfast	Department of Orthopaedic Surgery Shinshu University School of Medicine		Not Recruiting	50years-old	100years-old	Male and Female	140	Not applicable	Japan
332	NCT02760316	May 2, 2016	16 December 2017	A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567.	A Phase I, Randomised, Single-blind Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567 in Healthy Volunteers Using Prednisolone as Positive Control	Rheumatoid Arthritis	Drug: AZD9567 10 mg;Drug: AZD9567 20 mg;Drug: AZD9567 40 mg;Drug: AZD9567 80 mg;Drug: Prednisolone 20 mg;Drug: AZD9567 125 mg;Drug: AZD9567 155 mg;Drug: Prednisolone 5 mg;Drug: Prednisolone 40 mg	AstraZeneca		Not recruiting	18 Years	55 Years	All	64	Phase 1	Germany;United Kingdom
333	NCT01815411	May 2016	11 June 2018	Effect of Andosan in Patients With Rheumatoid Arthritis	Effect of the Mushroom Extract Andosan on Symptoms and Inflammatory Parameters in Patients With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Dietary Supplement: Mushroom extract	Egil Johnson	ImmunoPharma AS	Not recruiting	19 Years	75 Years	All	10	N/A	Norway
334	NCT02538341	May 2016	15 April 2019	Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)	Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)	Rheumatoid Arthritis;Inflammatory Arthritis;Arthritis;Psoriatic Arthritis;Psoriasis;Ankylosing Spondylitis;Enteropathic Arthritis;Crohn's Disease	Biological: Herpes Zoster Vaccine;Drug: Placebo	University of Alabama at Birmingham	Oregon Health and Science University	Not recruiting	50 Years	N/A	All	617	Phase 2	United States
335	NCT02665910	May 2016	2 May 2016	Multiple Doses Escalation Study of SHR0302 in Rheumatoid Arthritis (RA) Patients	A Phase I, Randomized, Placebo-Controlled, Multiple Doses Escalation Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics of SHR0302 in Patients With RA	Rheumatoid Arthritis	Drug: SHR0302;Drug: SHR0302 placebo comparator	Jiangsu HengRui Medicine Co., Ltd.		Not recruiting	18 Years	70 Years	Both	48	Phase 1	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
336	NCT02760368	May 2016	18 December 2018	Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease	A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy	Rheumatoid Arthritis	Drug: Olokizumab q4w;Drug: Olokizumab q2w;Drug: Placebo q2w	R-Pharm	Quintiles, Inc.;OCT Clinical Trials;Mene Research	Not recruiting	18 Years	N/A	All	428	Phase 3	Bulgaria;Russian Federation;Turkey
337	NCT02760407	May 2016	18 December 2018	Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease	A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy	Rheumatoid Arthritis	Drug: Olokizumab 64mg q4w;Drug: Olokizumab 64mg q2w;Drug: Adalimumab 40mg q2w;Drug: Placebo q2w	R-Pharm	Quintiles, Inc.;OCT Clinical Trials	Recruiting	18 Years	N/A	All	1575	Phase 3	United States;Argentina;Brazil;Bulgaria;Colombia;Czechia;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;China;Czech Republic
338	NCT02762123	May 2016	26 September 2016	A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates	Effects of Concomitant Administration of BMS-986142 on the Single-dose Pharmacokinetics of Probe Substrates for CYP2C8, CYP2C9, CYP2C19, CYP3A4, and P-gp in Healthy Subjects	Rheumatoid Arthritis	Drug: BMS-986142 200mg;Drug: BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin);Drug: BMS-986142 350mg	Bristol-Myers Squibb		Not recruiting	18 Years	50 Years	Both	28	Phase 1	United States
339	NCT02770794	May 2016	23 May 2016	Optimization of Infliximab Withdrawal Strategy for Rheumatoid Arthritis	Multicenter Prospective Trial to Investigate Accuracy of Ultrasound to Predict Relapse After Discontinuation of Infliximab and Efficacy/Safety of Readministration of Infliximab in Patients With Rheumatoid Arthritis in Low Disease Activity	Arthritis, Rheumatoid	Drug: Infliximab	Chiba University		Not recruiting	18 Years	N/A	Both	200	Phase 4
340	NCT02603146	April 27, 2016	28 October 2019	Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis	Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis	Healthy Participants;Rheumatoid Arthritis (RA) Prevention	Drug: Hydroxychloroquine;Drug: HCQ Placebo	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence	Recruiting	18 Years	N/A	All	200	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
341	NCT02714881	April 2016	23 July 2018	Lipids, Inflammation, and CV Risk in RA	Lipids, Inflammation, and Cardiovascular Risk in Rheumatoid Arthritis	Rheumatoid Arthritis;Cardiovascular Disease	Radiation: Stress myocardial perfusion PET;Drug: certolizumab	Brigham and Women's Hospital		Recruiting	35 Years	90 Years	All	75	N/A	United States
342	NCT02715908	April 2016	16 July 2018	A Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 in Subjects With Active RA Despite Methotrexate (MTX)	A Extension Clinical Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 When Co-administered With Methotrexate (MTX) for Additional 48 Weeks in Patients With RA Who Have Completed the Treatment Period of LG-ECCL002	Rheumatoid Arthritis	Drug: LBEC0101	LG Life Sciences		Not recruiting	20 Years	75 Years	All	148	Phase 3	Korea, Republic of
343	NCT02722044	April 2016	11 June 2018	Usability of an AI for M923 in Subjects With Moderate to Severe RA	An Open-label Single-arm Multicenter Study to Evaluate Usability of a Subcutaneous (SC) Autoinjector (AI) for a Proposed Adalimumab Biosimilar (M923) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Biological: M923;Device: Autoinjector	Momenta Pharmaceuticals, Inc.		Not recruiting	18 Years	N/A	All	33	Phase 3	United States
344	NCT02746380	April 2016	16 December 2017	A Study Comparing LBAL to Humira® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy	Multi-center (in Korea and Japan), Double-blind, Randomized, Parallel-group Study to Evaluate the Similarity of Efficacy and Safety of LBAL 40mg Subcutaneous Biweekly Injection to Humira® 40mg Subcutaneous Biweekly Injection, as Adjunctive Therapy to Methotrexate (MTX), in Patients With Active Rheumatoid Arthritis Who Had an Inadequate Response to MTX	Arthritis, Rheumatoid	Drug: LBAL;Drug: Humira®	LG Life Sciences	Mochida Pharmaceutical Company, Ltd.	Not recruiting	20 Years	75 Years	All	380	Phase 3	Japan;Korea, Republic of
345	NCT02573012	March 29, 2016	11 November 2019	Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants	Prospective, Multicentre, Placebo-controlled, Double-blind Interventional Study to Compare the Efficacy of Maintenance Treatment With Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: Placebo matched to prednisone;Drug: Prednisone;Biological: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	314	Phase 4	France;Germany;Italy;Russian Federation;Serbia;Tunisia;Egypt;Switzerland;Turkey
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
346	NCT02679001	March 24, 2016	20 August 2018	A Comparative Study to Observe the Effect of Concomitant Use of Corticosteroid Treatment in Rheumatoid Arthritis (RA) Participants Who Are Treated With a Tumor Necrosis Factor (TNF) Inhibitor or Tocilizumab (TCZ) as Their Second Biological Treatment.	A COMPARATIVE OBSERVATIONAL STUDY FOLLOWING THE USE OF CONCOMITANT CORTICOSTEROID TREATMENT IN RA PATIENTS WHO ARE TREATED WITH A TNF INHIBITOR OR TOCILIZUMAB AS THEIR SECOND BIOLOGICAL TREATMENT	Rheumatoid Arthritis	Drug: TNF inhibitor/TCZ	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	200	Phase 1/Phase 2	Sweden
347	NCT02720523	March 22, 2016	28 October 2019	A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs	A Phase 2b/3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Japanese Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs	Rheumatoid Arthritis	Drug: Placebo;Drug: Upadacitinib	AbbVie		Not recruiting	18 Years	N/A	All	197	Phase 2/Phase 3	Japan
348	NCT02682823	March 21, 2016	12 November 2018	Tocilizumab Real-Life Human Factors (RLHFs) Validation Study	Tocilizumab Real-Life Human Factors Validation Study	Rheumatoid Arthritis	Device: AI-1000 G2;Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	91	Phase 4	United States
349	EUCTR2015-002523-26-HU	08/03/2016	11 April 2016	Effects of JAK inhibition on rheumatoid arthritis-related comorbidities: link between bone and vascular effects (investigator-initiated grant proposal)	Effects of JAK inhibition on rheumatoid arthritis-related comorbidities: link between bone and vascular effects (investigator-initiated grant proposal)	Rheumatoid Arthritis MedDRA version: 18.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Tofacitinib Product Code: CP-690,55-10 Pharmaceutical Form: Film-coated tablet	Arthritis Alapítvány		Authorised			Female: yes Male: yes			Hungary
350	NCT01961310	March 8, 2016	11 June 2018	Evaluation of the Intestinal Microbiota and Bacterial Translocation in Patients With Rheumatoid Arthritis	Evaluation of the Intestinal Microbiota and Bacterial Translocation in Patients With Rheumatoid Arthritis	Arthritis, Rheumatoid	Biological: Plasma analysis for bacterial translocation;Biological: Stool analysis	Centre Hospitalier Universitaire de Nimes		Not recruiting	18 Years	N/A	All	55	N/A	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
351	NCT02547493	March 3, 2016	11 June 2018	Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis Patients	Comparison of Humoral Response to Conjugate Pneumococcal Vaccine and Polysaccharide Pneumococcal Vaccine in Rheumatoid Arthritis (RA) Patients Treated With Abatacept	Rheumatoid Arthritis	Biological: pneumococcal polysaccharide vaccine;Biological: pneumococcal conjugate vaccine;Drug: Abatacept	University Hospital, Montpellier	Bristol-Myers Squibb	Recruiting	18 Years	85 Years	All	80	N/A	France;Monaco
352	NCT02706951	March 2, 2016	18 March 2019	A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)	A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to MTX	Rheumatoid Arthritis	Drug: Methotrexate;Drug: ABT-494;Drug: ABT-494 matching placebo;Drug: Methotrexate matching placebo	AbbVie		Not recruiting	18 Years	99 Years	All	648	Phase 3	United States;Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Czechia;Estonia;Greece;Hungary;Israel;Italy;Japan;Mexico;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;Ukraine;Colombia;Czech Republic;New Zealand
353	JPRN-UMIN000021492	2016/03/01	2 April 2019	To investigate the safety of switch from infliximab biosimilar 1 in rheumatoid arthritis patients.		Rheumatoid arthritis	switch from infliximab to infliximab biosimilar 1 in rheumatoid arthritis patients.	Inoue Hospital		Not Recruiting	18years-old	Not applicable	Male and Female	40	Not selected	Japan
354	NCT02636829	March 2016	26 September 2016	Validation of Self-administered Questionnaire for Assessing Calcium Intake in Patients With Multiple Sclerosis or Chronic Inflammatory Arthritis	Validation of Self-administered Questionnaire Specifically for Assessing Calcium Intake (QALCIMUM®) in Patients With Multiple Sclerosis (MS) or Chronic Inflammatory Arthritis	Multiple Sclerosis;Rheumatoid Arthritis	Other: QALCIMUM questionnaire;Other: Determination of calcium intake by a dietician interview	Centre Hospitalier Universitaire de Nimes		Not recruiting	18 Years	69 Years	Both	100	N/A	France
355	NCT02652299	March 2016	25 March 2019	Fibrocytes in Early and Longstanding Rheumatoid Arthritis	Fibrocytes in Early and Longstanding Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: Synovial biopsy	Odense University Hospital		Not recruiting	18 Years	N/A	All	60	N/A	Denmark
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
356	NCT02714634	March 2016	11 April 2016	Clinical Trial Evaluating Methotrexate + Biologic Versus Methotrexate, Salazopyrine and Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate	Randomized Controlled Clinical Trial Evaluating Methotrexate + Biologic Versus Methotrexate, Salazopyrine and Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate	Rheumatoid Arthritis;Insufficient Response to Methotrexate.	Drug: Methotrexate + biologic administration;Drug: methotrexate + salazopyrine + hydroxychloroquine administration	University Hospital, Strasbourg, France		Not recruiting	18 Years	N/A	Both	286	Phase 4
357	NCT02728934	February 25, 2016	11 November 2019	Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis	Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis	Arthritis, Rheumatoid	Biological: Golimumab Intravenous (IV);Biological: Infliximab;Biological: Biosimilar Infliximab	Janssen Scientific Affairs, LLC		Not recruiting	18 Years	N/A	All	1279	N/A	United States
358	EUCTR2015-002924-17-BE	24/02/2016	23 July 2018	A Study To Evaluate The Efficacy And Safety Of Intravenous Nanocort Compared With A Intramuscular Injection of Methylprednisolone Acetate In Patients With Rheumatoid Arthritis	A Phase III, Randomized, Double-Blind, Double Dummy, Active Controlled, Multi-Center Study To Evaluate The Efficacy And Safety Of Intravenous Pegylated Liposomal Prednisolone Sodium Phosphate (Nanocort) Compared With Intramuscular Injection Of Methylprednisolone Acetate In Subjects With Active Rheumatoid Arthritis	Active Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Nanocort Pharmaceutical Form: Concentrate and solvent for solution for infusion INN or Proposed INN: prednisolone Other descriptive name: PREDNISOLONE Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 150- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Trade Name: Depo Medrol Product Name: Depo Medrol Pharmaceutical Form: Suspension for injection Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intramuscular use	Sun Pharma Global FZE		Not Recruiting			Female: yes Male: yes	330	Phase 3	Belgium;Netherlands
359	NCT02698657	February 23, 2016	15 July 2019	A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate	A Phase 1, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate	Rheumatoid Arthritis (RA)	Drug: ASP5094;Drug: Placebo	Astellas Pharma Global Development, Inc.		Not recruiting	18 Years	65 Years	All	30	Phase 1	United States;Poland
360	NCT02706873	February 23, 2016	25 March 2019	A Study to Compare ABT-494 Monotherapy to Methotrexate Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate	A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Naïve Subjects With Moderately to Severely Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: ABT-494 matching placebo;Drug: Methotrexate;Drug: Methotrexate matching placebo;Drug: ABT-494	AbbVie		Not recruiting	18 Years	99 Years	All	1002	Phase 3	United States;Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Estonia;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Kazakhstan;Latvia;Lithuania;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;Czech Republic;Finland;Malaysia;Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
361	NCT02638948	February 16, 2016	20 August 2018	Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis	Phase 2, Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety/Pharmacokinetics of BMS-986142 in Subjects With Moderate to Severe Rheumatoid Arthritis With an Inadequate Response to Methotrexate With or Without TNF Inhibitors	Rheumatoid Arthritis	Drug: BMS-986142;Drug: Placebo;Drug: Methotrexate	Bristol-Myers Squibb		Not recruiting	18 Years	120 Years	All	536	Phase 2	United States;Argentina;Austria;Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;Belgium
362	NCT02683564	February 2016	23 February 2016	BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis: The UNIFORM Study	A Study of BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis on Stable Methotrexate: The UNIFORM Study	Rheumatoid Arthritis	Drug: BOW015;Drug: Remicade	Epirus Biopharmaceuticals (Switzerland) GmbH		Not recruiting	18 Years	80 Years	Both	548	Phase 3
363	NCT03332719	February 2016	16 December 2017	Efficacy, Safety and Immunogenicity of Enerceptan Compared to Enbrel in Rheumatoid Arthritis	Multicentric Evaluator-blinded Randomized Non-inferiority Study, to Asses the Compared Efficacy, Safety and Immunogenicity of Enerceptan® With Enbrel® in Combination With Methotrexate for the Treatment of Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: Etanercept;Drug: Methotrexate	Gema Biotech S.A.	QUID-Quality in Drugs and Devices Latin American Consulting SRL	Not recruiting	19 Years	99 Years	All	168	Phase 3	Argentina
364	NCT03355872	February 2016	9 October 2018	A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDs	A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDs	Rheumatoid Arthritis	Drug: HLX01	Shanghai Henlius Biotech		Not recruiting	18 Years	65 Years	All	194	Phase 1/Phase 2
365	EUCTR2014-004868-38-GR	26/01/2016	14 March 2016	A study comparing the use of etanercept and methotrexate, used either alone or in combination, for maintaining remission in rheumatoid arthritis.	A Randomized Withdrawal Double-blind Study of Etanercept Monotherapy Compared to Methotrexate Monotherapy for Maintenance of Remission in Subjects With Rheumatoid Arthritis.	Rheumatoid arthritis MedDRA version: 18.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Enbrel Product Name: Enbrel Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use Trade Name: Methotrexate Product Name: methotrexate Pharmaceutical Form: Tablet INN or Proposed INN: methotrexate CAS Number: 59-05-2 Current Sponsor code: methotrexate Other descriptive name: METHOTREXATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Amgen Inc.		Authorised			Female: yes Male: yes	720		United States;Hungary;Czech Republic;Canada;Greece;Argentina;Spain;Bulgaria
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
366	NCT02925351	January 25, 2016	11 November 2019	Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases	The Biodistribution of 18F-Clofarabine in Patients With Autoimmune and Inflammatory Diseases	Autoimmune Disease;Crohn Disease;Inflammatory Disorder;Rheumatoid Arthritis;Systemic Lupus Erythematosus;Takayasu Arteritis	Procedure: Computed Tomography;Radiation: Fluorine F 18 Clofarabine;Procedure: Positron Emission Tomography	Jonsson Comprehensive Cancer Center	National Cancer Institute (NCI)	Not recruiting	18 Years	N/A	All	8	N/A	United States
367	NCT02640612	January 22, 2016	18 December 2018	Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis	Long-term Assessment of Safety, Efficacy, Pharmacokinetics and Immunogenicity of BI 695501 in Patients With Rheumatoid Arthritis (RA): an Open-label Extension Trial for Patients Who Have Completed Trial 1297.2 and Are Eligible for Long-term Treatment With Adalimumab	Arthritis, Rheumatoid	Drug: BI 695501	Boehringer Ingelheim		Not recruiting	18 Years	80 Years	All	430	Phase 3	United States;Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine
368	JPRN-UMIN000018931	2016/01/17	2 April 2019	Impact of intravenous acetaminophen on multimodal pain management after total knee arthroplasty: a double-blinded randomized controlled trial		Osteoarthritis, Avascular necrosis of femoral condyle, Rheumatoid arthritis	1000 mg of intravenous acetaminophen (100 ml) after total knee arthroplasty at 23:00 of day of surgery, 5:00, 11:00, 17:00, and 23:00 of one day after surgery, 5:00, 11:00, 17:00, and 23:00 of two days after surgery, and 5:00 of three days after surgery. 100ml of intravenous normal saline after total knee arthroplasty at 23:00 of day of surgery, 5:00, 11:00, 17:00, and 23:00 of one day after surgery, 5:00, 11:00, 17:00, and 23:00 of two days after surgery, and 5:00 of three days after surgery.	Nekoyama Miyao Hospital		Not Recruiting	20years-old	Not applicable	Male and Female	50	Not selected	Japan
369	EUCTR2014-004673-16-DE	12/01/2016	30 April 2018	Randomized, blinded, controlled study to compare the efficacy of treatment with tocilizumab with or without glucocorticoids in rheumatoid arthritis.	Prospective, multicentre, placebo-controlled, double-blind study to compare the efficacy of maintenance treatment with tocilizumab with or without glucocorticoid discontinuation in rheumatoid arthritis patients	Rheumatoid Arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: RoActemra 162 mg Product Code: RO487-7533/F10-04 Pharmaceutical Form: Solution for injection INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Other descriptive name: TOCILIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 180- Trade Name: Prednisone Tablets USP, 5 mg Product Code: RO001-9265/F04 Pharmaceutical Form: Capsule INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: Prednisone Tablets USP, 1 mg Product Code: RO 001-9265/F02-01 Pharmaceutical Form: Capsule INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: RoActemra Product Code: L04AC07 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: tocilizumab CAS Number: 375823-41-9 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	F. Hoffmann-La Roche Ltd		Not Recruiting			Female: yes Male: yes	226	Phase 4	Serbia;France;Egypt;Lebanon;Turkey;Russian Federation;Germany;Italy;Switzerland
370	EUCTR2015-003332-13-SK	12/01/2016	8 February 2016	A Study Comparing ABT-494 to Placebo in Subjects with Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response to csDMARDs Alone (SELECT-NEXT)	A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti- Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs	Moderately to Severely Active Rheumatoid Arthritis (RA) MedDRA version: 18.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: ABT-494 Pharmaceutical Form: Tablet INN or Proposed INN: ABT-494 CAS Number: 1310726-60-3 Current Sponsor code: ABT-494 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: ABT-494 Pharmaceutical Form: Tablet INN or Proposed INN: ABT-494 CAS Number: 1310726-60-3 Current Sponsor code: ABT-494 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	AbbVie Deutschland GmbH & Co. KG		Authorised			Female: yes Male: yes	600	Phase 3	Serbia;Belarus;United States;Taiwan;Hong Kong;Slovakia;Ukraine;Russian Federation;Chile;Israel;Colombia;Switzerland;Puerto Rico;Malaysia;Australia;South Africa;Bosnia and Herzegovina;Korea, Republic of;Turkey;Egypt;European Union;Mexico;Canada;Argentina;Brazil;Singapore;Kazakhstan;Japan;New Zealand
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
371	NCT02742597	January 12, 2016	8 January 2018	Patient-Centred Innovations for Persons With Multimorbidity - Ontario	Patient-Centred Innovations for Persons With Multimorbidity - Ontario	Hypertension;Depression;Anxiety;Musculoskeletal Pain;Arthritis;Rheumatoid Arthritis;Osteoporosis;Chronic Obstructive Pulmonary Disease (COPD);Asthma;Chronic Bronchitis;Cardiovascular Disease;Heart Failure;Stroke;Transient Ischemic Attacks;Ulcer;Gastroesophageal Reflux;Irritable Bowel;Crohn's Disease;Ulcerative Colitis;Diverticulosis;Chronic Hepatitis;Diabetes;Thyroid Disorder;Cancer;Kidney Disease;Urinary Tract Problem;Dementia;Alzheimer's Disease;Hyperlipidemia;HIV;Multimorbidity	Behavioral: TIP / IMPACT Plus Care Coordination	Lawson Health Research Institute	Western University, Canada;Université de Sherbrooke;Canadian Institutes of Health Research (CIHR);Sunnybrook Health Sciences Centre;St. Michael's Hospital, Toronto;University Health Network, Toronto;Toronto East General Hospital;Providence HealthCare;Mount Sinai Hospital, Canada;Toronto Central Community Care Access Centre;Women's College Hospital	Not recruiting	18 Years	80 Years	All	1980	N/A	Canada
372	EUCTR2012-002009-23-HU	07/01/2016	3 July 2017	Clinical trial to demonstrate that treatments with GP2015 and Enbrel® are comparable in patients with rheumatoid arthritis	A randomized, double-blind, parallel-group Phase III study to demonstrate equivalent efficacy and to compare safety and immunogenicity of GP2015 and Enbrel® (EU-authorized) in patients with moderate to severe, active rheumatoid arthritis - EQUIRA	Moderate to severe active rheumatoid arthritis MedDRA version: 18.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Code: GP2015 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Enbrel 50 mg solution for injection in pre-filled syringe Product Name: Enbrel 50 mg solution for injection in pre-filled syringe Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Hexal AG		Not Recruiting			Female: yes Male: yes	366	Phase 3	Serbia;United States;Estonia;Slovakia;Spain;Lithuania;Russian Federation;United Kingdom;Italy;France;Hungary;Czech Republic;Mexico;Poland;Bulgaria;Germany;Latvia
373	EUCTR2015-002634-41-HU	07/01/2016	11 December 2017	Long-term study of BI695501 in patients with active rheumatoid arthritis	Long-term assessment of safety, efficacy, pharmacokinetics and immunogenicity of BI 695501 in patients with rheumatoid arthritis (RA): an open-label extension trial for patients who have completed trial 1297.2 and are eligible for long-term treatment with adalimumab	Rheumatoid arthritis MedDRA version: 18.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Code: BI 695501 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: - CAS Number: - Current Sponsor code: BI 695501 Other descriptive name: BI 695501 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Boehringer Ingelheim International GmbH		Not Recruiting			Female: yes Male: yes	400	Phase 3	Serbia;United States;Estonia;Spain;Thailand;Ukraine;Chile;Russian Federation;Hungary;Malaysia;Poland;Bulgaria;Germany;Korea, Republic of
374	NCT02636907	January 6, 2016	16 December 2017	Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe	Assessment of Real-life Patient Handling Experience of BI 695501 Administered Subcutaneously With an Autoinjector in Patients With Rheumatoid Arthritis: an Open-label, Interventional Clinical Trial Followed by an Extension Phase of BI 695501 Administered With a Prefilled Syringe	Arthritis, Rheumatoid	Drug: BI 695501 Autoinjector;Drug: BI 695501 Prefilled syringe	Boehringer Ingelheim		Not recruiting	18 Years	80 Years	All	77	Phase 2	United States;Poland;Ukraine
375	NCT02321930	January 2016	16 December 2017	Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients	Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: tofacitinib 5mg po bid	University of California, Los Angeles		Not recruiting	18 Years	N/A	All	25	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
376	NCT02626026	January 2016	10 October 2016	Safety and Pharmacokinetics of GS-4059 in Healthy Volunteers and Subjects With Rheumatoid Arthritis (RA)	A Phase 1, Placebo-Controlled, Randomized Study Evaluating the Safety and Pharmacokinetics of GS-4059 in Healthy Volunteers and Subjects With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: GS-4059;Drug: Placebo	Gilead Sciences		Not recruiting	18 Years	65 Years	Both	42	Phase 1	United States
377	NCT02643823	January 2016	13 June 2016	Human Umbilical Cord-Mesenchymal Stem Cells for Rheumatoid Arthritis	Safety and Efficacy Study of Human Umbilical Cord-Mesenchymal Stem Cells for Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: hUC-MSC + DMARDs;Drug: DMARDs	Shenzhen Hornetcorn Bio-technology Company, LTD	Futian People's Hospital	Recruiting	18 Years	80 Years	Both	40	Phase 1	China
378	NCT02762838	January 2016	24 June 2019	Comparative Clinical Trial of Efficacy and Safety of BCD-055 and Remicade® in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis	International Multi-center Comparative Double-blind Randomized Clinical Trial of Efficacy and Safety of BCD-055 (JSC BIOCAD, Russia) and Remicade® in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: BCD-055;Biological: Remicade®;Drug: Methotrexate;Drug: Folic acid	Biocad		Not recruiting	18 Years	75 Years	All	426	Phase 3	Belarus;India;Russian Federation
379	NCT02878161	January 2016	29 August 2016	Predictability Studies on the Efficacy of TNF-a Inhibitors in Chinese RA From Real World	Screening Protein Predictive of Response to Tumor Necrosis Factor-a Inhibitors Treatment in Chinese Rheumatoid Arthritis From Real World and Investigating Its Mechanism Through Signal Pathway	Rheumatoid Arthritis	Drug: methotrexate(necessary);Biological: infliximab;Biological: etanercept;Biological: adalimumab;Drug: leflunomide (permitted, not necessary);Drug: NSAIDs (permitted,not necessary);Drug: Glucocorticoids (permitted,not necessary)	Fen Li		Recruiting	18 Years	75 Years	Both	240	Phase 4
380	NCT02608112	December 31, 2015	5 November 2018	Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year	Subcutaneous Tocilizumab in Monotherapy or in Combination With csDMARD in Patients With Moderate to Severe Active Rheumatoid Arthritis and Followed by Hospital and Office Based Rheumatologists: Non Interventional Study to Describe Real-World Drug Retention Rate of the Biotherapy at 1 Year	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	291	Phase 1	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
381	NCT02644499	December 31, 2015	14 October 2019	Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis	Comparison of Combination Disease Modifying Antirheumatic Drugs (DMARDs) With Single Drug (Methotrexate) Therapy in Early Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Leflunomide;Drug: Hydroxychloroquine;Drug: Prednisolone;Drug: Folic Acid	Jawaharlal Institute of Postgraduate Medical Education & Research		Not recruiting	18 Years	N/A	All	186	Phase 4	India
382	EUCTR2015-003333-95-SK	18/12/2015	6 November 2018	A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Rheumatoid Arthritis who are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (SELECT-COMPARE)	A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)	Moderately to Severely Active Rheumatoid Arthritis (RA) MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Upadacitinib Product Code: ABT-494 Pharmaceutical Form: Tablet INN or Proposed INN: Upadacitinib CAS Number: 1310726-60-3 Current Sponsor code: ABT-494 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Humira 40mg/0.8ml solution for injection in pre-filled syringe Product Name: Adalimumab Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use	AbbVie Deutschland GmbH & Co. KG		Authorised			Female: yes Male: yes	1500	Phase 3	Ukraine;Ireland;Chile;Israel;Russian Federation;Colombia;Puerto Rico;Malaysia;Denmark;Australia;South Africa;Latvia;Bosnia and Herzegovina;Korea, Republic of;Finland;Lithuania;Turkey;Austria;United Kingdom;Egypt;Czech Republic;Hungary;European Union;Mexico;Canada;Argentina;Belgium;Brazil;Singapore;Croatia;Kazakhstan;Bulgaria;Germany;New Zealand;Portugal;Serbia;Belarus;United States;Taiwan;Hong Kong;Slovakia;Greece;Spain
383	EUCTR2015-004173-32-DK	18/12/2015	30 April 2019	Personalized medicine: Administration of TNF-alpha inhibitor treatment due to serum concentration measuring.	Personalized medicine: Administration of TNF-alpha inhibitor treatment due to serum concentration measuring. A randomized and investigator initiated study.	Rheumatic diseases MedDRA version: 20.0 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000005156 ;Therapeutic area: Body processes [G] - Immune system processes [G12]	Trade Name: Enbrel Pharmaceutical Form: Solution for injection/infusion in pre-filled syringe INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Trade Name: Humira Pharmaceutical Form: Solution for injection/infusion in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Remsima Pharmaceutical Form: Solution for injection/infusion in pre-filled syringe INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Concentration unit: mg/kg milligram(s)/kilogram Concentration type: up to Concentration number: 5- Trade Name: Benepali Pharmaceutical Form: Solution for injection/infusion in pre-filled syringe INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 50- Trade Name: Remicade Pharmaceutical Form: Solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Concentration unit: mg/kg milligram(s)/kilogram Concentration type: up to Concentration number: 7,5-	Department of Clinical Biochemestry, Aarhus University Hospital		Not Recruiting			Female: yes Male: yes	500	Phase 4	Denmark
384	NCT02675426	December 17, 2015	18 March 2019	A Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone	A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs	Rheumatoid Arthritis	Drug: Placebo;Drug: ABT-494	AbbVie		Not recruiting	18 Years	99 Years	All	661	Phase 3	United States;Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czechia;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;Belarus;Brazil;Colombia;Czech Republic;Denmark;Israel;Netherlands;Norway;Serbia;Singapore
385	EUCTR2015-003334-27-SK	11/12/2015	6 November 2018	A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate Monotherapy in Subjects with Rheumatoid Arthritis (RA) Who have not Previously taken Methotrexate (SELECT-EARLY)	A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Naïve Subjects with Moderately to Severely Active Rheumatoid Arthritis	Moderately to Severely Active Rheumatoid Arthritis (RA) MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Upadacitinib Product Code: ABT-494 Pharmaceutical Form: Tablet INN or Proposed INN: Upadacitinib CAS Number: 1310726-60-3 Current Sponsor code: ABT-494 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Upadacitinib Product Code: ABT-494 Pharmaceutical Form: Tablet INN or Proposed INN: Upadacitinib CAS Number: 1310726-60-3 Current Sponsor code: ABT-494 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Methotrexate Pharmaceutical Form: Capsule INN or Proposed INN: Methotrexate Other descriptive name: METHOTREXATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7.5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Methotrexate Pharmaceutical Form: Capsule INN or Proposed INN: Methotrexate Other descriptive name: METHOTREXATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	AbbVie Deutschland GmbH & Co. KG		Authorised			Female: yes Male: yes	975	Phase 3	Portugal;Serbia;Belarus;United States;Taiwan;Hong Kong;Slovakia;Greece;Spain;Ukraine;Ireland;Russian Federation;Chile;Israel;Colombia;Switzerland;Puerto Rico;Malaysia;Australia;South Africa;Latvia;China;Bosnia and Herzegovina;Korea, Republic of;Slovenia;Finland;Lithuania;Turkey;United Kingdom;Egypt;Hungary;Czech Republic;European Union;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Croatia;Kazakhstan;Bulgaria;New Zealand;Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
386	NCT02680067	December 8, 2015	29 April 2019	NIR Fluorescence Imaging of Lymphatic Transport Using ICG	Near InfraRed Fluorescence Imaging of Lymphatic Transport Using Indocyanine Green	Rheumatoid Arthritis	Drug: Indocyanine Green;Device: MultiSpectral Imaging System	University of Rochester	National Institutes of Health (NIH);National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Recruiting	18 Years	89 Years	All	30	Phase 1	United States
387	ChiCTR-IPR-15007368	2015-12-01	18 April 2017	Clinical Research for the Effect of Chinese and Western Medicine on Treating Rheumatoid Arthritis	Comparative Study on the Influences of Gut Microbiota of Chinese and Western Medicine for Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis	1:HuaYuTongBiFang;2:HuaYuTongBiFang+MTX;3:ZhengQingFengTongNing Pills+MTX;4:Methotrexate;	Guangdong Provincial Hospital of Chinese Medicine		Not Recruiting	18	65	Male	1:96;2:96;3:96;4:96;	Pilot study	China
388	NCT02629159	December 1, 2015	25 February 2019	A Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate	A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)	Rheumatoid Arthritis	Drug: Placebo for Adalimumab;Drug: ABT-494;Drug: Adalimumab;Drug: Placebo for ABT-494	AbbVie		Not recruiting	18 Years	N/A	All	1629	Phase 3	United States;Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czechia;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;Czech Republic;Finland;Netherlands
389	NCT02944799	December 2015	22 October 2018	Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis	Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis - Indication and Duration: A Randomized, Double-blind, Placebocontrolled Study to Evaluate the Effects of Discontinuation of Alendronate in Patients With Both Rheumatoid Arthritis and Low Bone Mass	Rheumatoid Arthritis;Osteoporosis	Drug: Placebo;Drug: Alendronate;Drug: Calcium;Drug: Vitamin D	University of Aarhus		Recruiting	18 Years	N/A	All	160	Phase 2	Denmark
390	NCT02758769	November 30, 2015	16 December 2017	Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings	Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings	Rheumatoid Arthritis	Biological: ORENCIA Subcutaneous Injection	Bristol-Myers Squibb	Ono Pharmaceutical Co. Ltd	Recruiting	20 Years	N/A	All	300	N/A	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
391	NCT02557100	November 19, 2015	26 August 2019	Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis	A Randomized, Head-to-Head, Single-Blinded Study to Assess Changes in the Immune Profile in Response to Treatment With Subcutaneous Abatacept in Combination With Methotrexate Versus Subcutaneous Adalimumab in Combination With Methotrexate in Adults With Early Rheumatoid Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs	Rheumatoid Arthritis	Drug: Abatacept;Drug: Adalimumab;Drug: Methotrexate	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	120	Phase 4	United States;Algeria;Canada;Mexico
392	NCT02512575	November 18, 2015	9 October 2018	A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.	A Phase I, Randomized, Single-Blind, Placebo-Controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Ascending Oral Doses Of AZD9567 In Healthy Subjects.	Safety;Tolerability;Pharmacokinetics;Pharmacodynamics;Healthy Subjects;Rheumatoid Arthritis	Drug: AZD9567 Monohydrat;Drug: Placebo oral suspension/ Placebo capsule;Drug: Prednisolone	AstraZeneca		Not recruiting	18 Years	55 Years	Male	72	Phase 1	Germany
393	EUCTR2015-002809-12-HU	17/11/2015	2 October 2017	A Study to Compare YLB113 and Enbrel for the Treatment of Rheumatoid Arthritis	A comparative Study to Assess the Efficacy, Safety and Immunogenicity of YLB113 and Enbrel for the Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: YLB113 Product Code: YLB113 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Current Sponsor code: YLB113 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Enbrel Product Name: Enbrel Product Code: Enbrel Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-	YL Biologics Ltd		Not Recruiting			Female: yes Male: yes	500	Phase 3	Czech Republic;Hungary;Spain;Ukraine;Romania;Bulgaria;Latvia;Japan;India
394	EUCTR2013-000337-13-PT	13/11/2015	12 February 2018	Prediction of response to Certolizumab Pegol treatment with MRI of the brain. A multi-center, randomized double-blind controlled study Prediction of response to Certolizumab-Pegol in Rheumatoid Arthritis (PreCePRA)	Prediction of response to Certolizumab Pegol treatment by functional MRI of the brain. A multi-center, randomized double-blind controlled study Prediction of response to Certolizumab-Pegol in RA (PreCePRA) - PreCePRA	Patients with active Rheumatoid Artrhitis (DAS28 > 3.2) despite DMARD therapy MedDRA version: 20.0 Level: LLT Classification code 10040107 Term: Seropositive rheumatoid arthritis System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Cimzia Product Name: Cimzia Pharmaceutical Form: Suspension for injection in pre-filled syringe INN or Proposed INN: CERTOLIZUMAB PEGOL CAS Number: 428863-50-7 Current Sponsor code: UCB SA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Solution and suspension for suspension for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use	Universitätsklinikum Erlangen		Authorised			Female: yes Male: yes	156	Phase 3	Serbia;United States;Portugal;Germany
395	JPRN-UMIN000018848	2015/11/01	5 November 2019	Tapering and withdrawal of methotrexate and biologics in patients with rheumatoid arthritis	Tapering and withdrawal of methotrexate and biologics in patients with rheumatoid arthritis - Tapering and withdrawal of methotrexate and biologics in patients with rheumatoid arthritis	Rheumatoid arthritis	control: continue the present treatment intervention: reduce the dosage of methotrexate by half every 3 months and discontinue intervention: extend the interval of biologics to one and a half times every 3 months and discontinue	Keio University Hospital		Not Recruiting	Not applicable	Not applicable	Male and Female	900	Not applicable	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
396	NCT02534896	November 2015	26 November 2018	To Evaluate The Efficacy And Safety Of Sunpharma1505 Compared With Reference1505 In Subjects With Active Rheumatoid Arthritis	To Evaluate The Efficacy And Safety Of Sunpharma1505 Compared With Reference1505 In Subjects With Active Rheumatoid Arthritis	Active Rheumatoid Arthritis	Drug: Sunpharma1505 1;Drug: Sunpharma1505 2;Drug: Reference1505	Sun Pharma Global FZE		Not recruiting	18 Years	90 Years	All	330	Phase 3	Belgium;Netherlands
397	NCT02543931	November 2015	12 December 2016	Curcuma Longa L in Rheumatoid Arthritis	Phase Ib Randomized, Double-Blind, Placebo-Controlled Study of Meriva in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Meriva;Drug: placebo	University of Arizona	Vanderbilt University;National Center for Complementary and Integrative Health (NCCIH);National Institutes of Health (NIH)	Not recruiting	18 Years	N/A	Both	3	Phase 1	United States
398	NCT02723760	November 2015	11 April 2016	99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis Patients	Clinical Study of 99mTc-3PRGD2 SPECT/CT in Diagnosis and Efficacy Evaluation of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: 99mTc-3PRGD2	First Affiliated Hospital of Fujian Medical University		Recruiting	20 Years	70 Years	Both	40	Phase 0	China
399	NCT02552940	October 31, 2015	11 June 2018	An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice	A PROSPECTIVE, NON-INTERVENTIONAL STUDY TO EVALUATE THE CLINICAL EFFECTIVENESS, THE CONSISTENCY OF EVALUATION SCORES, QUALITY OF LIFE, SAFETY AND TOLERABILITY OF TOCILIZUMAB SUBCUTANEOUS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN DAILY CLINICAL PRACTICE	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche	nv Roche sa	Not recruiting	18 Years	N/A	All	140	N/A	Belgium;Luxembourg
400	ChiCTR-OPB-15007284	2015-10-30	18 April 2017	Characterization of linkage between symbiotic gut microbes and fatty acid metabolism in rheumatoid arthritis patients	Characterization of linkage between symbiotic gut microbes and fatty acid metabolism in rheumatoid arthritis patients	Rheumatoid Arthritis	RA group1:Doxycycline;RA group 2:Placebo;	Hong Kong Baptist University		Recruiting	18	80	Both	RA group1:20;RA group 2:20;	Pilot study	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
401	EUCTR2015-001246-28-BE	19/10/2015	16 November 2015	Ultrasound scores as imaging biomarkers of early response to subcutaneous tocilizumab in association with methotrexate in early rheumatoid arthritis (TOVERA study)	Ultrasound scores as imaging biomarkers of early response to subcutaneous tocilizumab in association with methotrexate in early rheumatoid arthritis (TOVERA study) - TOVERA	Rheumatoid Arthritis MedDRA version: 18.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: RoActemra Product Name: RoActemra Pharmaceutical Form: Solution for injection/infusion in pre-filled syringe	Cliniques Universitaires Saint-Luc, Université catholique de Louvain		Authorised			Female: yes Male: yes			Belgium
402	EUCTR2015-000581-58-CZ	14/10/2015	15 October 2018	A Randomized,Biomarker Trial to Predict Therapeutic Responses of Patients with Rheumatoid Arthritis to a Specific Biologic Mode of Action	A Randomized, Biomarker Trial to Predict Therapeutic Responses of Patients with Rheumatoid Arthritis to a Specific Biologic Mode of Action - BioBio	Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Remicade Product Name: Remicade Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 100- Trade Name: Orencia Product Name: Orencia Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ABATACEPT CAS Number: 332348-12-6 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 250- Trade Name: Ro-Actemra Product Name: Ro Actemra Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: tocilizumabum CAS Number: 375823-41-9 Other descriptive name: TOCILIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: up to Concentration number: 20- Trade Name: Mabthera Product Name: Mabthera Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: up to Concentration number: 10-	Revmatologicky ustav Praha		Not Recruiting			Female: yes Male: yes	40	Phase 4	Czech Republic
403	NCT02534311	October 13, 2015	12 March 2018	A Phase IV Study to Evaluate the Effect of Subcutaneous (SC) Tocilizumab Administered to Participants With Rheumatoid Arthritis (RA) Assessed Using Disease Activity Score (DAS28)	Prospective Evaluation of Rheumatoid Arthritis Activity Using DAS28 in Patients Treated With Subcutaneously Administered Tocilizumab on Local Level	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	60	N/A	Slovakia
404	NCT02778789	October 2015	7 October 2019	Comparing the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers	Non Randomized Parallel-group Clinical Study to Compare the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers.	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: TNF-alpha Inhibitor	University of Erlangen-Nürnberg Medical School		Not recruiting	18 Years	N/A	All	66	N/A	Germany
405	NCT02780323	October 2015	16 December 2017	Study to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Patients With Rheumatoid Arthritis	A Multi-center, Double-blind, Active-controlled, Randomized, Parallel-group Clinical Trial to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CELBESTA® placebo;Drug: CELEBREX® placebo;Drug: CELEBREX®;Drug: CELBESTA®	Dong-A ST Co., Ltd.		Recruiting	19 Years	N/A	All	158	Phase 4	Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
406	NCT02882087	October 2015	15 April 2019	A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-a Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis	A Phase II, Placebo-Controlled, Multicenter, Dynamic Randomized, Double Blind Trial of RC18, a Recombinant Human B Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein in Subjects With Inadequate Response of TNF-a Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis	Moderate and Severe Rheumatoid Arthritis	Drug: RC18 160 mg plus MTX;Drug: Placebo plus MTX	RemeGen		Not recruiting	18 Years	65 Years	All	60	Phase 2	China
407	EUCTR2015-003638-28-DK	30/09/2015	30 April 2019	Treatment of osteoporosis in patients with rheumatoid arthritis.	ALOSTRA Alendronate treatment of osteoporosis in rheumatoid arthritis – indication and duration. A randomized, doubleblind, placebocontrolled multi-centre study to evaluate the effects of discontinuation of alendronate in patients with both rheumatoid arthritis and low bone mass. - ALOSTRA	Rheumatoid arthritis and osteoporosis MedDRA version: 20.0 Level: LLT Classification code 10031289 Term: Osteoporosis, unspecified System Organ Class: 100000004859 MedDRA version: 20.0 Level: LLT Classification code 10039076 Term: Rheumatoid arthritis and other inflammatory polyarthropathies System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Alendronat Teva Pharmaceutical Form: Tablet INN or Proposed INN: Alendronic Acid Other descriptive name: ALENDRONIC ACID Concentration unit: g gram(s) Concentration type: equal Concentration number: 0.07- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use	Aarhus University Hospital		Authorised			Female: yes Male: yes	160	Phase 2	Denmark
408	EUCTR2015-002284-42-FI	18/09/2015	28 September 2015	The rationale for this study is to gain insight in the extent and impact of immunogenicity of TNF inhibitors in the European daily clinical practice. Furthermore, an European wide database will give insight in factors influencing immunogenicity and treatment outcome in terms of disease activit	INTENT: immunogenicity in patients failing response on anti-TNF -Immunogenicity and pharmacokinetics in patients failing to respond to TNF inhibitors (phase 1); -Clinical effectiveness of subsequent TNF inhibitor treatment and predictive value of pharmacokinetics and immunogenicity (phase 2) - INTENT	rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis.;Therapeutic area: Not possible to specify	Trade Name: Enbrel Product Name: etanercept Pharmaceutical Form: Injection Trade Name: Humira Product Name: adalimumab Pharmaceutical Form: Injection Trade Name: Cimzia Product Name: certolizumab pegol Pharmaceutical Form: Injection Trade Name: Simponi Product Name: golimumab Pharmaceutical Form: Injection Trade Name: Remicade Product Name: infliximab Pharmaceutical Form: Infusion	READE		Authorised			Female: yes Male: yes	1650	Phase 1	Finland
409	NCT02605642	September 10, 2015	18 March 2019	Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade	PERSIST: PROSPECTIVE OBSERVATIONAL COHORT STUDY TO ASSESS PERSISTENCE OF CT-P13 (INFLIXIMAB) IN PATIENTS WITH RHEUMATOID DISEASES WHO ARE EITHER NAIVE TO BIOLOGICS OR SWITCHED FROM STABLE REMICADE(R) (INFLIXIMAB)	Rheumatoid Diseases;Rheumatoid Arthritis;Ankylosing Spondylitis;Psoriatic Arthritis	Drug: CT-P13	Pfizer	Hospira, now a wholly owned subsidiary of Pfizer	Not recruiting	18 Years	N/A	All	351	Phase 3	Bulgaria;Canada;Czechia;Germany;Greece;Spain;United Kingdom;Czech Republic;France;Italy
410	NCT02535832	September 2015	24 June 2019	Skeletal Muscle Dysfunction in Rheumatoid Arthritis (RA)	Skeletal Muscle Dysfunction in Rheumatoid Arthritis (RA)	Rheumatoid Arthritis;Insulin Resistance	Drug: Pioglitazone;Drug: Placebo	University of Alabama at Birmingham		Recruiting	35 Years	65 Years	All	36	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
411	NCT02553018	September 2015	16 December 2017	Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe	A National, Randomized, Open-label Study Comparing Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated With Methotrexate Administered by Auto-injector Versus Administration by Conventional Subcutaneous Injection.	Arthritis, Rheumatoid	Drug: Methotrexate	Nordic Pharma SAS		Not recruiting	18 Years	N/A	All	278	Phase 3	France
412	NCT02565810	September 2015	16 December 2017	An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis	An Open-labelled, Single-arm, Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Adalimumab PFS and Pen	Samsung Bioepis Co., Ltd.		Not recruiting	18 Years	55 Years	All	49	Phase 2	Poland
413	NCT02717988	September 2015	12 March 2018	Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers	A Phase 1, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers	Rheumatoid Arthritis	Drug: SKI-O-703 capsule;Drug: Placebo capsule	Oscotec Inc.	PPD	Not recruiting	18 Years	55 Years	All	48	Phase 1	United States
414	NCT02748785	September 2015	7 November 2016	MTX Discontinuation and Vaccine Response	Effect of Methotrexate Discontinuation on Efficacy of Seasonal Influenza Vaccination in Patients With Rheumatoid Arthritis: A Randomized Clinical Trial	Arthritis, Rheumatoid	Drug: Methotrexate;Biological: Seasonal Influenza vaccine	Seoul National University Hospital		Not recruiting	18 Years	N/A	Both	277	Phase 4	Korea, Republic of
415	NCT02764515	September 2015	16 December 2017	Kunxian for the Treatment of Rheumatoid Arthritis	Comparison of the Efficacy and Safety of Kunxian Capsule and Methotrexate for the Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Kunxian Capsule;Drug: Methotrexate	Chinese SLE Treatment And Research Group	CHENLIJI Pharmaceutical Company,Guangzhou Pharmaceutical Group;CHINESE RHEUMATISM DATA CENTER	Recruiting	40 Years	70 Years	All	428	Phase 4	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
416	JPRN-UMIN000027241	2015/08/31	2 April 2019	the change of IMT of carotide artery in RA with treatment of tocilizumab		rheumatoid arthritis	tofacitinib	hiroshima clinic		Not Recruiting	18years-old	80years-old	Male and Female	50	Not applicable	Japan
417	NCT02504268	August 31, 2015	22 October 2019	Effects of Abatacept in Patients With Early Rheumatoid Arthritis	A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults With Early Rheumatoid Arthritis Who Are Methotrexate Naive	Rheumatoid Arthritis	Drug: Abatacept;Drug: Methotrexate;Other: Abatacept Placebo;Other: Methotrexate Placebo	Bristol-Myers Squibb		Not recruiting	18 Years	N/A	All	1067	Phase 3	United States;Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Singapore;South Africa;Spain;Sweden;Taiwan;United Kingdom;Czech Republic;Puerto Rico;Saudi Arabia;United Arab Emirates
418	NCT02350426	August 12, 2015	16 December 2017	A Study to Assess Inflammation in Rheumatoid Arthritis Using Molecular Imaging Techniques	An Adaptive Design Open Label Pilot Study in Rheumatoid Arthritis Patients to Assess Inflammation Using Molecular Imaging Techniques	Arthritis, Rheumatoid	Other: Gadobutrol;Other: 18F-FDG;Other: 18F-GE-180	GlaxoSmithKline	Cambridge University Hospitals NHS Foundation Trust	Not recruiting	30 Years	85 Years	All	10	Phase 1	United Kingdom
419	JPRN-JapicCTI-153081	01/8/2015	16 July 2019	Effects of Abatacept in Patients With Early Rheumatoid Arthritis	A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults With Early Rheumatoid Arthritis Who Are Methotrexate Naive	Rheumatoid Arthritis	Intervention name : Abatacept + Methotrexate Dosage And administration of the intervention : Abatacept 125 mg subcutaneous injection once per week + Methotrexate at least 15mg per week tablet or capsule orally once per week Control intervention name : Methotrexate Dosage And administration of the control intervention : Methotrexate at least 15mg per week tablet or capsule orally Control intervention name : Abatacept Placebo Dosage And administration of the control intervention : Placebo for Abatacept subcutaneous injection once per week Control intervention name : Methotrexate Placebo Dosage And administration of the control intervention : Placebo to match Methotrexate capsule orally once per week	Bristol-Myers Squibb K.K.		Not Recruiting	18		BOTH	1000	Phase 3
420	NCT02451748	August 2015	29 April 2019	IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA	IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells, Peripheral Blood Monocytes or Differentiated Macrophages of Rheumatoid Arthritis Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA	Rheumatoid Arthritis	Other: Lab Work;Drug: Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg);Drug: Certolizumab pegol (CDP870, tradename Cimzia)	University of Illinois at Chicago	UCB Pharma	Not recruiting	18 Years	N/A	All	32	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
421	NCT02797769	August 2015	21 July 2016	A Time to Cardiovascular Event Analysis Comparing Tocilizumab to Other Biologics in Patients With Rheumatoid Arthritis (RA)	Risk of Cardiovascular Events in Patients Using Tocilizumab as Compared With Other Biologics in Multiple Large Healthcare Databases	Rheumatoid Arthritis	Drug: Other Biologics;Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	Both	75000	N/A
422	NCT02481180	July 31, 2015	22 July 2019	Tolerance, Pharmacokinetics and Preliminary Efficacy of T0001 in RA (Rheumatoid Arthritis)	An Open, Dose Escalation, Multiple Dose Study to Assess Tolerance?Pharmacokinetics?Preliminary Efficacy of T0001 in RA (Rheumatoid Arthritis)	Rheumatoid Arthritis	Drug: T0001;Drug: Enbrel	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.		Not recruiting	18 Years	65 Years	All	36	Phase 1	China
423	EUCTR2015-000665-30-GB	30/07/2015	27 August 2018	Coherus Open-Label Safety Extension Study	An Open-Label Safety Extension Study (OLSES) Evaluating the Long term Safety and Durability of Response of CHS 0214 (CHS 0214-05) - OLSES	Rheumatoid arthritis Chronic Plaque Psoriasis MedDRA version: 18.0 Level: LLT Classification code 10042952 Term: Systemic rheumatoid arthritis System Organ Class: 100000004859 MedDRA version: 18.0 Level: LLT Classification code 10071117 Term: Plaque psoriasis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Code: CHS-0214 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Etanercept CAS Number: 185243-69-0 Current Sponsor code: CHS-0214 Other descriptive name: BGX-0214 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-	Coherus BioSciences, Inc.		Not Recruiting			Female: yes Male: yes	447	Phase 3	France;Canada;Spain;Australia;Israel;South Africa;Germany;Japan;Italy;United Kingdom
424	NCT02504671	July 23, 2015	15 April 2019	Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis	A Phase IIb, Double-Blind, Placebo-Controlled, Dose-Adaptive, Study of the Efficacy and Safety of GSK3196165 in Combination With Methotrexate Therapy, in Subjects With Active Moderate-Severe Rheumatoid Arthritis Despite Treatment With Methotrexate	Arthritis, Rheumatoid	Drug: GSK3196165;Drug: MTX;Drug: Folic acid;Drug: Placebo	GlaxoSmithKline		Not recruiting	18 Years	N/A	All	222	Phase 2	Bulgaria;Canada;Czechia;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;Czech Republic
425	EUCTR2012-003876-38-DE	21/07/2015	28 November 2016	Clinical study to find out if the biologically similar medicine GP2013 is safe in patients with rheumatoid arthritis who have been treated with Rituxan® or MabThera® in the past	A randomized, double- blind, controlled, parallel-group, multicenter study to assess the safety and immunogenicity of transitioning to GP2013 or re-treatment with Rituxan® or MabThera® in patients with active rheumatoid arthritis, previously treated with Rituxan® or MabThera® - ASSIST-RT	Rheumatoid Arthritis MedDRA version: 19.0 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000004870 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: GP2013 Product Code: GP2013 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Current Sponsor code: GP2013 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- Trade Name: MabThera® Product Name: MabThera® Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500-	Hexal AG (a Sandoz company)		Not Recruiting			Female: yes Male: yes	100	Phase 3	United States;Hungary;Poland;Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
426	NCT02242474	July 2015	20 August 2018	Anti-TNFa Use During Elective Foot and Ankle Surgery in Patients With Rheumatoid Arthritis	Prospective Randomized Multicentric Trial on Anti-TNFa Treatment and Infection Risk in the Perioperative Period During Elective Foot and Ankle Surgery in Patients With Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: Anti-TNF suspended perioperatively;Drug: Anti-TNFa continued perioperatively	CHU de Quebec-Universite Laval		Recruiting	18 Years	N/A	All	660	Phase 4	Canada
427	NCT02467504	July 2015	23 November 2015	Low-dose Recombinant Human IL-2 for the Treatment of Rheumatoid Arthritis	A Randomized, Double Blind, Placebo-controlled Pilot-study to Evaluate Efficacy and Safety of Low-dose hrIL-2 in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-Naive Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: hrIL-2 active;Drug: hrIL-2 placebo;Drug: MTX;Drug: Folic Acid;Drug: Loxoprofen	Peking University People's Hospital	Monash University;Beijing ShuangLu Pharmaceutical Co., Ltd.	Recruiting	18 Years	70 Years	Both	60	Phase 2	China
428	NCT02480946	July 2015	16 December 2017	Safety and Tolerability Study of MBS2320 in Healthy Subjects and Subjects With Rheumatoid Arthritis	A Four-Part Phase-1 Study Investigating the Tolerability, Safety and Pharmacokinetics (PK) of MBS2320 in Healthy Subjects and in Subjects With Rheumatoid Arthritis (RA) Also Treated With Methotrexate	Arthritis, Rheumatoid	Drug: MBS2320;Drug: Placebo;Drug: Methotrexate	Modern Biosciences plc	Covance	Not recruiting	18 Years	70 Years	All	105	Phase 1	United Kingdom
429	NCT02486939	July 2015	16 December 2017	A Long Term Safety Extension Study (CHS-0214-05)	An Open-Label Safety Extension Study (OLSES) Evaluating the Long Term Safety and Durability of Response of CHS-0214 (CHS-0214-05)	Rheumatoid Arthritis;Plaque Psoriasis	Drug: CHS-0214	Coherus Biosciences, Inc.	Daiichi Sankyo Co., Ltd.;Shire	Not recruiting	18 Years	N/A	All	359	Phase 3	Japan
430	NCT02514772	July 2015	16 December 2017	GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®	A Randomized, Double- Blind, Controlled, Parallel-group, Multicenter Study to Assess the Safety and Immunogenicity of Transitioning to GP2013 or Re-treatment With Rituxan® or MabThera® in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®	Rheumatoid Arthritis	Biological: GP2013 - A Proposed biosimilar rituximab;Biological: Originator rituximab - Rituxan ® or MabThera ®	Sandoz	Hexal AG	Not recruiting	18 Years	N/A	All	107	Phase 3	United States;Germany;Hungary;Poland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
431	NCT02518620	July 2015	26 August 2019	An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid Arthritis	A Phase II Multicenter, Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects With Moderate to Severe Rheumatoid Arthritis Who Have Completed One of the Preceding Phase IIb Studies With ALX-0061	Rheumatoid Arthritis	Biological: ALX-0061	Ablynx		Not recruiting	18 Years	74 Years	All	406	Phase 2	Belgium;Bulgaria;Georgia;Germany;Hungary;Mexico;Moldova, Republic of;North Macedonia;Poland;Romania;Serbia;Spain;Macedonia, The Former Yugoslav Republic of
432	NCT02531178	July 2015	11 April 2016	A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABBV-257 in Subjects With Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ABBV-257	Rheumatoid Arthritis	Biological: ABBV-257;Biological: Placebo	AbbVie		Not recruiting	18 Years	75 Years	Both	8	Phase 1	Germany
433	NCT02598466	July 2015	15 February 2016	Patient-Reported Efficacy of Subcutaneous (SC) Abatacept in Rheumatoid Arthritis (RA) - South Africa	Patient-Reported Efficacy of Subcutaneous Abatacept in Rheumatoid Arthritis: An Evaluation Of Patients In a Compassionate Use Programme in South Africa	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb	Hexor, South Africa	Not recruiting	18 Years	N/A	Both	69	N/A
434	NCT02480153	June 25, 2015	4 February 2019	A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).	A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY ASSESSING THE EFFICACY AND SAFETY OF PF-06410293 AND ADALIMUMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO METHOTREXATE	Rheumatoid Arthritis	Biological: PF-06410293;Biological: Adalimumab	Pfizer		Not recruiting	18 Years	N/A	All	597	Phase 3	United States;Australia;Brazil;Bulgaria;Colombia;Czechia;Estonia;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;Canada;Czech Republic
435	EUCTR2014-003453-34-EE	18/06/2015	29 January 2018	Study of a new drug’s effect in people with rheumatoid arthritis who have not responded sufficiently well to treatment with Methotrexate.	A Phase IIb, Double-Blind, Placebo-Controlled, Dose-Adaptive, Study of the Efficacy and Safety of GSK3196165 in Combination with Methotrexate Therapy, in Subjects with Active Moderate-Severe Rheumatoid Arthritis Despite Treatment with Methotrexate.	Rheumatoid Arthritis MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Code: GSK3196165 Pharmaceutical Form: Solution for injection INN or Proposed INN: INN not available CAS Number: 1638332-55-4 Current Sponsor code: GSK3196165 Other descriptive name: Anti human granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	GlaxoSmithKline Research & Development Limited		Not Recruiting			Female: yes Male: yes	210	Phase 2	Estonia;Spain;Ukraine;Russian Federation;United Kingdom;Italy;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;South Africa;Bulgaria;Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
436	NCT02405780	June 10, 2015	5 March 2018	A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients	An Open-label Extension Study to Compare the Long-term Efficacy, Safety, Immunogenicity and Pharmacokinetics of FKB327 and Humira® in Patients With Rheumatoid Arthritis on Concomitant Methotrexate	Arthritis, Rheumatoid	Drug: FKB327;Drug: Humira®	Fujifilm Kyowa Kirin Biologics Co., Ltd.		Not recruiting	18 Years	N/A	All	645	Phase 3	United States;Canada;Chile;Czechia;Germany;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;Bulgaria;Czech Republic
437	EUCTR2015-000538-31-DE	01/06/2015	4 August 2015	Application into the joint of opioids in chronic arthritis of the knee joint	NEUORIMPA - Intraarticular Application of Opioids in Chronic Arthritis of the knee joint - Neuroimpa - knee joint	chronic arthritis of the knee joint effusion as part of spondyloarthritis (Assessments in SpondyloArthritis international Society, ASAS criteria), Rheumatoid Arthritis, RA (according to American Col-lege of Rheumatology, ACR criteria), undifferentiated mono- or oligoarthritis, Osteoarthritis of the knee, OA. MedDRA version: 18.0 Level: LLT Classification code 10067624 Term: Knee arthritis System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Morphine Hexal Pharmaceutical Form: Solution for injection INN or Proposed INN: Morphinsulfat Other descriptive name: MORPHINE SULFATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: Triam 40 mg Lichtenstein Pharmaceutical Form: Suspension for injection INN or Proposed INN: TRIAMCINOLONACETONID Other descriptive name: TRIAMCINOLONACETONID EP Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 40-	Charité University medicine Berlin		Authorised			Female: yes Male: yes			Germany
438	NCT02402686	May 20, 2015	11 November 2019	Non-Interventional Study of Tocilizumab Subcutaneous (SC) Monotherapy in Participants With Rheumatoid Arthritis (RA)	Open-Label, Multi-Center, Non-Interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab SC Monotherapy in Daily Clinical Practice (SIMPACT)	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	353	N/A	Hungary
439	EUCTR2014-004904-31-NL	19/05/2015	5 September 2016	A clinical study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission.	An open-label, multicentre, phase IV study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission.	Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA).;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Remsima (infliximab) Pharmaceutical Form: Powder for concentrate for solution for injection/infusion	Mundipharma Pharmaceuticals B.V.		Authorised			Female: yes Male: yes		Phase 4	Netherlands
440	JPRN-UMIN000017440	2015/05/18	7 October 2019	In methotrexate resistant rheumatoid arthritis, switching methotrexate to tofacitinib versus adding tofacitinib to methotrexate, open labeled, multicenter randomized non-inferiority study.	In methotrexate resistant rheumatoid arthritis, switching methotrexate to tofacitinib versus adding tofacitinib to methotrexate, open labeled, multicenter randomized non-inferiority study. - RAXEL study	Rheumatoid arthritis	for 3 months Tofacitinib 5mg BID everyday for 3 months Tofacitinib 5mg BID everyday for 3 months Methotrexate6mg-16mg/week	Graduate School of Medicine and School of Medicine, Chiba University the department of allergy and clinical immunology		Not Recruiting	18years-old	90years-old	Male and Female	134	Phase 4	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
441	EUCTR2014-000110-61-CZ	11/05/2015	19 February 2018	Study to assess the long-term efficacy and safety of FKB327 compared with Humira®, when each is administered in combination with Methotrexate in patients with Rheumatoid Arthritis.	An Open-label Extension Study to Compare the Long-term Efficacy, Safety, Immunogenicity and Pharmacokinetics of FKB327 and Humira® in Patients with Rheumatoid Arthritis on Concomitant Methotrexate - ARABESC-OLE	Rheumatoid Arthritis MedDRA version: 18.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Code: FKB327 PFS Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Current Sponsor code: FKB327 Concentration unit: mg/l milligram(s)/litre Concentration type: equal Concentration number: 50- Trade Name: Humira Product Name: Humira Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Product Code: FKB327 AI Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Current Sponsor code: FKB327 Concentration unit: mg/l milligram(s)/litre Concentration type: equal Concentration number: 50-	Fujifilm Kyowa Kirin Biologics Co., Ltd.		Not Recruiting			Female: yes Male: yes	680	Phase 3	Bulgaria;Germany;United States;Serbia;Spain;Ukraine;Chile;Russian Federation;Czech Republic;Canada;Poland;Romania;Peru
442	EUCTR2014-003034-42-HU	08/05/2015	10 September 2018	An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects with Rheumatoid Arthritis	A Phase II Multicenter, Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects with Moderate to Severe Rheumatoid Arthritis who Have Completed One of the Preceding Phase IIb Studies with ALX-0061	Rheumatoid Arthritis (RA) MedDRA version: 18.1 Level: SOC Classification code 10021428 Term: Immune system disorders System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: ALX-0061 Product Code: ALX-0061 Pharmaceutical Form: Solution for injection INN or Proposed INN: Not available CAS Number: 1628814-88-9 Other descriptive name: ALX-0061 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150-	Ablynx NV		Not Recruiting			Female: yes Male: yes	501	Phase 2	Serbia;Spain;Hungary;Czech Republic;Mexico;Macedonia, the former Yugoslav Republic of;Argentina;Belgium;Poland;Romania;Bulgaria;Georgia;Germany;Moldova, Republic of
443	EUCTR2014-005418-45-SE	04/05/2015	22 May 2017	Are risk factors factors of pertaining to or involving the heart and blood vessels and markers characterized or caused by inflammation in Rheumatoid Arthritis (a chronic, systemic inflammatory disorder that primarily affects joints) and Systemic Lupus Erythematosus (systemic disease in which the body’s immune system mistakenly attacks healthy tissue)improved? New aspects of Hydroxychloroquine – an interventional study (HCQCVDRASLE)	Improved cardiovascular risk factors and inflammatory markers in Rheumatoid Arthritis and Systemic Lupus Erythematosus? New aspects of Hydroxychloroquine – an interventional study (HCQCVDRASLE) - HCQCVDRASLE	Rheumatoid Arthritis and Systemic Lupus Erythematosus;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Plaquenil Pharmaceutical Form: Film-coated tablet INN or Proposed INN: HYDROXYCHLOROQUINE CAS Number: 118-42-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200-	Christine Bengtsson	Solveig Wållberg-Jonsson	Not Recruiting			Female: yes Male: yes		Phase 2	Sweden
444	NCT02404558	May 2015	11 April 2016	Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis	An Open-label, Randomized, Parallel Group, Single-dose Study to Describe the Safety of IL-6 Receptor Blockade With Sarilumab or Tocilizumab Monotherapy in Japanese Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: sarilumab SAR153191 (REGN88);Drug: tocilizumab	Sanofi	Regeneron Pharmaceuticals	Not recruiting	20 Years	N/A	Both	30	Phase 1	Japan
445	NCT02456844	May 2015	8 February 2016	Study to Investigate the Effect of BMS-986142 on the Pharmacokinetics (PK) of Methotrexate and Probe Substrate Cocktail in Healthy Patients	Effects of BMS-986142 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates Montelukast (CYP2C8), Flurbiprofen (CYP2C9), Midazolam (CYP3A4), Digoxin (P-gp), and Pravastatin (OATP1B1) in Healthy Subjects	Rheumatoid Arthritis	Drug: Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142;Drug: Methotrexate, Leucovorin and BMS-986142	Bristol-Myers Squibb		Not recruiting	18 Years	50 Years	Both	24	Phase 1
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
446	NCT02460393	May 2015	8 January 2018	A Trial With Humanized TNFa Monoclonal Antibody Injection by Single Dose and Dose Escalation in Healthy Subjects	A Randomized, Double Blind, Placebo Controlled Trial With Humanized TNFa Monoclonal Antibody Injection by Single Dose and Dose Escalation to Explore the Tolerance, Safety and Pharmacokinetic Characteristics in Healthy Subjects	Rheumatoid Arthritis	Drug: Humanized TNFa monoclonal antibody;Other: placebo	Shenyang Sunshine Pharmaceutical Co., LTD.		Not recruiting	18 Years	45 Years	All	72	Phase 1	China
447	NCT02566967	May 2015	15 July 2019	An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective	An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve LDA or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective When Treating to Target	Rheumatoid Arthritis	Drug: tofacitinib	Norman B. Gaylis, MD		Not recruiting	18 Years	N/A	All	20	Phase 3	United States
448	EUCTR2014-003307-30-HU	16/04/2015	22 May 2017	Multiple dose study of UCB4940 as add-on to Certolizumab Pegol in subjects with rheumatoid arthritis	A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Multiple Doses of UCB4940 Administered as Add-On to Certolizumab Pegol Therapy in Subjects with Moderate-to-Severe Rheumatoid Arthritis	Rheumatoid arthritis MedDRA version: 18.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: BIMEKIZUMAB Product Code: UCB4940 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Bimekizumab CAS Number: 1418205-77-2 Current Sponsor code: UCB4940 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 80- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Trade Name: Cimzia Product Name: Cimzia Pharmaceutical Form: Solution for injection INN or Proposed INN: CERTOLIZUMAB PEGOL CAS Number: 428863-50-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 200-	UCB Celltech, UK Registered Branch of UCB Pharma SA		Not Recruiting			Female: yes Male: yes	180	Phase 2	Czech Republic;Hungary;Slovakia;Russian Federation;Georgia;United Kingdom;Moldova, Republic of
449	NCT02387762	April 2015	8 April 2019	ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate	A Phase 2a, 4-Week, Double-Blind, Proof-of-Concept Efficacy and Safety Study of ACP-196 Versus Placebo in Subjects With Active Rheumatoid Arthritis on Background Methotrexate	Rheumatoid Arthritis	Drug: acalabrutinib;Drug: Placebo	Acerta Pharma BV		Not recruiting	18 Years	75 Years	All	31	Phase 2	United States
450	NCT02423538	April 2015	1 February 2016	First-in-Human Single Ascending Dose of SHR0302	A Phase I, Randomized, Placebo-Controlled, Single Dose Escalation Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics of SHR0302 in Healthy Volunteers	Rheumatoid Arthritis	Drug: SHR0302;Drug: SHR0302 placebo comparator	Jiangsu HengRui Medicine Co., Ltd.		Not recruiting	18 Years	45 Years	Both	64	Phase 1	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
451	NCT02499315	April 2015	17 May 2016	Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid Arthritis	A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 357 in Female Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: AMG 357;Drug: Placebo	Amgen		Not recruiting	25 Years	70 Years	Female	32	Phase 1	United States
452	NCT02800811	April 2015	8 August 2016	Safety, Tolerability, PK, PD, and Immunogenicity of Single and Multiple Ascending Intravenous Doses of FR104	Randomized, Double-blind, Placebo-controlled, Dose-escalation Study for the Assessment of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Intravenous Doses of FR104 in Healthy Subjects	Rheumatoid Arthritis;Complication of Transplant	Drug: FR104;Drug: Placebo	OSE Immunotherapeutics		Not recruiting	18 Years	60 Years	Both	64	Phase 1	Belgium
453	ChiCTR-IPR-15006107	2015-03-30	18 April 2017	The clinical trial of tolerance of Ginsenoside compound K	To study the pharmacokinetics and tolerance of Ginsenoside compound K tablet in healthy volunteers after multiple dosing administration	rheumatoid arthritis	three groups:Ginsenoside compound K is administrated after single dose or multiple doses;	Institute of Clinical Pharmacology, Central South University		Not Recruiting	18	45	Male	three groups:12;	Phase 1 study	China
454	JPRN-UMIN000016950	2015/03/27	2 April 2019	Clinical outcome in patients with rheumatoid arthritis switched to tumor nesrosis factor blockers after tocilizumab or abatacept		rheumatoid arthritis	Infliximab or adalimumab or golimumab	Osaka Medical College		Not Recruiting	20years-old	Not applicable	Male and Female	50	Not selected	Japan
455	EUCTR2015-000089-72-IT	26/03/2015	19 February 2018	abatacept in obese and overweight RA patiens	FAT GENE EXPRESSION IN OVERWEIGHT AND OBESE PATIENTS WITH PERSISTENTLY ACTIVE RHEUMATOID ARTHRITIS TREATED WITH ABATACEPT AND CLINICAL RESPONSE	MedDRA version: 17.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: ORENCIA Product Name: Orencia abatacept Pharmaceutical Form: Solution for injection	Policlinico Gemelli-CIC- UCSC		Not Recruiting			Female: yes Male: yes	40	Phase 4	Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
456	NCT02486302	March 24, 2015	5 February 2018	A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.	A Prospective, Multicenter Non-interventional Study To Evaluate The Efficacy Of Enbrel (Registered) (Etanercept) Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis With Particular Focus On The Clinical Status Improvements Still Observable After 12 Weeks Of Treatment	Rheumatoid Arthritis;Psoriatic Arthritis;Axial Spondyloarthritis;Plaque Psoriasis	Drug: Etanercept	Pfizer		Not recruiting	18 Years	N/A	All	1535	N/A	Germany
457	EUCTR2014-001471-31-HU	23/03/2015	13 June 2016	This is a Phase 2, multicenter, 24-week, open-label extension (OLE) study to assess the safety and tolerability of ABT-122 in rheumatoid arthritis (RA) subjects who have completed Study M12-963.	Phase 2, Multicenter, Open-Label Extension (OLE) Study with ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Phase 2 Randomized Controlled Trial (RCT)	Rheumatoid Arthritis MedDRA version: 18.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: ABT-122 Product Code: ABT-122 Pharmaceutical Form: Lyophilisate for solution for injection INN or Proposed INN: na Other descriptive name: ABT-122 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Product Name: ABT-122 Product Code: ABT-122 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: na Other descriptive name: ABT-122 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100-	AbbVie Deutschland GmbH & Co. KG		Not Recruiting			Female: yes Male: yes	160	Phase 2	Czech Republic;Hungary;Canada;Poland;Romania;Bulgaria;Germany;New Zealand
458	EUCTR2014-003033-26-BE	23/03/2015	12 September 2016	A clinical trial testing different doses of investigational drug ALX-0061 combined with Methotrexate to treat patients with Moderate to Severe Rheumatoid Arthritis	A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination with Methotrexate, in Subjects with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy	Rheumatoid Arthritis (RA) MedDRA version: 18.0 Level: SOC Classification code 10021428 Term: Immune system disorders System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: ALX-0061 Product Code: ALX-0061 Pharmaceutical Form: Solution for injection INN or Proposed INN: Not available Other descriptive name: ALX-0061 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Ablynx NV		Not Recruiting			Female: yes Male: yes	330	Phase 2	Serbia;United States;Spain;Czech Republic;Hungary;Mexico;Macedonia, the former Yugoslav Republic of;Argentina;Belgium;Poland;Romania;Bulgaria;Georgia;Germany;Moldova, Republic of
459	EUCTR2014-004419-35-GB	18/03/2015	17 August 2015	Inhibition of Co-Stimulation in Rheumatoid Arthritis	Inhibition of Co-Stimulation in Rheumatoid Arthritis - Inhibition of Co-Stimulation in Rheumatoid Arthritis (ICoSRA)	Rheumatoid Arthritis: patients who are dual ACPA and HLA-DR4 positive MedDRA version: 17.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Abatacept Product Name: Abatacept Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Abatacept CAS Number: 332348-12-6 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 125-	Greater Glasgow Health Board	University of Glasgow	Authorised			Female: yes Male: yes	25		United Kingdom
460	EUCTR2013-005524-42-NL	10/03/2015	28 November 2016	STAtins to Prevent Rheumatoid Arthritis (STAPRA)	Prevention of rheumatoid arthritis by atorvastatin in seropositive arthralgia patients: a multi-center doubleblind randomized placebo-controlled trial - STAtins to Prevent Rheumatoid Arthritis (STAPRA)	Rheumatoid arthritis MedDRA version: 19.0 Level: PT Classification code 10039080 Term: Rheumatoid factor positive System Organ Class: 10022891 - Investigations ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Atorvastatin Product Name: Atorvastatin Product Code: C10AA05 Pharmaceutical Form: Tablet INN or Proposed INN: ATORVASTATIN CAS Number: 134523-00-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Reade		Authorised			Female: yes Male: yes		Phase 4	Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
461	NCT02304354	March 9, 2015	7 October 2019	Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)	Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)	Rheumatoid Arthritis	Drug: Rituximab	University Hospital, Tours		Not recruiting	18 Years	N/A	All	70	Phase 3	France
462	JPRN-UMIN000015433	2015/03/01	2 April 2019	Safety study of methotrexate low-dose once daily administration in rheumatoid arthritis patients		rheumatoid arthritis	methotrexate	Department of Medical Pharmaceutics , Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama		Recruiting	20years-old	Not applicable	Male and Female	35	Not selected	Japan
463	NCT02287922	March 2015	26 August 2019	A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis	A Phase IIb Multicenter, Randomized, Double-blind Study of ALX-0061 Administered Subcutaneously as Monotherapy, in Subjects With Moderate to Severe Rheumatoid Arthritis Who Are Intolerant to Methotrexate or for Whom Continued Methotrexate Treatment is Inappropriate	Rheumatoid Arthritis	Biological: ALX-0061;Biological: Placebo;Biological: Tocilizumab	Ablynx		Not recruiting	18 Years	74 Years	All	251	Phase 2	United States;Belgium;Bulgaria;Czechia;Georgia;Germany;Hungary;Mexico;Moldova, Republic of;North Macedonia;Poland;Romania;Serbia;Spain;Czech Republic;Macedonia, The Former Yugoslav Republic of
464	NCT02353780	March 2015	11 June 2019	Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept	Mechanistic Studies of B- and T-Cell Function in Rheumatoid Arthritis Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept	Rheumatoid Arthritis (RA)	Drug: TNF Antagonist (enbrel, humire, remicade, cimzia, symponi);Drug: Abatacept;Drug: Tocilizumab	Dr. Larry W. Moreland	Genentech, Inc.;Bristol-Myers Squibb	Not recruiting	18 Years	64 Years	All	10	Phase 4	United States
465	NCT02414984	March 2015	16 December 2017	Registry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to Golimumab	Registry of Patients With Rheumatoid Arthritis Exposed to Golimumab (Go-Compl-Ar): Review and Analysis of Compliance in Colombia	Rheumatoid Arthritis	Biological: Golimumab	Janssen-Cilag, S.A.		Not recruiting	18 Years	N/A	All	37	N/A	Colombia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
466	NCT02620189	March 2015	14 December 2015	Th17 Responses Evaluated in RA Patients on Inhibitors of TNFa	A Study to Investigate the Role of IL-17 and Th17 Pathway Activation in RA Patients With Inadequate Response to Anti-TNFa Therapies	Rheumatoid Arthritis	Drug: Anti-TNF Biologics Therapy	Queen Mary University of London		Recruiting	18 Years	N/A	Both	50	N/A	United Kingdom
467	NCT02638259	February 21, 2015	1 October 2018	Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis	A Randomized, Double-blind, Parallel-group Phase III Study to Demonstrate Equivalent Efficacy and to Compare Safety & Immunogenicity of GP2015 and Enbrel® (EU Authorized) in Patients With Moderate to Severe, Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: GP2015	Sandoz		Not recruiting	18 Years	N/A	All	376	Phase 3	United States;Bulgaria;Czechia;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;Czech Republic
468	NCT02373813	February 20, 2015	4 November 2019	Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission	A Randomized Withdrawal Double-blind Study of Etanercept Monotherapy Compared to Methotrexate Monotherapy for Maintenance of Remission in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: etanercept pre-filled syringe sq injection;Drug: Oral methotrexate;Drug: Placebo for etanercept sq injection;Drug: Placebo for methotrexate	Amgen		Not recruiting	18 Years	N/A	All	371	Phase 3	United States;Argentina;Bulgaria;Canada;Czechia;France;Germany;Greece;Hungary;Italy;Mexico;Poland;Portugal;South Africa;Spain;Czech Republic
469	EUCTR2014-002945-23-GB	18/02/2015	11 April 2016	A 24 week Phase 2 study in subjects with moderate to severe early Rheumatoid Arthritis who’s symptoms are not fully controlled by treatment with methotrexate alone. Subjects will be told if they are in the group receiving either 150 mg namilumab injected under the skin or adalimumab. Responses to the medicine will be measured using MRI.	A 24-week Randomized, Open-Label, Parallel-Group, Active-Controlled, Exploratory, Proof-of-Mechanism Imaging Study Investigating the Efficacy of 150 mg of Namilumab Administered Subcutaneously vs Adalimumab in Patients With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate - A Phase 2 Study of Namilumab vs Anti-Tumor Necrosis Factor in Patients With Rhematoid Arthritis.	Rheumatoid Arthritis (RA) MedDRA version: 18.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Namilumab Product Code: MT203 Pharmaceutical Form: Solution for injection INN or Proposed INN: namilumab CAS Number: 1206681-39-1 Current Sponsor code: MT203 Other descriptive name: NAMILUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150- Trade Name: Humira 40 mg solution for injection in pre-filled syringe Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-	Takeda Development Centre Europe Ltd.		Not Recruiting			Female: yes Male: yes	36	Phase 2	Estonia;Czech Republic;Spain;Russian Federation;United Kingdom
470	EUCTR2013-005418-37-DE	05/02/2015	29 January 2018	A multicenter, placebo-controlled phase II study to evaluate safety and clinical efficacy of two different doses of F8IL10 administered subcutaneously to patients with active rheumatoid arthritis receiving Methotrexate.	A multicenter, randomized, double-blind, placebo-controlled phase II study to evaluate safety and clinical efficacy of two different doses of F8IL10 (Dekavil) administered subcutaneously to patients with active rheumatoid arthritis receiving Methotrexate.	Patients with active Rheumatoid Arthritis despite methotrexate therapy that had unsuccessful response to at least one anti-TNF treatment. MedDRA version: 17.1 Level: LLT Classification code 10003268 Term: Arthritis rheumatoid System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Dekavil Product Code: F8IL10 Pharmaceutical Form: Solution for injection INN or Proposed INN: dekavil Current Sponsor code: F8IL10 Other descriptive name: F8IL10 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 3.75-20 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Philogen S.p.A.		Authorised			Female: yes Male: yes	87	Phase 2	Germany;Italy;Switzerland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
471	EUCTR2013-004569-16-HU	03/02/2015	8 August 2016	A Single-Arm, Open-Label Study to Assess the Immunogenicity, Safety, and Efficacy of Etanercept Manufactured Using the High Capacity Process Administered to Subjects with Rheumatoid Arthritis	A Single-Arm, Open-Label Study to Assess the Immunogenicity, Safety, and Efficacy of Etanercept Manufactured Using the High Capacity Process Administered to Subjects with Rheumatoid Arthritis	Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Etanercept Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ETANERCEPT CAS Number: 185243-69-0 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Pfizer Inc., 235 East 42nd Street, New York, NY 10017		Not Recruiting			Female: yes Male: yes	180	Phase 3	Serbia;Slovakia;Greece;Russian Federation;Colombia;Italy;Hungary;Mexico;Poland;Croatia;South Africa;Bulgaria;Germany
472	JPRN-JapicCTI-152979	01/2/2015	2 April 2019	Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)	A 24-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study to Evaluate the Efficacy and Safety of 3 Doses of Namilumab (20 mg, 80 mg and 150 mg) in Combination With Methotrexate (MTX) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Intervention name : Namilumab Dosage And administration of the intervention : Namilumab 20 mg, 80 mg or 150 mg subcutaneous (SC) injection, once on Days 1, 15, 43, 71 and every 4 weeks up to Week 24 and a stable dose of methotrexate (15-25 mg weekly, 6-16 mg weekly in Japan), and folic acid (at least 5 mg/week), orally, throughout the duration of the study. Control intervention name : Placebo Dosage And administration of the control intervention : Namilumab placebo-matching SC injection, once on Days 1, 15, 43, 71 and every 4 weeks up to Week 24 and a stable dose of methotrexate (15-25 mg weekly, 6-16 mg weekly in Japan), and folic acid (at least 5 mg/week), orally, throughout the duration of the study.	TAKEDA PHARMACEUTICAL COMPANY LTD.			20		BOTH	108	Phase 2
473	NCT02332590	February 2015	28 October 2019	Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)	A Randomized, Double-blind, Parallel-group Study Assessing the Efficacy and Safety of Sarilumab Monotherapy Versus Adalimumab Monotherapy in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Sarilumab;Drug: Adalimumab;Drug: Placebo (for sarilumab);Drug: Placebo (for adalimumab)	Sanofi	Regeneron Pharmaceuticals	Not recruiting	18 Years	N/A	All	369	Phase 3	United States;Chile;Czechia;Germany;Hungary;Israel;Korea, Republic of;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;Czech Republic;France
474	NCT02357069	February 2015	18 January 2016	A Study Comparing LBEC0101 to Enbrel® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy	Multi-center (in Korea and Japan), Double-blind, Randomized, Parallel-group Study to Evaluate Similarity of Efficacy and Safety of LBEC0101 50mg Subcutaneous Weekly Injection to Enbrel® 50mg Subcutaneous Weekly Injection, as Adjunctive Therapy to Methotrexate (MTX), in Patients With Active Rheumatoid Arthritis Who Had an Inadequate Response to MTX	Arthritis, Rheumatoid	Drug: Enbrel;Drug: LBEC0101	LG Life Sciences	Mochida Pharmaceutical Company, Ltd.	Not recruiting	20 Years	75 Years	Both	372	Phase 3	Japan;Korea, Republic of
475	NCT02373202	February 2015	9 January 2017	A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)	A Randomized, Double-blind, Multicenter Study Evaluating the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: sarilumab SAR153191 (REGN88);Drug: non-MTX DMARDs (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin);Drug: sulfasalazine;Drug: leflunomide;Drug: bucillamine;Drug: tacrolimus;Drug: mizoribin	Sanofi	Regeneron Pharmaceuticals	Not recruiting	20 Years	N/A	Both	91	Phase 3	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
476	NCT02390700	February 2015	28 November 2016	Observational Study of Golimumab Intravenous Infusion	Golimumab Intravenous Infusion Registry (GO-IV)	Rheumatoid Arthritis	Biological: Golimumab Intravenous	Janssen Inc.		Not recruiting	18 Years	N/A	Both	78	Phase 4	Canada
477	NCT02466581	February 2015	18 December 2018	Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity	A Multicenter, Randomized, Open-label, Blinded-assessor, Follow-up, Phase 4 Study in Patients With Rheumatoid Arthritis Who Have Completed the Initial Treatment Part in the NORD-STAR Study and Have Reached Stable Low Disease Activity	Rheumatoid Arthritis	Drug: Sulphasalazine + Hydroxychloroquine OR Prednisolone;Biological: Cimzia;Biological: Orencia;Biological: RoActemra	Karolinska Institutet		Recruiting	18 Years	N/A	All	500	Phase 4	Sweden
478	NCT02633332	February 2015	28 December 2015	Use of Well Known Drugs for New Destination - RA Improvement (RANT)	Observational Retrospective Study About the Use of Well Known Drugs in Combination to Obtain a New Drug to Improve Quality of Life/Health in Patient With Diagnosed Rheumatoid Arthritis Not Responding to Commonly Used Treatments	Rheumatoid Arthritis;Autoimmune Diseases;Disorder of Synovium;Sjogren's Syndrome;Acute and Chronic Inflammation;Disorder of Pleura and Pleural Cavity;Felty's Syndrome;Rheumatoid Nodules	Drug: Vitamin D3;Drug: Lipitor®;Drug: Acycloguanosine;Drug: Tetracycline;Drug: methotrexate;Drug: etanercept	Università Popolare Homo & Natura		Not recruiting	18 Years	75 Years	Both	15	Phase 1	Italy
479	EUCTR2014-002541-22-CZ	26/01/2015	9 January 2017	Efficacy and safety of Sarilumab and Adalimumab monotherapy in patients with Rheumatoid Arthritis	A randomized, double-blind, parallel-group study assessing the efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis - SARIL-RA-MONARCH	Rheumatoid Arthritis MedDRA version: 18.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Sarilumab Product Code: SAR153191 (REGN88) Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Sarilumab Current Sponsor code: SAR153191 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use Trade Name: Humira, 40 mg solution for injection in pre-filled syringe Product Name: adalimumab Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use Product Name: Sarilumab Product Code: SAR153191 (REGN88) Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Sarilumab Current Sponsor code: SAR153191 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-	sanofi-aventis recherche & développement		Not Recruiting			Female: yes Male: yes	540	Phase 3	United States;Spain;Ukraine;Russian Federation;Chile;Israel;United Kingdom;Czech Republic;Hungary;Puerto Rico;Poland;Romania;Peru;South Africa;Germany;Korea, Republic of
480	EUCTR2014-000109-11-DE	22/01/2015	16 August 2016	Study to assess the efficacy and safety of FKB327 compared with Humira®, when each is administered in combination with Methotrexate in patients with Rheumatoid Arthritis.	A Randomised, Blinded, Active-Controlled Study to Compare FKB327 Efficacy and Safety with the Comparator Humira® in Rheumatoid Arthritis Patients Inadequately Controlled on Methotrexate. - ARABESC	Rheumatoid Arthritis MedDRA version: 18.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Code: FKB327 Pharmaceutical Form: Solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Current Sponsor code: FKB327 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Humira Product Name: Humira Pharmaceutical Form: Solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Fujifilm Kyowa Kirin Biologics Co., Ltd.		Not Recruiting			Female: yes Male: yes	730	Phase 3	United States;Serbia;Spain;Ukraine;Chile;Russian Federation;Czech Republic;Canada;Poland;Romania;Peru;Bulgaria;Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
481	EUCTR2014-003255-54-CZ	21/01/2015	11 June 2018	A study evaluating the effects of RGB-03 and MabThera combined with Methotrexate in patients with Rheumatoid Arthritis	A Double-blind, Randomised, Comparative Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Evaluation of RGB-03 and MabThera® Combined with Methotrexate in Rheumatoid Arthritis Patients	Rheumatoid arthritis MedDRA version: 18.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: RGB-03 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Current Sponsor code: RGB-03 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: MabThera Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Gedeon Richter Plc		Not Recruiting			Female: yes Male: yes	142	Phase 1;Phase 3	Hungary;Estonia;Czech Republic;Poland;Belgium;Spain;Ukraine;Romania;Austria;Russian Federation;Israel;Germany
482	NCT03719469	January 20, 2015	5 November 2018	Circulating microRNAs as Novel Prognosis Biomarkers for Rheumatoid Arthritis	Circulating microRNAs Expression as Predictors of Clinical Response in Rheumatoid Arthritis Patients Treated With Green Tea	Rh Disease	Dietary Supplement: Green tea group	King Saud University		Not recruiting	18 Years	85 Years	All	150	N/A
483	ChiCTR-IPR-15005787	2015-01-15	18 April 2017	The effect of food on the pharmacokinetics of Ginsenoside C-K	To study the effect of food on pharmacokinetics of Ginsenoside C-K tablet in healthy volunteers	rheumatoid arthritis	Two groups:Ginsenoside compound K is administrated after taking food versus fasting;	Institute of Clinical Pharmacology, Central South University		Not Recruiting	18	45	Both	Two groups:24;	Phase 1 study	China
484	NCT02309359	January 2015	26 August 2019	A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis	A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy	Rheumatoid Arthritis	Biological: ALX-0061;Other: Placebo;Drug: Methotrexate	Ablynx		Not recruiting	18 Years	74 Years	All	345	Phase 2	United States;Belgium;Bulgaria;Czechia;Georgia;Germany;Hungary;Mexico;Moldova, Republic of;North Macedonia;Poland;Romania;Serbia;Spain;Czech Republic;Macedonia, The Former Yugoslav Republic of
485	NCT02371096	January 2015	2 March 2015	Comparative Pharmacokinetic Trial of RGB-03 and MabThera		Rheumatoid Arthritis	Drug: MabThera (rituximab);Drug: RGB-03	Gedeon Richter Plc.		Not recruiting	18 Years	75 Years	Both		Phase 1
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
486	NCT02744196	January 2015	5 February 2018	Clinical Trial to Evaluate Efficacy and Safety of Acellbia® (JSC BIOCAD) With Methotrexate in First Line Biological Therapy of Patients With Active Rheumatoid Arthritis	Multicenter Comparative Randomised Double-blind Placebo-controlled Clinical Trial to Evaluate Efficacy and Safety of Acellbia® (JSC BIOCAD) With Methotrexate in First Line of Biological Therapy of Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: Acellbia;Drug: Placebo;Drug: Methotrexate	Biocad		Not recruiting	18 Years	80 Years	All	159	Phase 3
487	NCT02837978	January 2015	25 February 2019	The Clinical Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months Treatment	Prospective Clinical Study to Observe the Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months Treatment in China	Arthritis, Rheumatoid	Drug: Tacrolimus;Drug: MTX	Qiang Shu		Recruiting	18 Years	80 Years	All	100	Phase 4	China
488	NCT02927535	January 2015	17 October 2016	Evaluation of TNFa Blockers Monotherapy in Early Rheumatoid Arthritis in France		Rheumatoid Arthritis	Drug: TNF blockers monotherapy	Centre Hospitalier Universitaire de Nimes	Pfizer;Pfizer	Not recruiting	18 Years	70 Years	Both	813	N/A
489	EUCTR2015-002466-22-Outside-EU/EEA		28 December 2015	A Randomized, Multi-center, Blinded, Placebo-controlled Study With an Openlabel Run-in Period to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daily, Single, Subcutaneous Injections of r-metHuiL-1ra (Anakinra) in Polyarticular-Course Juvenile Rheumatoid Arthritis	A Randomized, Multi-center, Blinded, Placebo-controlled Study With an Openlabel Run-in Period to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daily, Single, Subcutaneous Injections of r-metHuiL-1ra (Anakinra) in Polyarticular-Course Juvenile Rheumatoid Arthritis	Juvenile Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: anakinra Pharmaceutical Form: Solution for injection INN or Proposed INN: ANAKINRA CAS Number: 143090-92-0 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Amgen Inc		Not Available			Female: yes Male: yes	90		United States;Australia;Canada;Costa Rica;New Zealand
490	JPRN-UMIN000012650	2014/12/31	2 April 2019	In vivo kinematic analysis of total knee arthroplasty with 3-dimensional registration technique.		osteoarthritis or rheumatoid arthritis of the knee joint	Fluoroscopy was performed to continuously capture the knee from the lateral direction in a weight-bearing position and knee bending position.	Dept. of orthopedic surgery, Osaka Medical College		Recruiting	20years-old	90years-old	Male and Female	60	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
491	EUCTR2014-003529-16-GB	16/12/2014	4 December 2018	Stratification of biologic Therapies for Rheumatoid Arthritis by Pathobiology	Stratification of Biologic Therapies for RA by Pathobiology (STRAP): A randomised, open-labelled biopsy-driven stratification trial in DMARD inadequate responder patients randomised to Etanercept, Tocilizumab or Rituximab. - STRAP	Rheumatoid Arthritis MedDRA version: 20.0 Level: LLT Classification code 10003268 Term: Arthritis rheumatoid System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: MabThera Product Name: MabThera Pharmaceutical Form: Concentrate for solution for infusion Trade Name: RoActmera Product Name: RoActmera Pharmaceutical Form: Solution for injection Trade Name: Enbrel Product Name: Enbrel Pharmaceutical Form: Solution for injection in pre-filled pen	Joint Research & Development Office (QMUL)		Authorised			Female: yes Male: yes	219	Phase 3	United Kingdom
492	JPRN-UMIN000020663	2014/12/16	2 April 2019	A clinical study to evaluate the correlation between the efficacy and the immunological markers in patients with rheumatoid arthritis treated with Tofacitinib.		Rheumatoid arthritis	Period :12 months Patients take Tofacitinib 5mg twice a day.	Kyusyu University Hospital Medicine and biosystemic science		Not Recruiting	20years-old	Not applicable	Male and Female	20	Not applicable	Japan
493	JPRN-UMIN000015794	2014/12/15	2 April 2019	Efficacy of monthly sodium risedronate for the treatment of corticosteroid induced osteoporosis in patients with rheumatoid arthritis (multicenter, double-blind, randomized, placebo-controlled, parallel-group study )		osteoporosis, rheumatoid arthritis	monthly risedronate sodium 75mg for 6 months monthly placebo for 6 months	Division of rheumatology, endcrinology and nephrology, Hokkaido University Graduate School of Medicine		Not Recruiting	20years-old	Not applicable	Male and Female	165	Phase 4	Japan
494	NCT02198651	December 15, 2014	27 August 2018	A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects	A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects (PREDICTRA)	Rheumatoid Arthritis;Musculoskeletal and Connective Tissue Diseases	Drug: Adalimumab;Other: Placebo	AbbVie		Not recruiting	18 Years	99 Years	All	149	Phase 4	United States;Australia;Austria;Canada;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom
495	EUCTR2014-000993-20-SE	04/12/2014	5 February 2018	Dosing of glucocorticoid (triamcinolone hexacetonid) when injecting knee joints of rheumatic diseases	Dosing of intraarticular triamcinolone hexacetonid for knee synovitis in chronic polyarthritis	Psoriatic arthritis and rheumatoid arthritis with synovitis of the knee;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: triamcinolone hexacetonide (Lederspan) Product Name: triamcinolone hexacetonid (Lederspan) Product Code: 9512 Pharmaceutical Form: Injection Trade Name: triamcinolone hexacetonide (Lederspan) Product Name: triamcinolone hexacetonid (Lederspan) Product Code: 9512 Pharmaceutical Form: Injection	Center for Research and Development Uppsala University/County Council of Gävleborg		Not Recruiting			Female: yes Male: yes	160	Phase 4	Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
496	ChiCTR1800014846	2014-12-01	12 February 2018	Effect of preemptive analgesia with parecoxib sodium on multimodal analgesia in primary unilateral total hip arthroplasty	Effect of preemptive analgesia with parecoxib sodium on multimodal analgesia in primary unilateral total hip arthroplasty: A prospective randomized double-blind controlled trial	osteonecrosis of the femoral head, femoral neck fracture, developmental dysplasia of hip, osteoarthritis, rheumatoid arthritis or ankylosing spondylitis	Experiment group:preoperative intravenous parecoxib sodium and postoperative intravenous parecoxib sodium and patient-controlled analgesia;Control Group:preoperative intravenous pure 0.9% saline and postoperative intravenous parecoxib sodium and patient-controlled analgesia;	Peking Union Medical College Hospital		Not Recruiting			Both	Experiment group:50;Control Group:50;	Post-market	China
497	NCT02260791	December 2014	16 December 2017	A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients	A Randomised, Blinded, Active-Controlled Study to Compare FKB327 Efficacy and Safety With the Comparator Humira® in Rheumatoid Arthritis Patients Inadequately Controlled on Methotrexate	Arthritis, Rheumatoid	Drug: FKB327;Drug: Humira®	Fujifilm Kyowa Kirin Biologics Co., Ltd.		Not recruiting	18 Years	N/A	All	728	Phase 3	United States;Bulgaria;Canada;Chile;Czechia;Germany;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;Czech Republic;Serbia
498	NCT02328027	December 2014	11 June 2018	99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS)	A Phase I-IIa Study of Safety, Tolerance, Pharmacokinetics, Dosimetry and Benefice of Early Nuclear Medicine Imaging of 99mTc-rhAnnexin V-128 in Patients With Rheumatoid Arthritis or Ankylosing Spondylitis	Rheumatoid Arthritis;Ankylosing Spondylitis	Drug: 99mTc-rhAnnexin V-128	Advanced Accelerator Applications		Not recruiting	18 Years	N/A	All	16	Phase 1/Phase 2	Switzerland
499	NCT02876874	December 2014	29 August 2016	Relationship Between the Activity of Rheumatoid Arthritis and Lymph Node Morphology and Lymphatics Drainage	the Relationship Between the Activity of Rheumatoid Arthritis(RA) and Popliteal/Epitrochlear Lymph Node Morphology and the Drainage of Hand/Foot Superficial Lymphatic Vessels	Rheumatoid Arthritis;Lymph Node Mass;Lymphatic Vessel; Dilatation	Drug: indocyanine green(ICG)	Shanghai University of Traditional Chinese Medicine		Recruiting	18 Years	65 Years	Both	21	N/A	China
500	EUCTR2014-001114-26-GB	25/11/2014	28 February 2019	A study of subjects with rheumatoid arthritis who are in clinical remission to investigate patient and disease characteristics that could help identify which subjects may lose disease control upon reducing their adalimumab dose	A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) subjects (PREDICTRA)	Rheumatoid arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Humira 40 mg/0.8 ml solution for injection Product Name: ADALIMUMAB Product Code: 331731-18-1 Pharmaceutical Form: Solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Current Sponsor code: Humira Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	AbbVie Deutschland GmbH & Co. KG		Not Recruiting			Female: yes Male: yes	150	Phase 4	United States;Greece;Spain;Ireland;Austria;United Kingdom;Italy;Hungary;Canada;Australia;Germany;Netherlands;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
501	EUCTR2014-002374-36-SE	19/11/2014	1 December 2014	A study with dose de-escalation of coventional or biologic treatments in early rheeumatoid arthritis in patients with low disease activity.	A multicenter, randomized, open-label, blinded-assessor, follow-up, phase 4 study in patients with rheumatoid arthritis who have completed the initial treatment part (active conventional therapy versus three biologic treatments) in the NORD-STAR study and have reached stable low disease activity - CO-STAR	Rheumatoid arthritis (RA) MedDRA version: 17.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Cimzia Pharmaceutical Form: Injection Trade Name: Orencia Pharmaceutical Form: Solution for infusion in pre-filled syringe Trade Name: RoActemra Pharmaceutical Form: Infusion Trade Name: Methotrexate Pharmaceutical Form: Tablet Trade Name: Metoject Pharmaceutical Form: Trade Name: Azathioprine Pharmaceutical Form: Tablet Trade Name: Leflunomide Pharmaceutical Form: Tablet	The Karolinska Institutet, ClinTRID		Authorised			Female: yes Male: yes	500	Phase 4	Sweden
502	NCT02281552	November 18, 2014	16 December 2017	A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis	A Multicenter, Randomized, Double-blind, Parallel-group, Phase 3 Study To Demonstrate Non-inferiority For The Efficacy Of A Once Daily Dose Of Tofacitinib Modified Release Tablet To A Twice Daily Dose Of The Immediate Release Tablet In Adult Patients With Rheumatoid Arthritis On Background Methotrexate	Rheumatoid Arthritis	Drug: Tofacitinib	Pfizer		Not recruiting	20 Years	N/A	All	209	Phase 3	Japan
503	JPRN-UMIN000015616	2014/11/04	2 April 2019	Biologic MateR clinical performance test for ADA and TCZ Efficacy prediction		rheumatoid arthritis	Adalimumab plus Methotrexate Tocilizumab plus Methotrexate	Biologic Mate Study Group		Not Recruiting	20years-old	75years-old	Male and Female	300	Not selected	Japan
504	NCT02030028	November 2014	18 March 2019	ACTH Gel Therapy in Rheumatoid Arthritis	Open Label Study to Evaluate Efficacy and Safety of Short-Term, Adjunctive Adrenocorticotropic Hormone (ACTH) Gel in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: ACTHAR gel	Dr. Larry W. Moreland	Mallinckrodt	Recruiting	18 Years	100 Years	All	20	N/A	United States
505	NCT02287610	November 2014	16 December 2017	A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis	A Non-Interventional Study to Evaluate the Effectiveness of Delayed-Release Prednisone (RAYOS) on Clinical Assessments and Serologic Disease Activity in Patients With Active Rheumatoid Arthritis in the Clinical Practice Setting	Rheumatoid Arthritis	Drug: RAYOS (delayed-release prednisone)	Horizon Pharma Ireland, Ltd., Dublin Ireland		Not recruiting	18 Years	N/A	All	75	N/A
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
506	NCT02293902	November 2014	9 January 2017	A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)	A Randomized, Double-blind, Multicenter Study With a Placebo-controlled Period Assessing the Efficacy and Safety of Sarilumab Added to Methotrexate (MTX) in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis Who Are Inadequate Responders to MTX Therapy	Rheumatoid Arthritis	Drug: sarilumab SAR153191 (REGN88);Other: placebo;Drug: methotrexate;Drug: folic acid	Sanofi	Regeneron Pharmaceuticals	Not recruiting	20 Years	75 Years	Both	243	Phase 3	Japan
507	NCT02296775	November 2014	19 February 2015	Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis		Rheumatoid Arthritis	Biological: DRL_RI;Biological: Rituxan;Biological: MabThera	Dr. Reddy's Laboratories Limited		Recruiting	18 Years	65 Years	Both	276	Phase 1/Phase 2	India;Ukraine
508	NCT02342977	November 2014	5 September 2016	Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty:	Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty: A Randomized Double -Blinded, Placebo-controlled Pilot Study.	Osteoarthritis;Rheumatoid Arthritis;Avascular Necrosis	Drug: Placebo;Drug: Lacosamide	Indiana University School of Medicine	VA Office of Research and Development	Not recruiting	18 Years	70 Years	Both	0	Phase 2	United States
509	NCT02551575	November 2014	27 June 2016	Efficacy and Safety of Traditional Chinese Medicine (TCM) Comprehensive Therapy in Patients With Rheumatoid Arthritis	Efficacy and Safety of Qingre Huoxue Comprehensive Therapy in the Treatment of Rheumatoid Arthritis (RA): A Randomized, Double-blind, Double-dummy, Multi-center Trial	Rheumatoid Arthritis	Drug: Treatment of MTX and HCQ;Drug: Treatment of TCM;Drug: Integrative Medicine	Guang'anmen Hospital of China Academy of Chinese Medical Sciences		Not recruiting	18 Years	65 Years	Both	468	Phase 2/Phase 3	China
510	EUCTR2014-000352-29-CZ	27/10/2014	8 January 2018	A Study of PF-06410293 (Adalimumab-Pfizer) and Adalimumab (Humira) in Combination with Methotrexate in Subjects with Active Rheumatoid Arthritis (REFLECTIONS B538-02).	A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY ASSESSING THE EFFICACY AND SAFETY OF PF-06410293 AND ADALIMUMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO METHOTREXATE	RHEUMATOID ARTHRITIS MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Adalimumab-Pfizer Product Code: PF-06410293 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB Current Sponsor code: PF-06410293 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: HUMIRA Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: ADALIMUMAB-EU CAS Number: 331731-18-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Product Name: Adalimumab-Pfizer Product Code: PR-06410293 Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: ADALIMUMAB Current Sponsor code: PF-06410293 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Pfizer Inc.		Not Recruiting			Female: yes Male: yes	560	Phase 3	Serbia;Taiwan;Estonia;Spain;Ukraine;Russian Federation;Colombia;France;Australia;Peru;South Africa;Korea, Republic of;Lithuania;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Brazil;Poland;Croatia;Bulgaria;Georgia;Germany;Japan;New Zealand
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
511	EUCTR2014-001299-79-DK	06/10/2014	2 October 2017	Pnemococcal vaccination of rheumatoid arthritis patients in biological treatment	Pneumococcal vaccination of rheumatoid arthritis patients in immunomodulatory therapy - Immunovax_RA	Immunoresponse on pneumococcal vaccination of rheumatoid arthritis patients in immunomodulatory therapy MedDRA version: 18.0 Level: LLT Classification code 10069594 Term: Pneumococcal immunization System Organ Class: 100000004865 ;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]	Trade Name: Prevenar 13 Pharmaceutical Form: Suspension for injection INN or Proposed INN: pneumococcal polysaccharide serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F Other descriptive name: PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (13-VALENT, ADSORBED) CONJUGATED TO CRM197 CARRIER PROTEIN AND ADSORBED ON ALUMINIUM PHOSPHATE Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 30.8- Trade Name: Pneumovax Pharmaceutical Form: Suspension for injection INN or Proposed INN: pneumococcal polysaccharide serotype 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F Other descriptive name: PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT) Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 575-	Department of Infectious Diseases, Odense University Hospital		Not Recruiting			Female: yes Male: yes		Phase 3	Denmark
512	JPRN-UMIN000015217	2014/10/01	2 April 2019	Identification of Antibodies Involved in Atherosclerosis Progression and Evaluation of Orencia`s Efficacy on Antibodies, Atherosclerosis Biomarkers and Structural Markers in Orencia-Treated Patients with Rheumatoid Arthritis Complicated by Atherosclerosis	Identification of Antibodies Involved in Atherosclerosis Progression and Evaluation of Orencia`s Efficacy on Antibodies, Atherosclerosis Biomarkers and Structural Markers in Orencia-Treated Patients with Rheumatoid Arthritis Complicated by Atherosclerosis - Orencia Atherosclerosis And Rheumatoid Arthritis Study (ORACLE Arthritis Study)	RA patients aged 20 years or older and have never been treated with biological products or molecular targeted drug therapy.	Abatacept	Yokohama City University Graduate School of Medicine		Recruiting	20years-old	Not applicable	Male and Female	40	Not applicable	Japan
513	JPRN-UMIN000015462	2014/10/01	2 April 2019	Clinical study on drug holiday with regulated rheumatoid arthritis activity after treatment with tofacitinib (Xanadu study)		Rheumatoid arthritis	Continue current treatment Tofacitinib discontinuation MTX discontinuation	School of Medicine, University of Occupational and Environmental Health, Japan		Recruiting	18years-old	Not applicable	Male and Female	400	Not selected	Japan
514	NCT02102594	October 2014	10 December 2018	Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)	Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)	Myasthenia Gravis;Systemic Lupus Erythematosus;Rheumatoid Arthritis	Drug: Bortezomib	Charite University, Berlin, Germany	Prof. Dr. med. Falk Hiepe (Charité, Internal Medicine / Rheumathology);NeuroCure Clinical Research Center, Charite, Berlin	Recruiting	18 Years	75 Years	All	18	Phase 2	Germany
515	NCT02148640	October 2014	16 December 2017	The NOR-SWITCH Study	A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY	Rheumatoid Arthritis;Spondyloarthritis;Psoriatic Arthritis;Ulcerative Colitis;Crohn's Disease;Psoriasis Chronic	Drug: Innovator infliximab;Drug: Biosimilar infliximab	Diakonhjemmet Hospital	South-Eastern Norway Regional Health Authority	Not recruiting	18 Years	N/A	All	482	Phase 4	Norway
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
516	NCT02150473	October 2014	16 December 2017	The Effect of Adalimumab Plus Methotrexate (MTX) Versus Placebo Plus MTX on Cartilage in (RA) Patients	Delayed Gadolinium-enhanced Magnetic Resonance (MR) Imaging of Cartilage - A Pilot Study to Measure the Effect of Adalimumab Plus MTX Versus Placebo Plus MTX on Cartilage in Early RA Patients	Rheumatoid Arthritis	Drug: Adalimumab;Drug: Placebo	Heinrich-Heine University, Duesseldorf	Abbott	Not recruiting	18 Years	80 Years	All	21	Phase 3	Germany
517	NCT02221258	October 2014	17 October 2016	Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis(RA)	Phase 1 Clinical Trial to Evaluate the Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: FURESTEM-RA Inj.	Kang Stem Biotech Co., Ltd.		Not recruiting	19 Years	80 Years	Both	9	Phase 1	Korea, Republic of
518	NCT02265705	October 2014	25 March 2019	A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy	Rheumatoid Arthritis	Drug: Baricitinib;Drug: Placebo	Eli Lilly and Company		Not recruiting	18 Years	N/A	All	290	Phase 3	Argentina;Brazil;China
519	NCT02270632	October 2014	5 December 2016	A Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of F8IL10 (Dekavil) in Patients With Active RA Receiving MTX	A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate Safety and Clinical Efficacy of Two Different Doses of F8IL10 (Dekavil) Administered Subcutaneously to Patients With Active Rheumatoid Arthritis Receiving Methotrexate.	Rheumatoid Arthritis	Drug: F8IL10;Drug: MTX;Drug: Placebo	Philogen S.p.A.		Recruiting	18 Years	74 Years	Both	87	Phase 2	Germany;Italy;Switzerland
520	NCT02500498	October 2014	3 August 2015	Safety Profile of Nulojix in Home Infusion Settings	Safety Profile of Nulojix in Home Infusion Settings	Rheumatoid Arthritis	Drug: Nulojix	Bristol-Myers Squibb	BiologicTx, LLC	Not recruiting	18 Years	N/A	Both	37	N/A
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
521	EUCTR2012-002945-40-DE	22/09/2014	14 November 2016	BI695501 compared to adalimumab in patients with active rheumatoid arthritis	Efficacy, safety and immunogenicity of BI 695501 versus adalimumab in patients with active rheumatoid arthritis: a randomized, double-blind, parallel arm, multiple dose, active comparator trial	Rheumatoid arthritis MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Code: BI 695501 Pharmaceutical Form: Solution for injection INN or Proposed INN: - CAS Number: - Current Sponsor code: BI 695501 Other descriptive name: BI 695501 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Humira Product Name: Humira Pharmaceutical Form: Solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Boehringer Ingelheim International GmbH		Not Recruiting			Female: yes Male: yes	650	Phase 3	United States;Serbia;Estonia;Thailand;Spain;Ukraine;Chile;Russian Federation;Hungary;Malaysia;Poland;Bulgaria;South Africa;Germany;New Zealand;Korea, Republic of
522	EUCTR2013-005418-37-IT	15/09/2014	23 March 2015	A multicenter, placebo-controlled phase II study to evaluate safety and clinical efficacy of two different doses of F8IL10 administered subcutaneously to patients with active rheumatoid arthritis receiving Methotrexate.	A multicenter, randomized, double-blind, placebo-controlled phase II study to evaluate safety and clinical efficacy of two different doses of F8IL10 (Dekavil) administered subcutaneously to patients with active rheumatoid arthritis receiving Methotrexate.	Patients with active Rheumatoid Arthritis despite methotrexate therapy that had unsuccessful response to at least one anti-TNF treatment.;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Dekavil Product Code: F8IL10 Pharmaceutical Form: Solution for injection INN or Proposed INN: dekavil Current Sponsor code: F8IL10 Other descriptive name: F8IL10 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 3.75-20 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Philogen S.p.A.		Authorised			Female: yes Male: yes	87	Phase 2	Germany;Italy
523	EUCTR2013-002805-76-CZ	11/09/2014	2 October 2017	A 24-week placebo-controlled clinical study to evaluate the adequate dose, efficacy and safety of 3 doses of namilumab combined with methotrexate in subjects with moderate to severe rheumatoid arthritis.	A 24-week randomized, double-blind, placebo-controlled, phase 2 dose finding study to evaluate the efficacy and safety of 3 doses of namilumab (20 mg, 80 mg and 150 mg) in combination with methotrexate (MTX) in subjects with moderate to severe rheumatoid arthritis (RA) NEXUS.	Rheumatoid Arthritis (RA) MedDRA version: 19.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Namilumab Product Code: MT203 Pharmaceutical Form: Solution for injection INN or Proposed INN: namilumab CAS Number: 1206681-39-1 Current Sponsor code: MT203 Other descriptive name: NAMILUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: Namilumab Product Code: MT203 Pharmaceutical Form: Solution for injection INN or Proposed INN: namilumab CAS Number: 1206681-39-1 Current Sponsor code: MT203 Other descriptive name: NAMILUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 80- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: Namilumab Product Code: MT203 Pharmaceutical Form: Solution for injection INN or Proposed INN: namilumab CAS Number: 1206681-39-1 Current Sponsor code: MT203 Other descriptive name: NAMILUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Takeda Development Centre Europe Ltd.		Not Recruiting			Female: yes Male: yes	108	Phase 2	Czech Republic;Poland;Spain;Russian Federation;Bulgaria;Japan;United Kingdom
524	JPRN-UMIN000014624	2014/09/01	2 April 2019	Effects of postoperative administration of celecoxib on postoperative pain management in patients after total knee arthroplasty. A randomized controlled study.		Osteoarthritis, Rheumatoid arthritis	Administration of celecoxib from 2 hours after TKA surgery Administration of celecoxib from 2 days after TKA surgery	Mito medical center, Mito Kyodo General Hospital, University of Tsukuba		Not Recruiting	20years-old	Not applicable	Male and Female	120	Phase 4	Japan
525	NCT01717859	September 2014	20 May 2019	Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab	Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab	Rheumatoid Arthritis	Drug: Tocilizumab	University of California, Los Angeles	Genentech, Inc.	Not recruiting	18 Years	N/A	All	74	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
526	NCT02154425	September 2014	11 June 2018	A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers	A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia® (Certolizumab Pegol)	Axial Spondyloarthritis (AxSpA);Non-radiographic Evidence-AxSpA;Ankylosing Spondylitis;Crohn's Disease;Psoriatic Arthritis;Rheumatoid Arthritis	Procedure: Breast milk sampling;Biological: Certolizumab Pegol	UCB BIOSCIENCES, Inc.	PPD;Parexel	Not recruiting	18 Years	N/A	Female	17	Phase 1	United States;Netherlands;Switzerland;France
527	NCT02246257	September 2014	10 December 2018	Early Rheumatoid Arthritis COR Intervention	Multifactorial Intervention to Prevent Cardiovascular Disease in Patients With Early Rheumatoid Arthritis	Rheumatoid Arthritis;Cardiovascular Diseases	Other: Simvastatin;Other: Losartan;Other: Metformin;Other: Outpatient rheumatology department;Other: Refered to general practice	MD, PhD, Annemarie Lyng Svensson		Recruiting	18 Years	N/A	All	300	N/A	Denmark
528	EUCTR2013-005543-90-HU	26/08/2014	4 December 2018	This trial is designed to determine the effects the investigational medicine, ABP 798 has on the human body, and what effects the investigational medicine after you have been given it, and if this is comparable to what is seen for the licensed medicine, rituximab, in patients with moderate or severe rheumatoid arthritis (RA). This study will assess if the investigational medicine is safe and effective in treating moderate or severe RA compared to the licensed medicine.	A Randomized, Double-Blind Study to Compare Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of ABP 798 With Rituximab in Subjects With Moderate to Severe Rheumatoid Arthritis - Not applicable	Rheumatoid arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: ABP 798 Product Code: ABP 798 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: rituximab CAS Number: 1446410-99-6 Current Sponsor code: ABP 798 Other descriptive name: ABP 798 - Biosimilar to rituximab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: Rituxan Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Other descriptive name: Rituxan Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: MabThera Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Other descriptive name: MabThera Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Amgen Inc		Not Recruiting			Female: yes Male: yes	300	Phase 1;Phase 3	United States;Estonia;Hungary;Canada;Poland;Bulgaria;Germany
529	NCT02222493	August 26, 2014	11 June 2018	A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).	A Phase 3 Randomized, Double-blind Study Assessing The Efficacy And Safety Of Pf-06438179 And Infliximab In Combination With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate	Rheumatoid Arthritis	Biological: PF-06438179;Biological: Infliximab	Pfizer		Not recruiting	18 Years	N/A	All	650	Phase 3	United States;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czechia;Georgia;Germany;Guatemala;Hungary;Israel;Japan;Jordan;Korea, Republic of;Lithuania;Mexico;Morocco;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Tunisia;Ukraine;United Kingdom;Colombia;Czech Republic;France
530	NCT02202837	August 12, 2014	16 December 2017	Study With Etanercept Focusing on Remission and Predictability of Remission in Real Life Clinical Practice	Defining Which Remission Criterion At Month 6 Predicts Remission At Month 12 In A Real Life Clinical Practice, In A Cohort Of Rheumatoid Arthritis Patients Treated With Etanercept (Enbrel (Registered))	Rheumatoid Arthritis	Drug: etanercept	Pfizer		Not recruiting	18 Years	N/A	All	135	N/A	Belgium
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
531	NCT02308163	August 8, 2014	15 July 2019	A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs	Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to DMARDs	Rheumatoid Arthritis	Drug: peficitinib;Drug: Placebo;Biological: Etanercept	Astellas Pharma Inc		Not recruiting	20 Years	N/A	All	509	Phase 3	Japan;Korea, Republic of;Taiwan
532	ChiCTR-RNC-14004887	2014-08-01	18 April 2017	The pharmacogenomics study on Methotrexate in treating rheumatoid arthritis	The pharmacogenomics study on Methotrexate in treating rheumatoid arthritis	rheumatoid arthritis	Case series:Methotrexate;	The people's hospital, Yichun City		Recruiting	18	65		Case series:400;	Post-market	China
533	JPRN-UMIN000014737	2014/08/01	2 April 2019	The effects of denosumab compared with oral bisphosphonates (BP) in patients with RA complicated with osteoporosis on the progression of structural damage, BMD and disease activity.		rheumatoid arthritis	Denosumab group: Denosumab 60mg is administered by subcutaneous injections every 6 months (at baseline, at 6 months and at 12 months). All patients are to take vitamin D. BP group: Patients take BP continuously. All patients are to take vitamin D.	Yokohama City University Medical Center		Not Recruiting	50years-old	90years-old	Male and Female	286	Not selected	Japan
534	NCT02176876	August 2014	3 August 2015	Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis	A Phase 1b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: GS-5745;Drug: Placebo to match GS-5745	Gilead Sciences		Not recruiting	18 Years	70 Years	Both	18	Phase 1	Czech Republic;Hungary
535	NCT02187055	August 2014	16 December 2017	An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate	A Phase 3b/4 Randomized Double Blind Study Of 5 Mg Of Tofacitinib With And Without Methotrexate In Comparison To Adalimumab With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis	Rhematoid Arthritis	Drug: Tofacitinib with methotrexate;Drug: Tofacitinib without methotrexate;Biological: Adalimumab with methotrexate	Pfizer		Not recruiting	18 Years	N/A	All	1132	Phase 4	United States;Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;Croatia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
536